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Abstract  
COMPARING ANTI-VEGF ANTIBODIES AND APTAMERS ON PAPER 
MICROFLUIDIC-BASED PLATFORMS 
By 
Katherine Clayton 
 
The field of microfluidics is expanding into what is known as paper microfluidics. 
This uses a paper platform rather than materials (i.e. PDMS, PMMA) that are commonly 
used in microfluidics research. Current devices require an expensive manufacturing 
process and external sources to power the device. Such devices are not practical in low 
resource environments. As a consequence, it is the goal of this Thesis to develop a three-
dimensional, multiplexed assay chip using nitrocellulose membranes. This device 
comprises of multiple layers of nitrocellulose membranes with defined fluidic channels. 
The multiple layers are bound together using double backed tape, and imbedded between 
the layers are conjugate reagents. In the detection region both antibodies and aptamers 
were evaluated.  
The fiberglass pad where conjugate reagents would be contained, were initially 
saturated in dye. As sample was inputted into the three-dimensional chip, the fluid path 
could be visualized. Without the use of the conjugate pad the chip’s four detection 
regions showed detection within one minute of one another. However, the addition of this 
fibrous pad skewed time points dramatically. The hypothesis that a three-dimensional 
chip could be designed to detect different biomarkers in a multi-analyte sample was 
satisfied. However, simultaneous detection was only possible if the conjugate pad was 
either neglected or, possibly, a different material was used.  
Additionally, current lateral flow assay technologies, another research area that paper 
microfluidics spawns from, use antibodies in order to capture biomarkers in sample and 
provide visual signal to the user. However, antibodies are sensitive to denaturation with 
pH and temperature, whereas aptamers can withstand much more extreme environmental 
conditions. A two-dimensional nitrocellulose chip was designed to compare antibodies 
and aptamers as capture reagents to detect VEGF, using colloidal gold as a particle to 
visualize detection. Both monoclonal and polyclonal anti-VEGF antibodies were used 
and showed no signal. On the other hand, the anti-VEGF aptamer produced a visual 
signal when conjugated to biotin on its 5’ end. This data was further validated by a 
separate project analyzing the binding kinetics of the antibody and the aptamer using 
Surface Plasmon Resonance. Therefore, the hypothesis that aptamers could be used as a 
possible capture reagent in a paper microfluidic chip for the detection of VEGF was 
satisfied.  
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Introduction 
 
 Paper microfluidics encompasses concepts used in traditional microfluidics in 
conjunction with lateral flow assays [1]. This research area allows for both sensitive and 
accurate detection of particles in a sample while maintaining low cost for each device. 
This technology – commonly referred to as a lab-on-a-chip (LOC) – is being further 
developed within the biomedical engineering field [2]. Advancement of this technique 
would allow for an alternative for disease diagnosis for both those in the developed and 
developing world. Paper microfluidics is an advantageous approach to diagnostics 
because it produces clear results and requires minimal training from the user [3]. By 
exploring this field further, it would allow for the dramatic innovation and improvement 
in diagnostics.  
 
Thesis Objective 
There are three main objectives of this thesis.  
• Characterize properties of nitrocellulose as a material platform for custom 
lateral flow assays.  
• Design, manufacture, and test a simultaneously detecting three-
dimensional multi-layer chip as a potential inexpensive and simplistic 
solution for multiplex point-of-care diagnostics.  
• Understand and implement biochemistry into the device by comparing 
antibodies and aptamers as potential solutions for detecting the growth 
factor, VEGF (vascular endothelial growth factor) [4].  
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Thesis Purpose 
The purpose of this thesis is to determine the feasibility of developing a three-
dimensional paper microfluidic device in-house that can simultaneously detect an 
inputted sample in multiple detection regions of the chip. Additionally, this thesis will 
compare the ability of using antibodies compared to aptamers as potential capture 
reagents to produce a visual signal if a particular concentration of VEGF is detected by 
the sample.  
Diagnostics for Global Health 
For a country to be considered as developed or developing it is either measured by 
its gross domestic product (GDP) per capita or Human Development Index (HDI) [5, 6]. 
The GDP measurement is purely economical, where a high income per capita would 
describe a developed country [5]. However, an HDI takes into account economy, income, 
life expectancy, and education. The higher ratings also denote a developed country [6]. 
Although these exist as possible quantitative measurements to explain a country’s 
development, generally, a developed country is defined as, “…one that allows all its 
citizens to enjoy a free and healthy life in a save environment” according to Kofi Annan 
(the former Secretary General of the United Nations) [7]. These definitions and concepts 
become important for understanding the dramatic differences in healthcare that is 
provided in these two different categories. 
In a developed country, disease diagnostics development is important because it 
provides more timely care to its patients, it helps to ensure safe blood banking, and it 
provides surveillance data for future emergency public health situations and long-term 
public health strategies [3]. Focusing on timely care to patients, in the developed world, a 
patient commonly goes to their general practitioner to seek initial medical advice. When 
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their blood, urine, or stool sample is taken, it is commonly sent to a laboratory either 
within the hospital or externally and results come back at a later time [3]. However, it 
would be beneficial to eliminate this wait time. Paper microfluidics allows for a doctor or 
nurse to evaluate patient health locally within minutes. 
In the developing world the need for paper microfluidics is just as important, if 
not more, than that in developing countries [3]. Paper microfluidics are a form of point-
of-care (POC) device. This means that a patient can be diagnosed on site, or at the point, 
in which they are receiving medical care. This could be at a hospital, local clinic, or even 
at home [3]. These POC devices are favorable in developing countries because they 
provide simple, reasonably accurate results that require minimal training, which is 
beneficial in low resource situations. One issue that must be addressed, however, is that 
most organizations that focus on healthcare in the developing world invest more heavily 
in drug discovery and vaccines rather than diagnostics, so that designing and 
implementing an low-cost device becomes even more crucial [3, 8]. 
Currently, there are no standards that are followed for diagnosing patients in the 
developing world [3]. Because of this, misdiagnosis is common [9]. However, the World 
Health Organization (W.H.O.) is working to implement a set of guidelines that they have 
developed, which provides a list of clinical symptoms and the appropriate examinations 
for them. The W.H.O. created this protocol in order to minimize misdiagnosis [3]. A 
serious issue in the developing world is that unnecessary medication is given to 
misdiagnosed patients. Although this may initially seem harmless, these inessential 
pharmaceuticals have led to haphazard spending, and eventual resistance of the disease to 
the drugs. Although the guidelines provided by the W.H.O. have led to a reduction in 
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disease burden worldwide, there is still significant room for improvement. The 
ambiguous directions continue to lead to false diagnosis and incorrect treatment of the 
patient [3].  
When approaching the development of diagnostic devices, the concept of 
appropriate technology (AT) must be considered. Appropriate technology is defined as 
the design and development of any object that can be appropriately used in the 
community that it is provided to. The World Health Organization specifies that the 
development of AT devices should follow the acronym “ASSURED” (Affordable, 
Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free, Deliverable) [10]. 
The importance of an affordable device is that people of all socio-economic backgrounds 
will be able to afford diagnostic healthcare [10]. In the developing world, a large portion 
of the population is of low income, and a small fraction has higher income, with a non-
existent middle-class. Commonly, these countries have private hospitals that only the 
affluent population can afford [3]. The rest of the population receives medical care from a 
low-resource clinic, or none at all. In light of these facts, it is crucial that low cost devices 
be developed that are sensitive enough to ensure rapid, first-time detection [10]. The 
sensitivity of the device saves repeat testing which lowers cost for the facility and patient. 
Specificity of the device, like sensitivity, must allow for accurate results, rather than 
inconclusive ones [10]. Since the medical equipment could be handled by anyone, from a 
doctor to a local volunteer, the diagnostic needs to be user-friendly so that anyone can 
determine its results [10]. At the moment, microscopes are the most common diagnostic 
tool in developing nations [3]. Although a powerful and sensitive device, it is not user-
friendly. The lack of the appropriate instrumentation and training commonly leads to 
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erroneous results from the untrained eye. A rapid and robust test is advantageous because 
a quick turnaround time would help aid in immediate treatments for the patients. Also, 
the device could be used in a hospital, a clinic without power, or on the battlefield [3]. An 
equipment-free device frees diagnostics from a power source, which tends to be 
unreliable in many parts of the world [3]. Additionally, less equipment would aid in 
affordability of the device. Finally, a deliverable device would be easily transportable to 
the area in which the diagnostic is needed at a minimal cost while maintaining its 
integrity [10].  
There is a clear need to for accurate and simple disease diagnosis in low-income 
countries. In the developing world, malaria, HIV, and tuberculosis comprise of 95% of 
the disease burden [3]. These diseases are commonly referred to as, “the big three”. 
These deleterious diseases often affect adults in developing nations, which leads to a 
considerable number of deaths. As a result, numerous children are orphaned throughout 
areas where these diseases run rampant and healthcare is not readily available. With that 
said, many children in the developing world are commonly affected by diarrheal diseases 
and acute respiratory infections [3]. The places in which these infectious diseases 
impinge the population compliment the fact that there is a lack of infrastructure in the 
area [3]. As these nations develop their infrastructure, the disease burden shifts from the 
plague of infectious diseases to non-communicable ones [1]. Additionally, with this shift 
there is an increase in obesity and diabetes. Looking at high-income countries, the non-
communicable diseases that plague a large percentage of the population are ischemic 
heart disease and cerebrovascular disease [3]. However, it is important to note that the 
developing world is facing a larger population affected by cancer – once thought to be a 
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disease that only affected the developed world [11, 12]. Therefore, there are numerous of 
diseases that can be further addressed through the advancement of diagnostic devices. 
Further focusing on diagnostics of infectious disease in the developing world, 
there are many issues with their healthcare systems. One reason is the lack of 
infrastructure in healthcare in developing countries [3]. This leads to minimally trained 
workers with equipment in clinics and laboratories that are beyond the scope of their 
background in healthcare. With minimal training, these workers are not able to 
appropriately use the technology leading to troubles when analyzing the biological 
samples of patients for diagnosis [3]. Therefore, when diagnostic equipment is purchased 
or donated to these low-income clinics, it is not used appropriately and therefore does not 
serve its function. Additionally, when the equipment breaks there is little incentive to 
repair it. This is due to the fact that there is little money to repair the technology as well 
as minimal education as of how to. This misuse and common failure of medical 
equipment leads to mistrust of these clinics as it leads to a considerable amount of 
erroneous results for patients. With a cost-effective, simple yet sensitive diagnostic 
device, many of these issues could be resolved [13]. 
Point-Of-Care Diagnostics 
Point-of-care diagnostics is defined as the capability of diagnosing a patient at the 
site of care – whether that be at a local doctor, or at home. There is a growing need for 
this around the world that the field of microfluidics attempts to solve.  
Currently, healthcare paradigms are set-up as having different diagnosis 
capabilities based on the location of which the sample is being studied. A central hospital 
is considered gold standard for patient disease diagnosis [3]. A central hospital allows for 
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a patient to receive appropriate care on-site while its location contains advanced 
technology for the rapid detection and determination of the sample. Additionally, an 
abundance of research and development takes place at a centralized hospital due to the 
vast amounts of money and the highly trained person working there. The next best place 
for disease diagnosis would be at a reference laboratory [3]. This is where biological 
samples are outsourced to from a local doctor’s office or clinic for testing. Following a 
reference laboratory, would be a local physician’s office [3]. Many times, a general 
doctor’s office does not contain devices allow for rapid and accurate diagnosis. 
Therefore, lateral flow assay tests are commonly used. Lateral flow assays, however, are 
qualitative rather than quantitative, which does not allow for a doctor to gage the degree 
of severity.  
The next best technology is an emergency first responder, where those that are in 
the field can test for biological threats in the water or air [3]. For example, an emergency 
first responder device could be dipped into a stream to see if it is safe for drinking or if 
there are toxic contaminates. However, these devices are not usually sensitive enough to 
detect a lethal dose of a chemical or pathogen. Additionally, there is the category of home 
diagnostics (i.e. a home pregnancy test). Patients tend to prefer having the ability to be 
diagnosed within their own homes because they maintain a sense of privacy [3]. 
However, these tests are typically not as sensitive as those in a laboratory setting, so 
therein contains the chance of false diagnosis. Finally, those in the armed forces need 
disease testing available to them [3]. These people are constantly exposed to harsh 
conditions and there are not many options for diagnostic devices that would maintain 
their sensitivity in a war zone. Additionally, those in the armed forced would need to be 
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able to easily carry the device as well as operate it and understand the results. This is 
where the concept of paper microfluidics becomes an advantageous option for medical 
diagnostics. There is once case recently in which a portable malaria test was developed 
by the United States Military for soldiers abroad [3]. This lateral flow assay allowed for a 
small pinprick of blood at its input and process it to see whether or not the sample was 
positive for malaria. Additionally, technologies that are successful within the military 
would also be feasible for use in the developing world. This is due to the commonality 
between the environmental conditions and untrained users that the devices are aimed 
toward. Therefore, paper microfluidics would be successful over a wide range of 
locations and education levels of people. 
Current Technologies 
As the field of diagnostics is advancing, there are simplistic technologies that are 
being developed that would prove useful in low-resource healthcare situations. Two main 
examples of this would be microfluidics and immunoassays. 
An immunoassay encompasses technologies that use antibodies or antigens in 
order to detect proteins or chemical substance from a sample. One example of an 
immunoassay is an enzyme linked immunoabsorbant assay (ELISA) [14]. Although there 
are several formats of the ELISA, one most often thinks of a microtiter plate an antigen 
sample that is attached to its surface, and is then exposed to a primary and secondary 
antibody with an enzyme. When the color in the well changes, this shows an immune 
reaction (or a detection between antibodies and antigen) and the intensity of the color is 
measured using a spectrometer [14]. Other common examples are Western, Northern, and 
Southern blots as well as immunochromatography (which implies a rapid diagnostic test 
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with a lateral flow assay) [15]. Examples of these range from an at home pregnancy test 
to an on site lateral flow assay that tests for West Nile Virus [16]. These tests can be used 
at the point-of-care and tend to be purely qualitative, meaning, the test can only prove 
positive or negative for a particular biomarker [3]. However, the simplicity and 
robustness of such a device allows for its use in any healthcare environment. 
Additionally, many researchers wish to use microfluidics technologies as a 
diagnostic solution in low-resource healthcare settings [3]. Using small amounts of 
sample (in the microliter range), a microfluidic apparatus determines its properties. This 
could be through using immunoassays within the chip, using electromagnetic or thermal 
sciences for cell separations, and more [17]. Although this technology field hopes to 
eventually take what are currently large laboratory procedures and instead solve the 
diagnostics on a chip, this field needs to dramatically develop before most of these chips 
can be used in the field. For example, these chips are made on an individual basis, where 
materials are laser cut and milled [3]. This adds cost to the device technology, making 
PDMS chips not feasible for low-resource settings at this current time.  
Paper microfluidics takes these two research areas and combines them together. It 
allows for small chip designs and required sample, similar to microfluidics, but uses 
inexpensive platforms and biochemical agents (like antibodies), which is similar to an 
immunoassay. Low-resource healthcare facilities in the developed and developing world 
could adopt these technologies, environmental and homeland security could use these to 
check for toxins, or a patient could use this at home as a private point-of-care diagnostic 
[3]. As long as the test remained both inexpensive and accurate, this would be favorable 
in numerous situations. 
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The movement toward developing paper microfluidics first became well known 
through the Harvard University professor George Whitesides [18]. His technologies 
began to be adapted further by other institutions and research groups. Currently these 
paper microfluidic devices are still in initial development stages through characterizing 
flow rates, using different platforms, finding optimal detector and capture reagents, and 
eventually seeing the feasibility of using them on-site in the developing world [1, 18-22].  
Lateral Flow Assays and Immunochromatography 
When first considering the idea of paper microfluidics, it is common to think of a 
rapid lateral flow test strip. A common example of this is an at home pregnancy test. This 
in vitro test strip inputs a sample of urine that flows down a series of membranes to detect 
human chorionic gonadotropin (hCG), a hormone found when a woman is pregnant [23]. 
Pregnancy tests are known as sandwich assays. Referring to Figure 1, the urine sample 
goes in through a sample port and reaches a sample pad. The purpose of this pad is to 
promote an even and controlled distribution and rate of the sample in the 
immunochomatographic device. This pad typically is made out of woven meshes and 
cellulose fibers [23]. 
 
Figure 1: Sample Pad. A schematic of the sample pad in a lateral flow test 
strip. This is the location in which biological sample is inputted into a lateral 
flow assay [23]. 
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As the sample moves down the sample pad via capillary action, this uniform 
sample is transferred to the conjugate pad. The conjugate pad is important in this device 
because it contains detector reagents. A detector reagent is a particle, such as colloidal 
gold or a latex bead, which forms a complex along with a biological sample that is to be 
detected, and the detector [23]. This detection particle allows for a reaction to happen to 
signal that the test is complete by creating a notable event – such as fluorescing for a 
positive result. This sample uniformly moves down the conjugate pad and as it flows, 
carries the detector particles with it. This membrane is commonly made of woven filters 
with cellulose, glass, or plastic fibers [23]. An example of the conjugate pad for a lateral 
flow test strip can be seen in Figure 2.  
 
Figure 2: Conjugate Pad. A schematic of the conjugate pad in a lateral flow 
test strip. This is where labeled antibodies are located that will rehydrate, bind, 
and move along with target analytes in the inputted biological sample for a lateral 
flow assay [23]. 
 
The sample and detection particles reach the membrane (as seen in Figure 3), 
where a series of antibodies or other capture reagents are located. This membrane in a 
lateral flow assay is most likely made with nitrocellulose. The capture reagents tethered 
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to this membrane identify whether or not a hormone or protein is present in a sample, 
creating an entire complex when it is identified. These reagents are commonly placed in 
one designated area called the detection line. When biochemically placing the antibodies 
or capture reagents on the membrane, it is important to know the binding mechanism of 
the biologics to the membrane in order to stabilize it to the surface (i.e. how 
nitrocellulose binds to proteins electrostatically). At this point, the detector reagents, 
along with the capture reagents and the target found in the sample will create and entire 
complex and change a color as a visualization that the protein or hormone was detected 
[23]. 
 
Figure 3: Entire Lateral Flow Assay. A schematic of an entire lateral flow 
assay with a cross-section through the plastic outer casing to show all 
components of a standard test [23]. 
 
Finally, the sample wicks to an absorbent pad. The absorbent pad soaks up 
unbound detector particles and excess sample fluid and hinders backflow onto the 
membrane. This is important for maintaining the sensitivity of the test. This is commonly 
made from cellulose filters [23]. This can be seen in Figure 4.  
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Figure 4: Absorbent Pad. A schematic of the absorbent pad in a lateral flow 
test strip. This region is located after the detection areas of the test and absorbs 
excess sample in order to prevent backflow, which would decrease sensitivity 
and increase the chance of an erroneous result [23]. 
 
There is also a backing commonly attached to the nitrocellulose membrane. 
Proteins have a naturally affinity to want to bind to nitrocellulose. The backing of the 
membrane limits the amount of surface area that proteins have to adhere to the 
nitrocellulose. Additionally, a backing on the membrane allows for more support for the 
nitrocellulose, because the un-backed material has minimal tensile strength. This 
adhesive backing is composed of a plastic packing, adhesive, and release liner [23].  
Another important aspect to consider in a lateral flow assay is whether housing is 
necessary. A case is important from the standpoint that it holds the entire test together 
into one sleek device, as well as the fact that it limits exposure to outside chemical and 
biological agents, which could alter the accuracy of the test. It will not only limit outside 
elements from altering test results, but it will also contain the patient sample [23]. 
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Paper Microfluidics  
Paper microfluidics, similar to a lateral flow assay, comprises of a paper base 
platform, capture reagents, detector reagents, conjugate pads, absorbent pads, and 
something different – a bridging layer [19, 23, 24].  
Paper Platforms  
Currently, a common paper platform material used in paper microfluidics is 
cellulose. However, nitrocellulose and nylon are alternative materials that are being 
researched and used – with this particular project focusing on the former. The paper 
platform represents the membrane aspect of the lateral flow assay [23]. 
The pore size of the paper makes a difference for the wicking of the biological 
sample through the entire apparatus. If the membrane has a larger pore size, this allows 
more biological sample to wick through, creating a quicker test. Although a short 
turnaround time for diagnosis is optimal, if a test is too short this can inhibit the ability of 
a capture reagent to attach onto a target molecule, therefore leading to erroneous results 
[23]. With a smaller pore size, this creates not only a longer test time, but depending on 
the sample, may not allow for any of the necessary target molecules to seep through the 
pore for detection. Once again, this could create incorrect results and is an important 
factor in considering platforms for paper microfluidics. 
Nitrocellulose was chosen as an alternative material to that of cellulose for a 
number of reasons. Primarily, nitrocellulose has an affinity for binding to capture 
reagents, which is important for creating a paper microfluidic device. Nitrocellulose’s 
primary binding mechanism is electrostatic [23]. This is determined by its surface area – 
which is further determined by its pore size, porosity, thickness, and structural 
characteristics [23]. The electrostatic binding mechanism happens due to dipoles in the 
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paper itself to that of the peptide bonds in the reagent. Additionally, nitrocellulose would 
not contaminate the sample that is wicking through the membrane, and would therefore 
maintain a sensitive and accurate result as the target molecules reach the control line. 
Bridging Materials  
Additionally, paper microfluidic devices that are three-dimensional require the 
bridging of the paper layers to allow for constant wicking of the biological sample 
throughout the test platform. Since the membrane material used is nitrocellulose, the 
bridging layer would be of the same material in order to maintain consistency throughout 
the chip. The process of developing this bridging layer is further explained in the 
Methods section. 
Capture and Detector Reagents 
Detector reagents are a vital part of a paper microfluidic apparatus. This is the 
part of the target molecule – capture regent – detector reagent complex that together 
creates the chemical reaction to visually prove to the patient or clinician that the test 
results are positive. As the detector particles that are located on the conjugate pad are 
exposed to the liquid sample, they flush out and eventually wick onto the detection 
membrane in the device. The detector particles and sample eventually reach a set of 
capture reagents on a control line and create an entire structure that allows for the test to 
turn a color for a positive result [23]. 
An important component of a detector reagent is that it must be spherical in shape 
to help with its attachment to the capture reagent and biomarker [23]. Additionally, they 
should all relatively be of similar size. This is due to the fact that as the fluid sample 
wicks down the lateral flow assay from the sample port to the detector pad to the 
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membrane, the detector reagents must evenly flow from the standpoint of sensitivity. 
Larger and smaller particulates will move along the membrane at different time points 
and therefore the test may not properly fluoresce if the particular biomarker is contained 
in the sample that it wishes to look for. There are many types of detector reagents that can 
be used in a lateral flow assays. Some examples are gold colloidal particles, other metal 
colloidal particles, magnetic particles, dye sacs, latex beads, fluorescence particles, and 
enzyme conjugates [23].  
Fabrication 
The fabrication techniques that are used in paper microfluidics are inexpensive 
and simple to replicate. These chips, known as µPads, can initially be made as a two-
dimensional or three-dimensional design. A two-dimensional design uses a single 
membrane of the paper-based platform, whereas a three-dimensional apparatus uses 
multiple layers that are adhered to one another [19].  
These designs are initially sketched out using a software design program such as 
AutoCAD or Adobe Illustrator. From there, the designs are directly printed onto the 
membrane of choice using a wax-based printer. The printer melts colored wax blocks that 
create ink and dispense it across the page [21]. As the ink quickly cools, this forms a wax 
layer on the surface of the platform. This provides the design of the chip, including its 
hydrophobic channels. These channels are what a biological fluid will wick down during 
testing. The printer that will transfer the CAD design onto the membrane is a XEROX 
wax block printer. This printer distributes fifty to sixty micrometer diameter ink droplets 
onto the paper [21]. The wax has a melting temperature of 120°C, which the printer heats 
the ink blocks up to during the printing process [21]. 
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The wax must impregnate the entire membrane in order to maintain the 
appropriate barricade of the hydrophobic channel [21]. Without the wax fully infused 
throughout the membrane, the biological sample will naturally wick through any part of 
the paper platform. This would not allow for the intended flow paths of the device. In 
order ensure the permeation of wax in the apparatus the printed pieces of the chip are 
placed in an oven at a specified temperature and time period (see the Methods section). 
As the wax melts into the pores of the paper, it diffuses in both the lateral and vertical 
directions. This dispersion takes the once sharp image and alters its defined edges. 
Therefore, the channels that the fluid wicks through decreases in size, and the barriers 
widen and seep into the wax-free areas [21]. An example of this melting can be seen in 
Figure 5, below. 
 
Figure 5: Wax Reflow. The reflow of wax post-melting the paper-based 
designs. The spreading of the wax causes a less distinct barrier between wax and 
wax-free areas on the paper, and how the spreading is noticeably different from 
one side of the paper to the other (i.e. top of the paper and bottom of the paper). 
This shows not only the spreading of wax laterally, but vertically as well [21]. 	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The effects of lateral melting can be accounted in the design using Washburn’s 
equation (Equation 1) [21]. 
       (1) 
In this case, L is the distance into the porous nitrocellulose,  is viscosity, D is pore 
diameter, t is time, and Υ is the surface tension [21]. Additionally, the width of the 
hydrophobic barrier is related to the width of the printed line (Equation 2) [21]. 
      (2) 
WB is the width of the barrier, WP is the width of the printed line, and L is the distance 
that the wax spreads from the edge of the line [21]. Therefore, the width of the 
hydrophilic channel is calculated using Equation 3 [21].  
      (3) 
In this case, WG is the width between the two printed lines and WC is the width of the 
hydrophilic channel [21].  	  
Biochemistry  
This thesis compares the ability to detect VEGF in sample on a two-dimensional 
nitrocellulose chip using both antibodies and aptamers as possible capture reagents.  
Comparing the capabilities of aptamers to antibodies would allow for possible 
alternatives in the biochemistry involved with a lateral flow assay or paper microfluidic 
platform.  
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Vascular Endothelial Growth Factor 
VEGF, or, vascular endothelial growth factor, is a signal protein found in the 
body as new vasculature is formed in the body [25]. This particular growth factor is 
found in high concentrations for a multitude of human diseases and conditions. Although 
common for a wide-range of health issues, this protein is a great starting point for 
developing a wide array of diagnostic devices for many disease types. 
There are many growth factors that are apart of the VEGF family, namely VEGF-
A, VEGF-B, VEGF-C, VEGF-D and PIGF (placenta growth factor) [25, 26]. However, 
because VEGF-A was the first protein discovered, it is commonly just referred to as 
VEGF [27].  VEGF-A is the overall biomarker that is of interest for this thesis – 
particularly focusing on VEGF165 isoform [28]. This particular isoform is of interest 
because of its abundance in angiogenesis (or vessel growth), which is implicative of 
possible tumor growth in a physiological system [29]. 
VEGF activity is commonly seen on endothelial cells, but can also be active on 
macrophages, neurons, cancer cells, and kidney epithelial cells [27]. Although this 
signaling protein is found in all humans, higher concentrations are typical in those with 
cancer, tuberculosis, macular degeneration, and POEMS syndrome [4, 26, 27, 30-33]. 
This is because in order to feed these diseases, an increase in blood vessels develops to 
provide nutrients to the affected area (i.e. blood to a growing tumor). Many of these 
diseases plague both the developed and developing world – implying the importance of 
understanding how to create a less expensive and simplistic device that would be 
sensitive in detecting this signaling protein.  
In low-resource areas, people will more commonly have to deal with tuberculosis 
or cancer than POEMS syndrome or macular degeneration, though detecting any of these 
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would be advantageous. The developing world is more commonly plagued by infectious 
diseases than by noncommunicable ones, and of those, tuberculosis is one of the top three 
that affect these areas [3]. However, there have been numerous efforts put forward for 
detecting tuberculosis using rapid diagnostic tests, and using more specific biomarkers as 
compared to VEGF [3]. However, the effort put forward toward the detection of cancer in 
the developing world is minimal. Yet, numbers of cancer patients have begun to 
skyrocket in recent years and there is a need to help detect this disease with lower cost 
platforms [11, 34]. 
 In particular, VEGF165 has two domains. One is the receptor-binding domain 
(RBD), and the other is the heparin-binding domain (HBD) [29]. All forms of VEGF 
have a receptor-binding domain, but it is VEGF165 that only has the HBD, which 
distinguishes it as an isoform [35]. Commonly the receptor-binding domain of VEGF 
binds to tyrosine kinase receptors and will trigger the cellular pathway that leads to 
angiogenesis [35]. That is why with the development of drugs to treat cancer and macular 
degeneration, antibody fragments are created that bind to the RBD of VEGF to inhibit the 
growth factor from instead binding to cells and creating vessel growth [35].   
Cancer 
Cancer is defined as an uncontrolled growth of abnormal cells in the body. 
Initially, a healthy human cell multiplies when needed for finding sickness, or growth. 
However, the body also knows to regulate the cells that multiplying, and to stop them 
from doing so [36]. However, with cancer, cells continually grow without regulation, and 
very few die. Cancer can occur in almost all organs and tissues within the body. Because 
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there is such a wide array of cancer types, there is not one overall symptom for the 
chronic disease. Additionally, its cause is unknown.  
Currently, cancer is diagnosed in a variety of ways. This spans from taking a 
biopsy of a tumor, to blood tests, bone marrow biopsies, chest x-rays, complete blood 
counts, computed tomography (CT) scans, and magnetic resonance imaging (MRI) scans 
[12, 27, 34, 37]. These diagnostic tools are used depending on the location and type of 
cancer that is suspected.  
Cancer treatments are also varied depending on the type and what stage the cancer 
is in. Cancer is separated into stages I through IV. The higher number implies that the 
tumor has grown larger, or the cancer has spread from the area in which it first appeared 
to other organs. With that said, the main three types of treatment out there currently are 
radiation, chemotherapy, and surgery [12, 27, 34, 37]. These therapies are often 
combined for one patient as well. Note that these treatments are usually costly and not 
widely spread throughout the developing world. 
As previously stated, infectious diseases, particularly HIV, malaria, and 
tuberculosis, plague the developing world [3]. However, much recognition has been 
gained, forming a large-scale effort to diagnose and treat these diseases abroad. There is 
now a growing burden for non-communicable diseases, such as cancer, in low-income 
countries [11, 12, 34, 37]. Yet, health systems in the developing world are designed to 
cope with infectious disease and do not have the resources to deal with chronic care [12]. 
Previously, non-communicable diseases were commonly associated with nations 
that were developed. However, it has been estimated that cancer fatalities are 74.5% in 
low-income countries versus 46.3% in high-income areas [11]. Because of the common 
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misconception that cancer affects developed nations more frequently, only five percent of 
global funds dedicated to cancer research and treatment are used in the developing world 
[12]. On the other hand, it is difficult to come up with treatments in these areas when 
there is no standardization of which to diagnose and treat cancer. Although middle and 
high-income areas have successful plans for approaching cancer, these are not applicable 
in low-income areas due to lack of communication, education, and resources [3]. It is 
interesting to see that worldwide, breast cancer in women and lung and bronchus cancer 
in men have the highest number of estimated deaths [11]. After recognizing the desperate 
need to treat cancer in both the developed and developing world, it is obvious that these 
two seemingly different worlds can coalesce to create one set of affordable, accurate, and 
successful solutions for the treatment of this disease. 
Although detecting VEGF would only imply the possibility of cancer in a patient 
rather than prove it, combining this detection with various other biomarkers in a 
multiplex assay could eventually allow for an alternative, simplistic, and less expensive 
design [36]. Earlier and inexpensive detection of cancer would also allow for efforts 
toward alternative techniques for the treatment of cancer. 
Antibodies 
In present day, antibodies are commonly used to detect proteins in biological 
samples for lateral flow assays [23]. An antibody, or immunoglobulin, in a physiological 
system is used for an immune response [38]. These immunoglobulins are made to 
particularly identify a foreign particulate, called an antigen. As antibodies are typically 
modeled in a Y-shaped formation, the tips of the bifurcated ends are what bind to an 
antigen [38]. This particular binding site on the antibody is what is called a paratope [38].  
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In the field of diagnostics, antibodies are developed from an array of species that 
are directed against very specific antigens. As they are developed, they can be used in an 
array of immunodiagnostic applications such as ELISA, Western blots, 
immunofluorescence, and so on [15, 16, 39]. Up to this point in time, antibodies are the 
main source of detection in lateral flow assays (i.e. a pregnancy test) [23].  
VEGF Antibody  
Anti-VEGF antibody is what specifically binds to VEGF. This monoclonal 
antibody has famous application outside of the human body. Bevacizumab is an anti-
cancer drug that is used to block angiogenesis by inhibiting VEGF-A from stimulating 
vessel growth [40].  
Seeing that this antibody has already been used as a metastatic cancer therapy 
treatment, this implies that VEGF and its monoclonal antibody are important to 
understand and use further in both cancer and diagnostics [40].  
In using anti-VEGF antibody in diagnostics, the biochemistry would be set up 
similarly to an ELISA sandwich assay. What this means is that a sample of VEGF would 
be inputted to the test and combine with a detector particle. In this thesis, the detector 
particle is gold tethered to anti-VEGF antibody. Then, the two would flow down the test 
channel and be captured by another set of anti-VEGF antibodies that are immobilized to 
the test platform. This is illustrated in Figure 6, below. 
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Figure 6: Sandwich ELISA. The demonstration of an immobilized antibody 
on a test platform. A capture antibody is immobilized onto a surface, then a target 
protein in sample and a detector antibody bind, creating a sandwich ELISA [41]. 	  
In other words, the two antibodies (in this case anti-VEGF and anti-VEGF conjugated 
with gold nanoparticle) sandwich the specific molecule, or VEGF, in the middle.  
Aptamers 
Aptamers are defined as oligonucleic acids or peptide molecules that bond to 
compatible biomarkers. This particular thesis will focus on the oligonucleic acids – or 
RNA and DNA strands. They bind to biomarkers in a sample as well as a detector reagent 
in the paper microfluidic chip in order to fluoresce for a positive result [42]. Aptamers 
have many uses in the field of diagnostics, including microarrays, microfluidics, 
sandwich assays, and electrochemical biosensors [29]. 
These manmade DNA or RNA strands were chosen by the disease or diseases that 
the µPad will detect. These coded strands are available in a database called the SELEX 
system [42]. This is a library of single-stranded oligonucleic acids going from the five-
prime end of the sequence to the three-prime end. These linear sequences are targeted in 
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the library until the particular chain regarding the aptamer of interest is selected. Then, 
the aptamer is amplified using polymerase chain reaction (PCR) and makes the double-
helix, reminiscent of a DNA strand. Then through transcription, the double helix is taken 
apart into single strands [42]. Transcription is when DNA unwinds from its helical 
structure and creates a complementary strand, where the tyrosine bases are then created 
as uracil, instead. This makes a since stranded tRNA.  
The central dogma of genetics states that DNA creates RNA through 
transcription, and RNA creates a protein through translation, completing the entire 
synthesis process of the cell’s peptide formation in the body. However, when PCR limits 
the process to only transcription, the single strands want to naturally form interactions 
within its own strand, pairing uracil with adenosine, and cytosine with guanine. This 
interaction will make for an ineffective aptamer, since it will no longer be able to 
appropriately bind with a biomarker in a sample. Therefore, while the strands are still 
being processed, they are incubated with their complemented substance of interest (i.e. 
their biomarker) [42]. They are then tethered to the nitrocellulose using filtration, so it 
creates the tethering effect. This is what will happen when fabricating the µPad. 
Additionally, these strands are tethered onto the paper platform at the control and test line 
[23].  
In many cases, aptamers are a better option than antibodies for diagnostic 
purposes. For one, aptamers can be created completely in vitro using the SELEX process. 
Antibodies, on the other hand, must come from in vivo, which adds to the complication in 
creating and gleaning the antibodies, which brings up the price of the aliquot and lowers 
specificity control by the scientist. In order to produce antibodies, an immune response 
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must be invoked from the physiological system. An aptamer, because it is created entirely 
in vitro, is screened to be very specific for its target protein [43]. And with that high 
control, the binding conditions can be controlled (i.e. salt concentration, temperature, and 
pH) [43].  Additionally, antibodies denature much more easily than an aptamer. 
Antibodies must remain in a specific temperature range and be stored for a very short 
amount of time before denaturation. Aptamers, on the other hand, can maintain their 
integrity over a much larger temperature range and can be stored for a significantly 
longer amount of time [43]. Finally, labeling antibodies can cause a loss in their affinity 
for target molecules, whereas aptamers can be labeled and their binding affinity is not 
compromised [43]. 
VEGF-A 165 Aptamer 
Development of VEGF aptamers has been sought after for an array of uses. An 
RNA aptamer has been developed (Macugen) as a drug that treats age-related macular 
degeneration [28, 29]. However, for this thesis the VEGF-A aptamer is a single stranded 
DNA sequence that is intended to work similarly to an antibody as a capture reagent in a 
lateral flow assay [29]. It is immobilized to the test surface and is intended to identify and 
capture VEGF in sample.  
VEGF-A has many different forms in the human body. There are several 
published aptamer DNA and RNA sequences for anti-VEGF in literature. However, after 
many experiments involving different aptamer sequences, it was seen that the isoform of 
human VEGF165 maintained a strong attachment and provided strong visual signal to this 
28 mer oligonucleotide sequence that acts as anti-VEGF [29]: 
5’ – GCACTCTGTGGGGGTGGACGGGCCGGGT – 3’  
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This oligonucleotide sequence, or aptamer, is known as Vap7. This aptamer-target 
complex has a dissociation constant (KD value) of 20 nM [29]. Copious amounts of 
VEGF165 isoform are seen in cancer patients because it is highly expressed in 
angiogenesis [29]. Therefore, an aptamer that is specific for this isoform would be 
advantageous to use as a capture reagent in detecting cancer biomarkers.  
Unlike an antibody, an aptamer made for VEGF165 can be made to attach to the 
HBD region of the analyte [29, 35]. Therefore, the aptamer sequence provided can attach 
to either the HBD or RBD region of VEGF165, whereas the antibody can only bind to the 
RBD region [35]. In a lateral flow assay, this allows for more opportunity for detection of 
VEGF using aptamers as a capture reagent as compared to antibodies.  
Advantages and Disadvantages 
The subject of paper microfluidics is continually being researched due to the fact 
that the advantages of this disease detection technology far outweigh the disadvantages. 
Yet, there are still problems and improvements that must be made with this concept in 
disease detection technology.  
There are several negatives that pertain to this technology. One con to this 
technology is that the diagnosis is purely qualitative rather than quantitative [3]. There 
are a wide variety of diseases that need quantitative measurement. One example would be 
with cancer diagnosis. Although these chips could detect whether VEGF is present in the 
blood, it is currently only qualitative [3]. A patient might need to know to what degree 
the disease is present. This would allow for those in clinics to see what approach should 
be taken to its treatment or a possible prognosis. Another issue is the lack of time control 
with the device [3]. Once a sample is in contact with the chip, it will wick due to the 
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material properties of the paper with the biological sample itself. This wicking time can 
be controlled to an extent by designing the paper platform using particular calculations 
and equations – however the density of the samples themselves can vary due to water or 
pathogen content. A final issue is possible sensitivity tissues. Some diseases and sample 
types do not have a concentrated amount of a biomarker within the fluid. This diluted 
sample may not have enough biomarkers that enough capture reagents could form a 
complex with in order to signal a positive or negative test [17, 44]. 
There are many advantageous aspects with this type of disease diagnostic device. 
Paper microfluidics is, for one, affordable. The affordability comes in the fact that paper 
is inexpensive, and because its size is so small, numerous samples can be made on a sheet 
of paper. The affordability also comes with the entire fabrication process – where simple 
materials like wax ink, a printer, and a hot plate or oven is used [18]. This removes the 
need for specialized and expensive equipment. Another positive facet of paper 
microfluidics is biosafety. The device can be burned after use and releases no noxious 
chemicals into the environment. Likewise, these µPads eliminate the need for sharps in a 
clinical or laboratory environment. That adds to safety in the diagnosis area so there is no 
exchange of bodily fluids, and inhibits healthcare-related injuries [17]. These devices are 
also storable, because they are commonly the size of a postage stamp. This storability is 
great from the standpoint of shipping and transportation, as well as the fact that its lack of 
bulkiness allows for more room in the clinical area for patient care rather than devices. 
Additionally, storage is important because the devices must maintain their integrity. With 
paper microfluidic devices, reagents and platform materials used typically do not degrade 
or lose sensitivity for long periods of time. Another practicality of this device is that it is 
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inexpensive, meaning that the device can be used by a multitude of people from varying 
socio-economic situations. These devices are simplistic in that they have one inlet for the 
sample, and the device changes color. This color can be interpreted from a chart, or 
possibly interpreted from a pre-programmed algorithm. This allows for minimal training 
of the user of the device and minimizes ambiguity in the results and incorrect diagnosis. 
Finally, this chip is advantageous in that it can be designed for testing multiple diseases at 
once [44]. By attaching multiple types of capture reagents, this can allow for a multitude 
of biomarkers to be detected in a patient sample to help assess the medical issues that 
they are experiencing.  
This thesis presents the development and testing of a paper microfluidic chip. In 
the following section, the methods are presented and discussed. Following, the results are 
reported and analyzed, with the discussion proceeding. Finally, the conclusions and 
future directions that stemmed from this research are considered.  
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Methods 
This thesis comprised of three main components – characterization, development 
of a three-dimensional paper microfluidic chip, and the implementation of biochemistry 
using antibodies and aptamers.  
Characterization 
As indicated in the Introduction, this thesis focuses on the detection of VEGF in 
sample using a paper microfluidic assay with a nitrocellulose-based platform. In order to 
initially start this project, several types of nitrocellulose paper were tested for their ability 
to wick through different designs impregnated onto the paper and its pore size. In order to 
further develop this diagnostic technique, the paper and chip designs needed to be 
analyzed in order to create an optimal chip for detection. 
Channel Widths and Wax Reflow 
Initially it was important to determine the capabilities of the XEROX Phaser 
8560DN/8570 (wax block printer) in regard to its control and spreading of ink on the 
nitrocellulose paper. Although it is known that the wax printer distributes 50 µm to 60 
µm diameter droplets onto paper [21], it was necessary to clarify if the channel widths 
were similar on the paper platform as to the designs created on CAD, or to see if 
spreading of the wax occurred. Therefore, a series of circular and linear patterns were 
developed using SolidWorks. For the circular patterns, a multitude of inner and outer 
radii were designed to create an array of circular channels. Additionally, lines were 
designed that were five centimeters in length with widths of 0.01 µm, 0.03 µm, 0.04 µm, 
0.05 µm, 0.1 µm, 0.5 µm, 1 µm, and 5 µm (these designs may be found in Appendix B). 
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There were many designs that needed to be fabricated and tested in order to 
implement the best channel distances for the most accurate and sensitive disease 
diagnostic devices possible. In Yao Lu’s paper Fabrication and Characterization of 
Paper-Based Microfluidics Prepared in Nitrocellulose Membrane by Wax Printing he 
tested channel widths of 100 µm, 200 µm, 300 µm, 400 µm, 500 µm, and 600 µm. This 
testing can be seen in Figure 7 [45]. He noted that the 200 µm and 100 µm channels were 
too small to allow for the analyte IgG to wick through. However, it was of further interest 
to determine how small the channel could possibly be designed before the liquid sample 
would no longer be able to wick through. Additionally, the paper noted that the minimum 
line thickness for a hydrophobic barrier is 60 µm, which fits within the specifications of 
the XEROX printer (due to its minimum thickness of printing).  
 
Figure 7: Varying Channel Thickness Yao et. Al. Varying channel 
distances (in µm) to find appropriate widths for the wicking of sample. Note that 
the 100 µm and 200 µm channels did not allow for the inputted sample to travel 
through these channels [45]. 
 
This idea was redesigned (to later be printed via the wax printer) to test channel 
thicknesses of 225 µm, 250 µm, 275 µm, and 285 µm. The dimensioned design, 
developed in AutoCAD, can be found in Figure 8. In Figure 9, a dimensionless drawing 
is presented with a black background – where the black represents wax. This was initially 
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printed onto standard 8.5” by 11” printing paper in order to see if the printer was even 
capable of producing these smaller channels, then melted in an oven at 150ºC for thirty 
seconds to see if the wax would reflow and block the small channels. From there, food 
coloring was inputted into the middle circular area to see if it would wick to the four end 
regions.  
	  
Figure 8: Dimensioned Drawing for Channel Thickness. A dimensioned 
drawing to study channel thicknesses of 225 µm, 250 µm, 275 µm and 285 µm as 
a proof-of-concept to see the capability of liquid flowing through small channels 
and to observe possible wax reflow on the membrane itself. 
 
 
Figure 9: Wax representation of Channel Thickness. A representation of 
how a chip containing channel thicknesses of 225 µm, 250 µm, 275 µm and 285 
µm would be printed – where the black area represents what would be printed in 
wax, and the white area would be exposed membrane.  
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Initially, a 0.45 µm pore size roll of nitrocellulose was purchased due to its 
common usage in referenced literature as a paper microfluidic platform. A multitude of 
linear and curved designs that fit onto a 1” by 1” square were designed on AutoCAD and 
then printed onto the nitrocellulose paper using the wax block printer. The designs were 
cut out from the sheet of paper into their outlined squares. The printed wax was then 
impregnated into the paper’s thickness via a hot plate which the chip was placed upon for 
two minutes at 75°C. The same process was replicated onto 4” by 6” bibulous paper 
(chosen due to its ability to dramatically wick fluids). Then, the two paper types were 
exposed to a droplet of water with green dye and its wicking down the channels was 
observed and compared.  
Optimal Channel Characteristics 
Several other pore sizes of nitrocellulose membrane were purchased and used for 
further characterization. Initially, channel thickness was characterized, observing the 
differences between 0.8, 1.6, and 2.4-millimeter channel widths on the same sheet of 
paper. This was done using a nitrocellulose membrane referred to as HF 135. Seven 
designs were created on AutoCAD, printed on the wax block printer, and melted in an 
oven at 150ºC for three minutes. Green food coloring combined with water were inputted 
into the chip and wicking time and visual determinations were made regarding the 
capabilities of channel widths, lengths, and curves. This was used to determine a general 
optimal channel width.  
Design Combinations and Wicking Times 
Further characterization was done in order to understand five topics regarding 
paper microfluidic properties and analyzed their effect on wicking time analyzed by using 
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a multi-way Analysis of Variance on Minitab. The considerations evaluated on two-
dimensional chips were porosity, size, width, curvature, and backing. For each of these 
factors, two categorical levels were examined (creating 25 or 32 combinations) in order to 
see the final wicking time. Two categorical levels intends that there are two factors being 
looked at – i.e. if the paper has more porous or less porous, a narrower channel width or a 
wider channel width, and so on. A faster wicking time would lead to a faster diagnosis for 
disease in a lateral flow assay. However, if the wicking time were too fast, this would not 
allow for a sensitive enough detection of VEGF in a sample, because the capture reagent 
would not have a sufficient amount of time to bind to VEGF in sample. Therefore, the 
results generated the factor level combinations desired for the most optimal wicking 
times was analyzed with a 10% overall significance level. An Analysis-of-Variance 
(ANOVA) statistical method was done in order to analyze the five different 
characteristics and their wicking time through a two-dimensional platform.  
Two-dimensional nitrocellulose chips were designed and fabricated in a variety of 
ways for the purpose of fulfilling this project. In this project, the experimental units were 
the chips and the response was the amount of time it took for an inputted amount of dyed 
water to wick through the entire chip. This test was a five-factor completely randomized 
design. The five factors (porosity, size, width, backing, curving) at two levels each 
allowed for 32 possible treatments for this project. The first factor, porosity, was a 
categorical treatment where the levels were, “hi” and “lo”. Nitrocellulose paper’s 
porosity is described by Millipore through its capillary flow time (measured in seconds 
for the liquid to travel 4 centimeters). Therefore a higher number describes a longer time 
it takes for a solvent to wick through the paper, intending lower porosity. Therefore, “hi” 
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described the HF (high flow) 135 membrane paper (less porous) and “lo” described the 
HF 75 membrane paper (more porous) for non-backed nitrocellulose membrane. 
However, unbacked membranes were also analyzed, and in that case “hi” described the 
HF 180 membrane paper and “lo” described the HF 135 membrane paper. The next factor 
was referred to as size. Size implies the overall length of the channel of the chip. In this 
project, the lengths of this chip were “long” or “short” where long was a 63 millimeter 
length channel, and short was 31.5 millimeters. Additionally, the curving factor was 
whether the channel was designed linearly or as a single curve. Likewise, the backing 
factor was whether the nitrocellulose stood alone or was adhered to a plastic film on one 
side. Finally, width took into account whether the channel was 1.6 millimeters (narrow) 
or 3.2 millimeters wide (wide). All of these factors are categorical and the response was 
qualitative. This allowed for a multi-way analysis of variance in order to analyze how the 
five factors (and their interactions) affect the time it takes for the dyed solvent to wick 
through the chip.  
Two replicates were completed per combination and all the tests were completed 
in a random order. The order in which these treatments were randomly assigned was by 
inputting the thirty-two different combinations into Microsoft Excel on two separate 
spreadsheets. The five treatments were inputted into separate columns and the thirty-two 
different combinations were inserted. In a sixth column the function “rand()” was 
implemented for all thirty-two adjacent rows. Following that, all of the data in the six 
columns were selected and the “Sort A-Z” command was chosen in order to randomly 
assign the treatments. These randomized data entries are listed in Appendix A. 
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All thirty-two combinations of chips were designed using AutoCAD and printed 
on a Xerox 8560DN wax-block printer. This printer deposited wax onto the paper 
(similar to an inkjet printer). These chips were then placed in an oven at 150˚C for three 
minutes. This allowed the wax to fully impregnate the chip and create hydrophobic 
barriers around the channel. This is so the fluid is forced down the channel when it is 
introduced to the chip. The chips were then removed from the oven and allowed to cool 
at room temperature for several minutes. The experimental order followed the random 
order displayed in the designed Excel document. In order to see the movement of the 
liquid through the chip, a combination of green food coloring and distilled water were 
combined to make an opaque solution. The liquid would then be captured using a dropper 
and placed onto the input channel of the chip. From the moment that the dye drop was 
released was when the stopwatch to measure time was started. The end point to evaluate 
wicking time was when the dye reached the very end of the chip and all of the exposed 
(non-waxed filled) nitrocellulose had the dye wick through its entirety. Time was 
measured in seconds.  
The ANOVA test was run using the general linear model in Minitab, a statistical 
analysis computer program. Since there were two replicates done during experimentation, 
all of the relevant interactions between the five factors were analyzed.  Once the general 
linear model ANOVA test was selected in Minitab, the following specifications were 
selected: 
• Response: Time 
• Predictors: Backing, Curving, Porosity, Size, Width (and all possible interactions 
indicated using the ‘!’) 
• Four-in-One Residual Plot 
• Cook’s Distance 
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The four assumptions that were considered when analyzing the data were normality, 
constant variance, independence, and model adequacy. These four assumptions are 
commonly analyzed in statistics in order to determine the viability of the test results in 
order to see if the response of the test result is significant. This thirty-two combination 
chip experiment was repeated twice and all results were analyzed.  
Wicking Time – Conjugate Pad vs. Membrane Paper 
Additionally, further characterization was done involving wicking time. Four 
simple linear channels were designed that involved using a conjugate pad versus four that 
had none at all. The drawing of these four channels with and without conjugate pads may 
be found in Figure 10. These were designed once again in AutoCAD and printed on the 
XEROX 8560DN printer and melted in the oven for three minutes at 150ºC. This step 
was taken in order to see how the conjugate pad affected the time difference for 
detection. This step was further analyzed for time differences when a three-dimensional 
chip was designed as well. By recording the wicking time in the two experiments, 
standard deviations and average times were calculated. This showed if there was or was 
not a major difference between different conjugate pads or different parts of a 
nitrocellulose membrane. From there a two-tailed t-test was performed to compare the 
experiments in order to see if there was a significant difference in time between using and 
not using a conjugate pad.  
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Figure 10: Conjugate Pad vs. No Pad. Designs of two experiments 
containing channels comparing the time it takes for liquid to flow from one side 
to another. The left involved no conjugate pad and the right was of the one with a 
conjugate pad. 
 
Imaging 
Paper was also analyzed visually in order to see how nitrocellulose paper looked 
at extremely different pore sizes and when it was impregnated with the wax ink. This was 
done using a tabletop Hitachi scattering electron microscope (SEM). Initially, a small 
piece of 0.45 µm pore size nitrocellulose was placed onto a small podium and adhered 
using double sticky back tape. In was then measured that the sample sat at a one-
millimeter distance away from the reader of the SEM. It was then placed into the SEM 
and the device was turned on. When using the SEM it pulled a vacuum and the sample 
was left uninterrupted until the machine was fully turned off. SEM images were taken at 
an area of different objectives (which will be demonstrated in the Results and 
Conclusions sections). This was also repeated for a piece of nitrocellulose that had both 
wax and did not have wax in order to determine if a difference could be seen at the seam, 
using the HF 135 membrane. Images simply with and without wax were also imaged 
using the HF 135 membrane.  
Development of a Three-Dimensional Paper Microfluidic Chip 
A three-dimensional paper microfluidic chip was designed in order to create a 
diagnostic that would allow for a simultaneous detection. If a single biological sample 
	  39 	  
were inputted into a three dimensional chip, it would be routed into a series of separate 
channels containing different analytes that could bind to different proteins found in a raw 
sample. Then, as the sample reached the final layer of the chip, there would be several 
regions that would provide visual signal simultaneously to determine if a sample were 
positive or negative for containing particular biomarkers. This chip was designed to have 
four detection regions in order to prove simultaneous detection of a paper microfluidic 
device could be created. In order to do this, on the bottom, or base layer, was designed in 
order to input a fluid sample and separate it into four equal channels that would provide 
equal sample amounts into the chip, and eventually for wicking up into the detection 
region.  All path lengths that the sample would wick through were equal in order to allow 
for simulatenous detection. 
Membrane Design and Development 
Each nitrocellulose paper layer was designed in AutoCAD and printed using a 
Xerox 8570, as well as a XEROX 8560DN printer. This printer, rather than using ink, 
melts different colored wax blocks and deposits them onto the paper where the wax 
quickly dries, being exposed to a much colder room temperature. Both backed and 
unbacked nitrocellulose paper were printed onto. Backed nitrocellulose (meaning that the 
nitrocellulose paper had a plastic film adhered to its surface) was directly fed through the 
printer after being cut to size (due to the fact that the paper does not appropriately fit into 
the printer). Unbacked nitrocellulose, in this thesis, was taped down on all four sides onto 
4” by 6” bibulous paper and fed through the printer then the outlines of each chip were 
cut out from the overall piece of nitrocellulose. Post-printing, the paper with the designs 
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were placed into an oven at 150°C for three minutes (or until the wax fully impregnated 
the paper). They were then removed and allowed to cool at room temperature.  
There were four main designs that were developed and fully tested in this thesis 
project. All were ideas that attempted to carry out simultaneous detection of a single 
sample at four detection wells. Additional designs that were not tested may be found in 
Appendix B. The first two designs tested were essentially the same. The base layer is the 
location in which sample is inputted. The only difference between the first and the second 
design are that the base layer is extended in the second design from the first. The first 
design can be seen in Figure 11 and the second in Figure 12, where the designs with the 
white background represent the nitrocellulose membrane layers embedded with wax, and 
the designs with the black background represent the laser cut double-sided tape.  
 
Figure 11: Design Iteration 1. Three-dimensional paper microfluidic chip 
design where the white background layers represent the nitrocellulose membrane 
embedded in wax and the back background layers are pieces of laser cut double-
sided tape. The layer assembly goes from left to right where the initial piece 
remains on the bottom and works its way upward.  
 
 
Figure 12: Design Iteration 2. White background layers represent the 
nitrocellulose membrane pieces embedded in wax and the back background 
layers are pieces of laser cut double-sided tape. The layer assembly goes from 
left to right.  
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A third design was developed in AutoCAD and also assembled and tested as a chip 
for simultaneous detection of sample. In this case there are only three layers of 
nitrocellulose membrane as opposed to the first two designs that had four layers. This 
design layout can be seen in Figure 13.  
 
Figure 13: Design Iteration 3. Sample is inputted on the layer to the far left 
and works its way up to the detection layer as seen on the far right. The layers 
containing white background represent nitrocellulose membrane with wax and 
those with black background are laser cut tape layers. 
 
The fourth and final chip tested for simultaneous detection can be found in Figure 14.  
 
 
Figure 14: Design Iteration 4. The layers containing white background 
represent nitrocellulose membrane embedded in wax and those with black 
background are laser cut tape layers, and are assembled from left to right. 
 
Tape Development 
Additionally, layers of tape were designed in AutoCAD. These were then 
implemented onto a computer that controlled a laser cutter and would read the design and 
implement it. Laser cutters commonly read AutoCAD designs in red, so the layers were 
set to that color in order for it to cut out the shapes that were designed. Like using a 
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regular printer, the designs were “printed.” The laser cutter settings were to cut 0.5 
millimeter thick mylar. Each process was done twice to ensure the entire width of the 
tape was cut through. The tape itself was double-sided and provided with one side 
covered in a waxy layer. The other exposed tape side, while being laser cut, was covered 
with a Reynold’s parchment paper. This tape was placed into the laser cutter and taped 
down using masking tape, in order to ensure level cutting on the tape, as a vent which 
provides air into the apparatus, will not make the sample move around in the machine. 
Bridging Layer 
In order to have an inputted sample wick through the layers of the chip, a bridging 
layer was developed. Initially, a powder layer was designed using pure acetone and 
unbacked nitrocellulose paper. This initial powder procedure looked at using both the 
0.45 µm pore size paper and the HF 135 or HF 180 membrane. This mixture was ground 
using a mortar and pestal and dried on bibulous paper. A second powder mixture was 
made using distilled water and nitrocellulose paper, grinding the mixture until paper was 
formed, and once again dried on bibulous. A third powder was developed solely using 
water and nitrocellulose membrane and grinding it into a powder. While still somewhat 
damp, it was placed onto the nitrocellulose membrane and molded into its necessary 
shape. Finally, a fourth powder was created by placing nitrocellulose paper into a beaker 
and saturating it in distilled water and allowing it to freeze overnight at -20ºC. The next 
morning it was removed and ground using a mortar and pestal. This procedure was 
repeated for several nights until the grains were small enough to be considered a powder 
(less than 1 mm in size). A lacquer was also considered, where the nitrocellulose paper 
was once again ground with a mortar and pestal with nail polish remover from the 
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grocery store (containing 99% acetone). Finally, a pure paper layer was considered for 
the final device, where, for this thesis, small pieces of nitrocellulose were cut using 
scissors, an Xacto-knife, or a small specialized hole punch into a similar shape of the 
design of the chip, where the liquid would be expected to transfer between layers.   
Conjugate Pads 
Four conjugate pads were prepared from strips of fiberglass provided by 
Millipore. They were cut out as equally as possible in order to aid in providing 
consistency between the four channels. For the purpose of providing a visual signal as to 
prove or disprove the possibility of simultaneous detection of a three-dimensional paper 
microfluidic chip, the conjugate pads were dyed using green food coloring. When a water 
sample was placed into the input of the chip, it would reach the conjugate pad and not 
only show green dye at the end for a visual, but prove the use of a conjugate pad. After 
cutting out the conjugate pad, the pieces had one to two drops of food coloring on their 
surface and allowed to absorb as they were placed in plastic weigh boats. They were then 
kept out to dry.  
Chip Assembly 
The tape, bridging layer, backed and unbacked paper layers, and conjugate pad 
were then placed together to manufacture a chip without any additional biochemistry. 
This was in order to solely study the workability of a three-dimensional chip before doing 
detection. Both the tape and the paper had small circles designed in two opposing corners 
in order to help with alignment. The bottom, backed layer had tape placed on top of it. 
While the other side of the tape is still covered with a backing, the bridging layer was 
carefully placed in the openings of the cut out tape using tweezers, then the next layer of 
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nitrocellulose, this time unbacked, was placed on top. For the layer that needed a 
conjugate pad, these were placed in their appropriate location with tweezers with the 
double-sided tape placed on top in order to provide permanent placement of the conjugate 
pad onto the paper. As the final layer of nitrocellulose is placed on top, a final layer of 
tape is placed on top, with a fit-to-size clear transparency as the last layer of the chip. 
This helps to protect the detection layer of the nitrocellulose while still being able to 
visualize if any detection has been made. Additionally, between the tape and the 
membrane on the final layer, an absorbent pad was placed at the test’s end to soak up any 
excess sample and prevent backflow of the sample in the test.  
A conceptual alignment tool was designed on Solidworks where one could align 
the layers of tape and paper on a podium with press fit standard size sewing needles 
guiding the alignment of the previously drawn holes onto the designed paper and tape. 
The podium can be rapid prototyped using stereo lithography or fused depositon 
modeling.  
Testing of Three-Dimensional Chip 
The chip was then tested to see wicking time to the detection region and the 
difference in time it took for each of the four regions. Water was inputted from a syringe 
until the input sample pad was filled, and the time on a stopwatch was started. Then, 
when the green dye could be seen at the detection region, the time was stopped and 
recorded.  
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Biochemistry   
A paper microfluidic chip contains both detector and capture reagents. Detector 
reagents comprise of an antibody conjugated with a nanoparticle of some sort, that when 
aggregated together produce a visual signal. These can be done with fluorophores, latex 
beads, magnetic beads, and in this particular case, gold colloidal particles [23]. Capture 
reagents are molecules that capture sample and are immobilized onto the membrane of 
the test chip. In this experiment, capture reagents are both antibodies and aptamers, which 
are being compared. All calculations for dilutions provided in the procedure may be 
found in Appendix D.  
Conjugating Gold to Antibodies 
Initially, 15 nanometer gold colloidal particles were purchased for conjugating to 
a mouse monoclonal anti-VEGF antibody that was reactive with human VEGF. This 
conjugation was done by initially diluting the antibody to a concentration of 20 µg/ml 
with phosphate buffered saline (PBS). The antibody was then placed in a buffer 
containng sodium tetraborate and 10e11 gold particles per milliliter at a pH of 8.5 [46-48]. 
The antibodies and buffer were combined and settled together for thirty minutes [46].  
A nitrocellulose membrane-based chip was designed on AutoCAD and printed on 
a wax block printer and melted at 150ºC for 3 minutes. This design can be found in 
Figure 15. This design had a sample input, where the VEGF would be pipetted into the 
device (labeled as 4 in Figure 15). Next (number 3 in Figure 15) a wax barrier was 
designed. In this area a conjugate pad containing gold-conjugated antibodies were placed. 
In theory, the VEGF sample in buffer would rehydrate anti-VEGF antibodies and 
together would wick through the rest of the chip to a detection area (number 2 in Figure 
15). In this initial design, the detection area was one well where both the detection and 
	  46 	  
control line were to be spotted down (anti-VEGF antibody and IgG). Finally, this led up 
to an absorbent well (number 1 in Figure 15) that would draw in excess sample from the 
input, and have an absorbent pad (made of cellulose Whatman paper). This prevented 
backflow of sample through the chip, hindering the possibility of inaccurate results. 
 
Figure 15: Small Square Biochemistry Chip. Initial 2D chip used for 
detection of VEGF where gold was experimentally conjugated to anti-VEGF 
antibodies. (1) the absorbent region; (2) is the detection region; (3) wax barrier; 
(4) the sample input region. 
 
The detection antibody, a monoclonal anti-VEGF, was reconstituted from its 
lyophilized form using 1 milliliter of distilled water in order to yield a concentration of 1 
mg/ml. Part of the sample was further removed in order to create a concentration of 20 
µg/ml for conjugating with gold. Then, 1 µl of the original 1 mg/ml sample was spotted 
onto the nitrocellulose membrane in the detection well.  
During the incubation time, the antibodies for the control line were prepared using 
rabbit anti-mouse IgG (immunoglobulin G) antibody, purchased from Thermo-Scientific. 
These antibodies were chosen as a control line antibody because their specificity allowed 
for them to capture the anti-VEGF antibody purchased for the test. The IgG that was 
attached to the paper would bind to the Fc region of the anti-VEGF antibody, so whether 
or not a sample contained VEGF, this region would tell the user that the test was run 
appropriately and nothing was detected, meaning there was no error with the detector 
particle (i.e. the anti-VEGF antibody and gold). A rabbit anti-mouse IgG was chosen for 
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the control line because the anti-VEGF antibody was from a mouse. This meant that the 
IgG would have an affinity to bind to any mouse-based antibody at the Fc region.  
The IgG antibody was diluted to a 1 mg/ml concentration using a mixture of 0.25 
M sodium chloride (NaCl) and 0.5 M sodium phosphate dibasic solution (Na2HPO4). 
These reagents were also diluted from stock using deionized water. The NaCl solution 
was measured out to 1.461 g using a scale, and mixed with 100 ml deionized water. Then, 
2 milliliters of Na2HPO4 solution was added. Its pH was measured using pH strips to 
ensure a value of 7.4. 2.4 microliters of this buffer was removed and 0.01 mL of IgG 
antibody was combined with it into a sterile conical tube. 1 µl of this solution was 
pipetted onto the nitrocellulose membrane in the detection well, along with the anti-
VEGF antibody. Both were allowed to dry by covering the membrane and leaving out at 
room temperature for two hours.  
After drying, the membrane was placed in 5% bovine serum albumin (BSA) that was 
reconstituted from powder form using 5 grams of the BSA with 100 ml of phosphate 
buffered saline (PBS) for ten minutes. This was in order to block any bare areas of the 
membrane to remove any chance of non-specific binding from detector particles to the 
paper.  
The anti-VEGF antibody that was being conjugated to the 15 nanometer gold was 
then used for the conjugate pad. This solution was spotted onto a piece of 3 millimeter by 
1 millimeter fiberglass membrane using a pipette, until the pad was entirely saturated at 
around 8 µl. It was then allowed to dry in a six-well plate for an hour at room 
temperature.  
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The conjugate pad and a fiberglass absorbent pad were placed down onto the 
designed nitrocellulose chip. Tape was placed on top of the entire chip with the exception 
of the area containing the sample input. This created a positive pressure to allow easier 
bridging between the paper and fiberglass pads for the VEGF sample. Then, a cut piece 
of polyethylene transparency (from Staples) was placed on top of the exposed double-
sided tape.  
20 µL of 0.17 µg/ul recombinant human VEGF 165 was pipetted into the input of 
the chip. Then the test was allowed to run and signified its finish as the absorbent pad 
began to soak up the excess sample in the test. A table demonstrating the concentrations 
and volumes associated with this test may be found in Table 1. 
Table I: Conjugating Gold to Antibody Concentrations 
 Volumes and Concentrations of Antibodies and VEGF Used in the development of a two-
dimensional lateral flow assay where gold was conjugated to the detection particle. 
Antibody  Volume 
of 
Antibody 
Concentration 
of Antibody 
VEGF 
Volume 
VEGF 
Concentration 
Gold 
Volume 
Gold 
Concentration 
IgG 1 µL 1 mg/ml 20 µL 0.17 µg/ul 8 µL 20 µg/ml 
VEGF 1 µL 1 mg/ml 20 µL 0.17 µg/ul 8 µL 20 µg/ml 
 
Monoclonal Antibody Detection   
Following the gold-antibody conjugation experiments, additional monoclonal 
anti-VEGF antibodies were purchased that previously were conjugated to 30 nanometer 
gold particles. 30 to 50 nanometer gold particles sizes are frequently used in lateral flow 
assays [47-49]. This detector particle was purchased from BIOSS-USA. The antibody 
was conjugated to gold upon purchase in its fragment crystallizable (Fc) region. Its 
immunogen sequence is: 
PQTCKCSCKNT 158-168/191 [50] 
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The letter sequence provided is representative of the amino acids between numbers 158 
and 168 of a 191 total letter sequence.  This means as the antibody is exposed to the 
VEGF signal protein, it will attach to a particular area of the protein, and no longer allow 
for any other antibodies to bind to this region. This provided immunogen sequence was 
run to see its specificity of attachment to different proteins using a Basic Local 
Alignment Search Tool (BLAST) [50, 51]. A BLAST finds regions of similarity between 
biological sequences, whether it is through analyzing a nucleotide or protein sequence. 
Using a protein BLAST, the given sequence was entered, and run through a database, 
which produced proteins with sequences that had significant and less than significant 
alignment with the particular antibody or protein of interest. Significance is defined as the 
closer the protein’s E-value (Expect-value) is to zero [51]. An E-value is defined as, “a 
parameter that describes the number of hits one can "expect" to see by chance when 
searching a database of a particular size. It decreases exponentially as the Score (S) of the 
match increases. Essentially, the E value describes the random background noise. For 
example, an E value of 1 assigned to a hit can be interpreted as meaning that in a 
database of the current size one might expect to see 1 match with a similar score simply 
by chance” [51].  When a BLAST was run, one significant match was human VEGF165 
isoform, which was the particle that the experiment was designed to detect. Therefore, it 
was appropriate to proceed using this antibody as a detector particle in the experiment. 
Further step-by-step instructions on the usage of BLAST may be found in Appendix E. 
The initial antibody that was used as a capture reagent was identical to the VEGF 
antibody purchased from BIOSS-USA, but without conjugated gold nanoparticles.  
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To place antibodies at the detection line, a spotting technique (known as a spot 
blot) was used. Initially, the lyophilized VEGF antibodies were reconstituted using 1X 
PBS. Their concentrations, for both gold conjugated and no gold, were kept at 1 mg/ml. 
However, according to literature the gold conjugated antibody was also diluted to a 
concentration of 10 µg/ml to test as well [52]. Dilution calculations for these antibodies 
may be found in Appendix D. A fine tip pipette was filled with 2 µL of the non-
conjugated VEGF antibody and a line was slowly drawn across the membrane in its 
appropriately designed well in for its application. Additionally, 2 µL of IgG was 
deposited in a detection well (see instructions for using IgG in the Conjugating Gold to 
Antibodies section in the Methods). These were dried at both room temperature and in an 
oven at 37ºC for two hours. Also, of these, half were incubated in 1% BSA (fully 
submerged) for 7 minutes and washed in 0.05% SDS and 2 mM Na2HPO4 solution for 10 
minutes. 
In this experiment, several designs were produced using AutoCAD. Unlike the 
design that was developed for conjugating gold to antibodies, this design had two wells 
instead of one and the detection regions were made much larger to help aid in 
visualization by the user for detection. The purpose of the two wells was to allow for 
further separation the IgG and anti-VEGF detection antibodies on the membrane. Two 
different channel widths (2.4 millimeters and 1.2 millimeters) were tested in order to see 
if this made any significant differences in detection signal from the gold. These two 
designs may be seen in Figure 16 and Figure 17.  
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Figure 16: Large Square Well Biochemistry Chip. 2D chip used for 
detecting VEGF with 30 nanometer gold particle and a channel width of 2.4 
millimeters. (1) Absorbent region; (2) control region; (3) the detection region; (4) 
wax barrier; (5) the sample input region. 
 
 
Figure 17: Large Square Well Biochemistry Chip Iteration 2. 2D chip 
used for detecting VEGF with 30 nanometer gold particle and a channel width of 
1.2 millimeters. (1) Absorbent region; (2) control region; (3) the detection region; 
(4) wax barrier; (5) the sample input region. 
 
Commonly wicking of the capture reagents would take place to a point that the 
antibodies in one well would travel to another detection well of the design. This could 
add to erroneous results, so a third iteration of the design was developed in order to help 
limit the travel of liquid from one area to another. Wax barriers were printed between the 
wells so that when antibodies were placed down on the nitrocellulose surface, they could 
not wick. From there, a set of “jumpers” were developed, which involved small hand cut 
pieces of unbacked nitrocellulose membrane. Therefore, as a VEGF sample would travel 
from the input region down the 2.4 millimeter channel, it would reach the nitrocellulose 
jumper and wick onto it and through it, into the detection wells. The ability for the VEGF 
sample to transfer from the base membrane to the jumper and back into the detection well 
was aided by positive pressure provided by double-sided tape that was laid on top of and 
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pressed down upon the chip’s apparatus, and covered with an optically clear transparency 
for viewing purposes. The AutoCAD design of this concept may be found in Figure 18.  
 
Figure 18: Jumper Design Biochemistry Chip. 2D chip used for detecting 
VEGF in sample where with 30 nanometer gold particle and a channel width of 
2.4 millimeters. (1) Absorbent region; (2) jumper wax barrier; (3) control region; 
(4) detection region; (5) wax barrier for conjugate pad; (6) the sample input 
region. 
 
Additionally, with the procedure stated above for the monoclonal antibodies, 
different combinations of the washes and post-treatments, as well as time taken for those 
procedures were varied in order to see if there was an optimal combination to yield the 
strongest signal for detection of VEGF. These combinations of each test may be found in 
Table II (for anti-VEGF) and Table III (for IgG). To note, many of these tests show 
repeated post-treatments and washes of the membrane, however these tests also 
incorporated other combinations of treatments with the information provided in Table II 
and III, which will be explained further. 
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Table II: Post-treatment and Washes for Monoclonal anti-VEGF Antibody 
Capture antibody anti-VEGF and the respective post-treatments and washes that were 
tested in order to find the optimal combination that yielded the strongest signal for VEGF 
detection. 
Capture Antibody: Anti-VEGF 
Test Post-Treatment Wash 
1 None None 
2 
1% BSA for 10 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 7 min 
3 None None 
4 None None 
5 
1% BSA for 12 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 11 min 
6 
1% BSA for 10 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 7 min 
7 
1% BSA for 10 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 7 min 
8 
1% BSA for 11 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 11 min 
9 
1% BSA for 11 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 11 min 
10 
1% BSA for 10 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 11 min 
11 
1% BSA for 10 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 11 min 
 
Table III: Post-Treatment and Washes for IgG Antibody 
 Capture antibody IgG and the respective post-treatments and washes that were tested in 
order to find the optimal combination that yielded the strongest signal for VEGF 
detection 
Capture Antibody: IgG 
Test Post-Treatment Wash 
1 None None 
2 
1% BSA for 10 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 7 min 
3 None None 
4 None None 
5 
1% BSA for 12 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 11 min 
6 
1% BSA for 10 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 7 min 
7 
1% BSA for 10 minutes 
0.05% SDS / 5 mM 
Na2HPO4 for 7 min 
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Other things that were varied included if the test was a lateral flow assay, or 
purely a spot test. A spot test was where the capture antibody was immobilized to the 
nitrocellulose membrane, the VEGF sample was spotted on top of it, and then the gold 
conjugated antibody was spotted on top of that. This was tested in compare signal 
strength to that of a lateral flow assay. A spot test was hypothesized to show a stronger 
visual signal, as reagent would not be lost through the channels of the device. 
Additionally, in some scenarios a conjugate pad containing gold colloidal particle 
with the antibody was used, and in other cases that detector particle was combined with 
VEGF and together was inputted into the test and run – in which case there was also a 
slight design alteration for the chip itself. In the lateral scenario, there was no conjugate 
pad used. This was in order to see if the conjugate pad aided in or hindered signal 
strength in detection.  
Likewise, drying the membrane and/or the conjugate pad via an oven for two 
hours at 37ºC or room temperature for one to two hours was also done. In literature, both 
have been used and aided in providing explanation for the results. A representation of 
these combinations and tests that were mentioned can be found in Appendix F.  
Polyclonal Antibody Detection 
The next anti-VEGF antibody used as a capture reagent was a polyclonal anti-
VEGF antibody. In general, most epitopes have not been mapped that are validated for 
use in ELISA or sandwich ELISA assays using human sample (in this case human 
VEGF165 isoform). Because of this, it was important to use an antibody that was raised 
against the full length of the VEGF protein. This was to ensure that it would be able to 
detect epitopes that are not blocked by the detection antibody, explained previously.  It 
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was discovered that when the same immunogen sequence was of use for both antibodies, 
this would create a competitive attachment between the antibodies in the detection and 
capture regions, and no signal would be found in the test. Therefore, this full sequence 
polyclonal anti-VEGF antibody from Abcam was used for the next set of experiments.  
The capture region for the detection line of the experiment was designed as a 
sandwich ELISA. This means, as explained in the Introduction, the capture antibody 
(polyclonal anti-VEGF) is tethered down to the nitrocellulose paper, while the inputted 
VEGF sample and anti-VEGF antibody run through the test. As they reach the detection 
region, the tethered antibody attaches to one region of the VEGF and the detector 
antibody conjugated to gold attaches to a separate, and specified, region of the VEGF 
sample. This entire apparatus looks like a “sandwich” as the sample is wedged between 
two antibodies. 
A control line was no longer viable at this point of the experiment. As with 
before, the previous IgG that was purchased was a rabbit anti-mouse antibody. Due to the 
change in purchased antibodies, the only available conjugated gold anti-VEGF antibody 
in this experiment was an anti-rabbit formulation. This confliction removes the ability of 
the antibodies to bind to one another because they would either have to be rabbit and anti-
rabbit, or mouse and anti-mouse. Therefore, this set of experiments removed the ability 
for use of a control line.  
As previously, the gold conjugated anti-VEGF antibody was diluted to a 
concentration of 1 mg/ml.  This time when being diluted, distilled water was used rather 
than phosphate buffered saline (either can be used). Prior to the addition of the distilled 
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water, its pH was checked to be around 7.4. When the pH was not around this range, 
buffers were added and pH strips were used in order to ensure correct a correct level.  
Instead of spot blotting the designed nitrocellulose chip in free-form, designs were 
implemented to spot a unique pattern onto the chip’s surface. A design was laser cut into 
a standard transparency, made from cellulose acetate. This transparency design was used 
as a grid that aided in maintaining a consistent application of antibody onto the two-
dimensional nitrocellulose chip. An “X” shape design was implemented using AutoCAD, 
for the area in which the capture reagent would be applied on the chip (this can be found 
in Figure 19). This design was chosen alternatively to a dot or a line in order to allow for 
visual detection of a distinct shape. The settings for the laser cutter were set to mylar with 
a 0.05 inch depth for cutting. The end result of the laser cut transparency may be found in 
Figure 20. With these “X” shaped designs, more two-dimensional nitrocellulose chips 
were developed in AutoCAD. Unlike with previous designs, the detection regions were 
rounded as opposed to square in order to limit dead area for the colloidal gold or VEGF 
sample to congregate. Two designs were developed in order to see if there were any 
differences in detection signal strength as opposed to size of the chip and channel 
distance. These designs are further described in Figures 21.  
 
Figure 19: X-Shaped Transparency. Design of “X” shaped transparency to 
use as a striper pattern in order to lay down capture reagents onto the 2D paper 
microfluidic chip. 
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Figure 20: Laser Cut X-Shaped Transparency. “X” shaped transparency 
made of cellulose acetate post-laser cutting to use as a striper pattern for capture 
reagents. 
 
 
Figure 21: Labeled Circular 2D Chips for Biochemistry. 2D chips used 
for detecting VEGF in sample where with 30 nanometer gold particle and a 
channel width of 2.4 millimeters. (1) Sample input region; (2) wax barrier; (3) 
the detection region; (4) the absorbent region. 
 
This design was laid over the top of the nitrocellulose chip and 3 µL of the 
capture antibody solution was spotted onto the paper, following the X-shaped pattern. 
The spotted solution was dried by placing the nitrocellulose chips in the oven for two 
hours at 37ºC. The chip was removed from the oven and entirely submerged in 1% BSA 
for 7 minutes time. It was then “washed” – i.e. completely submerged – in a 0.05% SDS 
and 0.5 M Na2HPO4 for 10 minutes. The chips were then dried at room temperature for 
an hour.  
In the meantime, a conjugate pad was prepared to place the anti-VEGF antibodies 
with gold on. The fiberglass pads were cut to a size of 5 millimeters by 2 millimeters. 
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They were pretreated by being dipped in a solution of 1% sucrose and 2 mM borate 
solution and allowed to dry at room temperature for about an hour’s time. The conjugate 
pads were then submerged in the diluted gold-antibody solution and dried on a non-
wicking surface (i.e. a 6-well plate made from polycarbonate) at 37ºC for two hours. 
Additionally, 20 µL of VEGF 165 signal protein and 10 µL were added together into a 
conical tube, vortexed for 30 seconds, and allowed to incubate at room temperature for 20 
minutes.  
The chips were assembled by placing down the prepared conjugate pad down on 
the chip and the cellulose Whatman absorbent pad at their appropriate locations and 
taping them down onto the nitrocellulose chip. This promotes positive pressure to allow 
for a better bridge that the VEGF sample can bridge between the nitrocellulose and 
conjugate pad. Then, a cut-to-size transparency is placed on top of the tape in order to 
allow the experiment to be viewed, but to remove the double-sided tape from sticking to 
any other surfaces.  
Three tests were conducted. The initial test served as a control. A sample of pure 
PBS with no trace of VEGF was inputted into the chip and allowed to run through the 
conjugate pad and to the detection region. If a band of colloidal gold could be seen, then 
the test would have a false positive, and if there was no band, that means that the test 
would have run appropriately to show no VEGF was detected. The second test that was 
run was the incubated sample of VEGF and anti-VEGF gold conjugated antibody. The 
entire 120 µL solution was inputted into the chip and the test was allowed to run and see 
if there was detection of VEGF. If the band appeared, this would mean that the reagent 
was detected, and if not that means an error was made in the procedure (see the Results 
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section for possibilities of error). Additionally, the solution was commonly followed by 
inputting PBS in order to push the sample entirely through the test – known as a pulse 
chase assay. The design for the first and second tests are somewhat altered from the 
design seen in Figure 20, and can be found in Appendix C. The third experiment involved 
pipetting a sample of VEGF into the chip and having it wick through the treated 
conjugate pad, and to run through the test. This addition of the conjugate pad would 
allow for the paper microfluidic chip to closely follow a lateral flow assay found on the 
market. However, if it did not work it would allow for further investigation on the 
improvement for a conjugate pad containing gold and antibodies, as many errors arise 
with this portion of the test. 
Further calculations were completed in order to determine optimal concentrations 
to use in this experiment. Initially, an experiment was conducted in order to determine the 
lowest concentration of gold conjugated antibody that would allow for optimal 
visualization by naked eye. A design was created in AutoCAD that had six wells (as a 
circular shape) that were two-millimeters in diameter. Six concentrations were prepared 
(1 mg/ml, 0.5 mg/ml, 0.1 mg/ml, 0.05 mg/ml, 0.01 mg/ml, and 0.002 mg/ml) and 3 
microliters from each were pipetted and deposited into their corresponding well. The 
wells were analyzed for the opacity of color created from the gold, and the lowest 
concentration that provided noticeable color was chosen. From there, that concentration 
along with the molecular weight of the antibody (4.50 x 10-4 grams/mole) was used in 
order to determine the molar concentration of the gold conjugated antibody (this is 
demonstrated in Equation 4). MW represents molecular weight, ci is the molar 
concentration, and ρi is the mass concentration. 
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€ 
ci(moles /ml) =
ρi(g /ml)
MW (g /mole) 	   	   	   	   	   (4) 
Finally, using the molar concentration and Avogadro’s number (6.022 x 1023 molecules) 
the amount of molecules per milliliter of solution was determined for the gold conjugated 
antibody. Ci represents the number concentration. 
€ 
Ci(molecules /ml) = ci(moles /ml)[ ] NA[ ] 	   	   	   	   (5)	  
In theory, every antibody can bind to two separate antigens. Additionally, human 
VEGF165 isoform is smaller in size than anti-VEGF monoclonal or polyclonal antibody. 
Therefore, theoretically, if there is a major excess of VEGF165 in solution, it can bind to 
the two sites on the gold conjugated monoclonal anti-VEGF antibody and, because it’s 
smaller, can wick down the chip at a faster rate than the gold antibodies and bind to the 
monoclonal anti-VEGF antibody. If these proteins bound to all open sites of the 
antibodies, this means that it would not allow for antibodies to create a sandwich ELISA 
assay because all binding sites would be filled before the detector reagent reached the 
location of the capture reagent antibody. Therefore, there needed to be an even amount of 
VEGF165 molecules to polyclonal anti-VEGF antibody (capture reagent) in the test, 
however it was allowable to have an excess of gold conjugated antibodies in the solution. 
So, a concentration below the optimal visual gold concentration was chosen to analyze 
for molecular concentration. This value was applied to analyzing VEGF and polyclonal 
anti-VEGF concentrations. One important thing to note is that VEGF165 needs to have a 
molecular concentration twice as large as that of the polyclonal anti-VEGF antibody, 
because the antibodies have two binding sites. The table providing the values of these 
calculations (all originating from Equations 1 and 2) can be found in Table IV. 
Table IV: Initial Concentration Calculation for VEGF Antibodies 
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  Calculations	  for	  appropriate	  concentrations	  of	  capture	  reagents,	  detection	  reagents,	  and	  VEGF	  sample	  for	  antibody-­‐based	  lateral	  flow	  assay	  
Concentration Calculations for VEGF Lateral Flow Assay 
True Colloidal Gold Concentration + Anti-VEGF Antibody Concentration 
Concentration 0.75 mg/ml 
Molecular Weight 4.50 x 104 g/mole 
Molar Concentration 1.67 x 10-8 moles/ml 
Molecular Concentration  1.00 x 1016 molecules/ml 
Colloidal Gold Concentration for Anti-VEGF Antibody and VEGF Concentrations 
Concentration 0.50 mg/ml 
Molecular Weight 4.50 x 104 g/mole 
Molar Concentration 1.11 x 10-8 moles/ml 
Molecular Concentration  6.69 x 1015 molecules/ml 
VEGF Concentration 
Concentration 4.27 x 10-4 g/mole 
Molecular Weight 19200 g/mole 
Molar Concentration 2.22 x 10-8 moles/ml 
Molecular Concentration  1.34 x 1016 molecules/ml 
Polyclonal Anti-VEGF Concentration 
Concentration 4.27 x 10-4 g/mole 
Molecular Weight 38200 g/mole 
Molar Concentration 1.11 x 10-8 moles/ml 
Molecular Concentration  6.69 x 1015 molecules/ml  
 
The three experiments mentioned previously were repeated, using these calculated 
concentrations.  
An alternative way to attach and test antibodies used a much different protocol 
than previous methods. This procedure was applied to both the previous concentrations as 
well as the calculated concentrations seen in Table IV. In this procedure, 3 µL of the 
VEGF antibody was spotted down onto the detection region of the nitrocellulose 
membrane in an X pattern. The membrane was allowed to dry, covered, at room 
temperature for one hour. The membrane was then blocked in 1% w/v BSA by 
immersion for thirty minutes time. The platform was then rinsed once with water and 
allowed to fully dry at room temperature (taking around an hour). Then, the membrane 
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was dipped in 5% w/v sucrose solution and dried, to allow for the gold colloidal particles 
attached to antibodies to move easily down the membrane. The gold conjugated 
antibodies were spotted directly onto the membrane, near where the sample input was 
located on the test platform. This was allowed to dry for around an hour. 120 µL of 
VEGF sample was inputted and the test was allowed to run. The test was declared 
finished as the sample reached the absorbent pad at the test’s end.  
All procedures mentioned previously that were used to test antibodies as capture 
reagents with the calculated concentrations, were repeated, but this time involving the 
aspect of humidity. As the nitrocellulose membranes were set to dry in either an oven at 
37°C or room temperature, they were enclosed in a chamber containing small aliquots of 
water. In many cases, lack of humidity causes evaporation of the antibody from the 
material surface [38]. Therefore, in order to aid in antibody binding to the surface of the 
nitrocellulose, this step was implemented into the procedure.  
Further calculations regarding antibody and VEGF concentrations were done. 
These calculations were important for recognizing the amount of gold that could be seen 
by the human eye, considering number of gold colloidal particles, visible depth of the 
lateral flow assay, and sample spot volumes. Initially the molecular weight of colloidal 
gold, mass concentration of gold conjugated antibodies, density of gold, and radius of the 
gold particle were given values. The volume of the gold particles was calculated and 
from there, and from considering liquid loss throughout the chip’s length and depth, the 
amount of molecules present at detection was determined. However, the depth of which 
one can see gold signal was also taken into account using Equation 6 [23]. 
	   	   	   	   (6)	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Considering	  these	  values,	  the	  volume	  as	  well	  as	  concentrations	  of	  VEGF	  gold	  conjugated	  anti-­‐VEGF	  antibody,	  and	  polyclonal	  anti-­‐VEGF	  antibody	  were	  determined.	  Further	  calculations	  and	  steps	  may	  be	  found	  in	  Appendix	  G.	  The	  calculated	  concentrations	  and	  volumes	  for	  the	  VEGF,	  polyclonal	  capture	  antibody,	  and	  gold	  conjugated	  anti-­‐VEGF	  antibody	  are	  located	  in	  Table	  V.	  	  
Table V: Minimum Concentration Calculations Calculated	  Concentrations	  and	  Volumes	  For	  Antibody	  Lateral	  Flow	  Assay	  Test	  	  
Reagent	   Volume	   Concentration	  VEGF	   120	  µL	   6.40	  ng/ml	  Polyclonal	  Anti-­‐VEGF	  Antibody	   0.988	  µL	   0.25	  µg/ml	  Gold	  Conjugated	  Anti-­‐VEGF	  Antibody	   N/A	  –	  conjugate	  pad	  saturation	   0.75	  mg/ml	  Note	  that	  these	  concentrations	  are	  theoretically	  the	  minimum	  amounts	  of	  each	  concentration	  and	  volume	  that	  would	  be	  needed	  in	  order	  to	  show	  visual	  signal.	  The	  volume	  for	  the	  gold	  conjugated	  antibody	  was	  not	  specified	  due	  to	  the	  fact	  that	  the	  material	  was	  dipped	  into	  the	  solution	  and	  therefore	  it	  could	  not	  be	  determined.	  
Aptamer Testing 
For the aptamer, a concentration of 5 mM was applied using 3 µL of reconstituted 
oligos. In order to resuspend the aptamers, the tube must be briefly spun before opening. 
Then, mix the dried aptamer with a pH of between 7.0 and 8.0 in distilled water and 
vortex the solution. Distilled water tends to have a much lower (or more acidic) pH, so a 
buffer with a pH of 8 was commonly added prior to exposing it to the aptamers. The 
solution was then equilibrated and after five minutes. The oligonucleotides were vortexed 
again in order to fully finish its resuspension. The reconstituted aptamers were further 
diluted to a concentration of 10 mg/ml using deionized water as a buffer solution. Using a 
narrow-mouth pipette tip, 1.5 µL of the sample was spotted onto the nitrocellulose.  This 
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was spotted in the same manner as the antibodies were onto nitrocellulose, using a laser 
cut transparency with a unique design to distinguish signal as being positive rather than a 
false positive. The membrane was dried via baking in an oven for two hours at 80ºC [52, 
53]. After drying, the membrane was blocked so that no non-specific binding could occur 
using 1% BSA for seven minutes room temperature. This was followed by a 0.05% SDS 
and 2 mM Na2HPO4 wash for ten minutes [23]. Then the chip was dried at room 
temperature. 
As was done for the antibody experiments, three tests were set up. One 
experiment was a control, where a sample of PBS that did not contain any VEGF was 
inputted into a two-dimensional chip. The second experiment was combining VEGF 
sample and anti-VEGF antibodies conjugated to colloidal gold and inputting those into 
the test chip. The final test was using a conjugate pad loaded with gold conjugated anti-
VEGF antibody, and inputting a sample of VEGF to the chip, similar to a lateral flow 
assay, and seeing if sample could be detected. For further detail, refer to experimental 
description in Gold Conjugated to Antibodies in the Methods section. 
In order to prove that the antibodies and aptamers were functional, a two 
dimensional chip was designed that had one channel and one conjugate pad with anti-
VEGF antibody conjugated with 30 nm colloidal gold. The membrane was spotted, as 
mentioned above, as well. A sample containing human VEGF was inputted into the chip 
and allowed to wick down the entirety of the chip to the detection region to observe 
possible detection of the signaling protein. 
Additionally, biotinylated aptamers were purchased. Commonly it is difficult to 
detect visual signal from an aptamer that has less than 500 base pairs (in this case there 
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are 28). Therefore, by adding a biotin to the 5’ end of the custom Vap7 sequence, it will 
have a high affinity for binding to streptavidin [54]. The streptavidin was pipetted to the 
nitrocellulose membrane surface in the regions of detection. Per each detection region, 4 
µL at a concentration of 1 mg/ml was spotted down onto the membrane and set to dry for 
around 45 minutes time (or until the nitrocellulose membrane was entirely dry). 
Afterwards, the diluted biotinylated aptamer (4 µL with a 1 mg/ml concentration) was 
again spotted down in the detection region and allowed to dry. Important to note is that as 
the chips were drying, they were placed in a chamber containing wells with water in 
order to maintain humidity in the chamber (like with the antibody procedure) in order to 
limit any evaporation from the surface of the membrane and to promote binding. The 
membrane was blocked using 1% BSA for seven minutes and followed by a 0.05% SDS 
and 2 mM Na2HPO4 wash for ten minutes [23]. The conjugate pad process followed the 
same procedure as previously used. VEGF sample at a concentration of 50 ng/ml was 
processed through the chip and the test was visually analyzed for detection. Rather than 
spotting a particular volume onto the chip, it was dipped into the VEGF solution and 
allowed to run for its duration.  
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Results 
Following the completion of experiments requiring numerical data, all points 
were organized into tables using Microsoft Excel and transferred to Minitab if statistical 
analysis was necessary. Statistical analyses used multi-way analysis of variance. Both 
observational and numerical results will be presented within this section. For further 
explanation of the results and its relationship with the overall objectives of this thesis 
project, this will be found in the Discussion section.  
Characterization 
The characterization portion of this thesis considered a multitude of factors that 
could contribute to the flow of sample throughout a nitrocellulose membrane and 
compared it to other materials as well as different pore sizes of the nitrocellulose itself.  
Channel Widths and Wax Reflow 
The line and circle designs with different thicknesses were developed in order to 
analyze limits of detection. However, after developing these channels, they were not 
analyzed in this project but were instead implemented into another thesis project 
regarding the limits of detection of wax channels in paper microfluidics. These channel 
designs may be found in Appendix B. However, master’s student Ryan Silva carried on 
this project. The importance of such a project can be found in the Discussion.  
In attempting to compare channel widths to that of Yao Lu et al., channel 
thicknesses of 225 µm, 250 µm, 275 µm and 285 µm were printed on standard 8.5” by 
11” printer paper and melted. However, from this print it was seen that these channels 
were far too small and could barely be seen by the human eye. Post-melting the wax into 
the chips on an open-face hot plate, the wax completely reflowed into the smaller 
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channels making them unable to be seen, and therefore unable to run any liquid sample 
through the channel whatsoever. These designs were additionally printed onto the 0.45 
µm and the 285 µm and 275 µm channels were relatively visible, but the small pore size 
and surfactant of the material did not allow for wicking through the membrane 
whatsoever.  
Two types of paper, bibulous paper, and 0.45 µm pore size nitrocellulose paper 
was testing for wicking times. The bibulous paper and printer paper wicked within 
seconds to minutes. This observational step also proved that the larger the channel width 
was designed into the paper, the quicker the liquid wicked from start to finish. It was also 
observed that curved channels took a longer time to wick than straight channels. The 0.45 
µm nitrocellulose platform did not wick whatsoever, after placing down a droplet of 
green dye into the input of the paper and waiting for an hour time. The end of this test 
may be seen in Figure 22. 
 
Figure 22: Bibulous and Nitrocellulose Comparison. Comparison of 
wicking for bibulous paper (top) versus 0.45 µm pore size nitrocellulose (bottom) 
where green food coloring was used as a way to visualize the movement of 
sample through the channels. 
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Optimal Channel Characteristics  
A high flow 135 nitrocellulose membrane with a plastic backing adhered was 
analyzed for wicking time. Using three different channel widths, it was seen that the 
smallest channel width of 0.8 millimeters had the longest wicking time, to which some 
channels did not have completion of the liquid’s passage from start to end.  The fastest 
wicking time overall were for the 1.6-millimeter channel width designs, and the middle 
time was for that of the 2.4 millimeter channel widths. An image of the tests during their 
run may be found in Figure 23. Note how the smallest channel width (top) had two chips 
wicking at the same time that six of the seven middle channel width (middle) chips had 
completed their run.  
 
Figure 23: Channel Thickness Wicking Comparison. Backed HF 135 
nitrocellulose membrane comprised of three channel widths (0.8 mm, 1.6 mm, 
and 2.4 mm from top to bottom, respectively) tested with green dye for wicking 
time differences for different channel widths, length and curvature. 
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It was also noted that the curved patterns on the nitrocellulose wicked slower than 
the linear patterns, if at all. It can be seen from Figure 1 that the curved channels in the 
middle set of designs has no green dye along its channels – showing that it did not wick 
whatsoever. The concept of wicking time was tested in further detail and statistically 
measured for significance to provide further detail. 
Design Combinations and Wicking Times 
As stated in the Methods section, statistical analysis was completed that took into 
account the porosity of the paper, whether or not the membrane had a backing on it, 
curvature of the designs that were created, length of the channels, and the width of the 
channels. The initial model of the 2D chip multi-way analysis of variance (ANOVA) was 
done using a completely randomized design (CRD) with five factors.  All of the factors, 
as mentioned earlier, were fixed categorical variables containing two levels each.  The 
two sets of experiments that were done were randomized using Microsoft Excel. These 
tables for all combinations and their experimental order can be found in Appendix A.  
This data was run through Minitab (which can be found in Appendix A) and a 
four-in-one box plot was generated. When analyzing ANOVA, for the statistical method 
to be viable, four assumptions must be maintained, normality, constant variance, 
independence, and model adequacy. Because these assumptions were violated, the data 
first run in its original form, and then transformed using a logarithm (base ten), which 
was applied to all data points. This transformation allowed for all assumptions to be 
maintained. The non-transformed four-in-one box plot can be found in Figure 24 and 
transformed box plot can be found in Figure 25. Further explanation of the assumptions 
can be found in the Discussion. The analysis of variance results yielded significance for 
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characteristics of the platform that had significant interactions for 
Backing*Curving*Porosity*Width and Backing*Size*Width by using an overall 
significance level of 10% and an individual significance level of 0.323%. The Minitab 
output of this interaction can be found in Appendix A. The significance of these 
interactions and how these results were concluded is further explained in the Discussion 
section. For the interactions between the backing of the paper, curvature of the channel 
design, the porosity of the paper, and the width of the designed channel, had a p-value of 
0.001 (which is less than 0.323%, or a p-value of 0.00323). The next interaction to be 
significant (p-value of 0.002) contained Backing*Size*Width. The Minitab output for 
this interaction may also be found in Appendix A. 
 
Figure 24: Untransformed Four-in-One Box Plot. Four-in-one box plot of 
original untransformed data that analyzes the backing of the membrane, porosity, 
curvature in the channels, channel width, and channel length.  
 
	  71 	  
 
Figure 25: Transformed Four-in-One Box Plot. Four-in-one box plot of 
logarithmically transformed data in order to appropriately analyze the statistical 
data on wicking time without violating the assumptions of an ANOVA. 
Wicking Time – Conjugate Pad vs. Membrane Paper 
Because a large portion of this thesis was devoted to developing a three-
dimensional chip that allowed for simultaneous detection of target analytes from a single 
sample, it was important to characterize the materials used in order to see if this was 
possible (i.e. if there are changes in fiber orientation, if its an anisotropic material, et 
cetera). The two experiments were set up where four channels, one using a conjugate pad 
and one not using a conjugate pad, were compared to see the time difference between the 
channels in each experiment, and against one another (Table VI).  
Table VI: Wicking Comparison Times 
Times for testing four channels with and without an attached conjugate pad for 
overall wicking time 
 Test With Conjugate Pad Time 
(seconds) 
Without Conjugate Pad Time 
(seconds) 
1 207.8 41.1 
2 429.6 43.1 
3 392.1 42.6 
4 701.9 44.1 
Standard deviation 203.9 1.25 
Average 432.85 42.73 
p-value: 0.0314 
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The experiment yielded a standard deviation of 203.9 seconds and an average 
wicking time of 432.85 seconds for the experiment involving use of a conjugate pad, 
whereas the experiment without the conjugate pad had a standard deviation of 1.25 
seconds and an average wicking time of 42.73 seconds. Comparing the two tests to one 
another using a t-test, this yielded a p-value of 0.0314. 
Imaging 
Using the SEM, several nitrocellulose membranes were imaged that were both 
impregnated with wax and had none. In Figure 26, 0.45 µm pore size nitrocellulose was 
imaged using a 3000X objective lens with no wax.  
 
Figure 26: Smallest Nitrocellulose Pore Size SEM Image. A 0.45 µm 
pore size piece of bare nitrocellulose membrane imaged using SEM at a 3000X 
objective lens. 
 
Additionally, the HF 135 membrane was imaged in order to determine visual 
differences between a membrane that is impregnated with wax and one that is bare. 
Figure 27 demonstrates the membrane that has wax melted into its pores whereas Figure 
28 shows the membrane as bare. 
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Figure 27: Wax Impregnated Membrane on SEM. HF 135 backed 
nitrocellulose membrane impregnated with wax in at 1000X magnification using 
the SEM. 
 
 
Figure 28: Bare Nitrocellulose Membrane on SEM. HF 135 backed bare 
nitrocellulose membrane at 1000X magnification using the SEM. 
 
Likewise, it was of interest to determine if the SEM could detect the seam 
between where wax was melted into the pores of the paper and where the membrane was 
entirely bare. This was done at a 100X objective and may be found in Figure 29. 
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Figure 29: Seam Between Wax and Non-Wax on SEM. HF 135 backed 
nitrocellulose membrane at 100X objective lens showing the seam between wax 
(on right) and none (on the left) on the membrane’s surface. 
 
 
Development of a Three-Dimensional Chip 
A multitude of components were analyzed in order to propose a feasible design 
for the simultaneous detection of four analytes in one single sample. 
Bridging Layer 
Three bridging techniques between paper layers were demonstrated in this thesis. 
The initial bridging technique was a powder that was created by using the 0.45 µm pore 
size nitrocellulose saturated with acetone and grinding it with a mortar and pestal. 
However, after long amounts of hand grinding, the membrane failed to produce much, if 
any powdered substance of use.  
The second powder technique instead used HF 180 or HF 135 unbacked 
nitrocellulose membrane in combination with acetone, grinding the mixture, and drying it 
on bibulous paper for later use. The powder was somewhat difficult to control in the 
assembly of the three-dimensional chips. Figure 30 demonstrates the difficulty behind 
controlling the limited area in which the powder was supposed to remain.  
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Figure 30: Powder Bridging Set-Up. The spread of nitrocellulose powder 
from its designated area during the assembly of the three-dimensional chip. 
 
Additionally, the acetone and nitrocellulose yielded a wide range of powder particle sizes 
and shapes and each particle was relatively hard and brittle.  
The third powder, developed from mixing water with nitrocellulose, was ground 
and shaped into the areas of bridging during the assembly of the chip. The grinding took 
significantly longer than that of using acetone and still needed to remain damp for use in 
the assembly. Also, powder sizes were still a wide range of sizes, but soft and ductile. 
The fourth powder was ground into a much finer powder size than the previous three, was 
just as soft of a powder as that created using water and nitrocellulose at room 
temperature, and was much more uniform in size compared to all other powder making 
techniques. 
The lacquer, made from a 99% acetone and nitrocellulose membrane, yielded a 
gelatinous material that was wiped across the membrane’s surface. The lacquer material 
itself can be seen in Figure 31. When applying the lacquer to the surface of the 
nitrocellulose membrane, the nitrocellulose disintegrated, which is demonstrated in 
Figure 32. 
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Figure 31: Nitrocellulose Lacquer. Development of a nitrocellulose lacquer 
made from 99% acetone and HF 135 nitrocellulose paper using a mortar and 
pestal to grind and form the material. 
 
 
Figure 32: Application of Nitrocellulose Lacquer. Post-application of 
nitrocellulose lacquer onto nitrocellulose membrane surface during the 
manufacturing of a three-dimensional chip. 
 
The fourth bridging layer technique was a pure piece of nitrocellulose paper used 
to bridge the layers. This provided uniformity of liquid to bridge between the layers as 
compared to the powders. This worked in providing equal distribution of sample between 
layers in the assembly and testing of the three-dimensional simultaneously detecting 
paper microfluidic chip. 
Testing of Three-Dimensional Chip 
Four iterations of three-dimensional chips were developed in attempting to 
develop a simultaneous detecting chip. For the initial design, the channel in which was 
furthest from the sample input detected first, followed by the second closest to the sample 
input, then the closest, and finally one of the detection regions did not show up 
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whatsoever. The result of this chip is in Figure 33. The chip took several hours to show 
any detection whatsoever and between the three regions that did provide signal, it 
appeared over ten minutes apart from one another. 
 
Figure 33: Results of Design Iteration 1. Non-simultaneous detection of a 
three dimensional chip (this is realized from three different regions with dye at 
different areas of the chip, and the fourth with no dye at all – occurring 10 or 
more minutes apart from one another). 
 
The second and third design iterations also took a significant amount of hours to 
develop any signal, and when doing so were out of order and developed at completely 
different points in time. The detection region that showed signal first was random rather 
than following any pattern. An example of this may be found in Figure 34.  
 
Figure 34: Results of Design Iteration 2. The second developed design with 
only one of four regions showing any detection. 
 
The four design iteration yielded a result where it took around fifteen minutes to 
develop using a cut nitrocellulose paper bridging layer as opposed to a powder, which 
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took around thirty minutes to an hour of time. Detection on the fourth chip may be found 
in Figure 35.  
 
Figure 35: Results of Fourth Design Iteration. Running test of the fourth 
design iteration chip, noting detection within one to two minutes from the first to 
the last channels. 
Biochemistry 
The results for the biochemistry portion of this thesis were separated by the effort 
toward conjugating gold to antibodies, the antibody-based lateral flow assays, and the 
aptamer-based lateral flow assays.  
Conjugating Gold to Antibodies 
Following the protocol for developing a conjugated gold antibody, the solution 
was optically clear. Additionally, the test was run for both IgG as a control capture 
antibody and anti-VEGF as a detection capture antibody. The results yielded from this 
test can be found in Table VII.  
Table VII: Results of Conjugating Gold to Antibodies 
Results from lateral flow assay tests run for antibodies that were experimentally 
conjugated to 15 nanometer gold particles  
Test Antibody Result 
1 IgG No Visual Signal 
2 IgG No Visual Signal 
3 VEGF No Visual Signal 
4 VEGF No Visual Signal 
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Monoclonal Antibody Detection 
For the initial set of antibody tests, this involved spotting down monoclonal anti-
VEGF capture antibodies as well as capture line IgG antibodies to the nitrocellulose 
surface and exposing them to a sample with VEGF along with anti-VEGF antibody 
conjugated with 30 nanometer gold. For the IgG antibody, its spotted down concentration 
remained at 1 mg/ml for the duration of experiments and was exposed to 10 µg/ml VEGF 
sample concentration and 1 mg/ml colloidal gold antibody concentration. There were two 
tests types that were implemented – a spot test and a lateral flow assay test. Then, there 
were different post-treatments of the nitrocellulose pad and different ways in which the 
gold was applied to the test. These factors and the end result are demonstrated in Table 
VIII. 
Like with the IgG, anti-VEGF antibody had a series of different test procedures, 
post-treatments of the membrane, and the application of conjugated gold antibody. The 
results of different combinations and test procedures taken are presented in Table IX. 
Additionally, with these test combinations, several different designs were used from the 
Methods section. They were not represented in Table IX due to a similar set of end results 
as well as some discoveries that were later made and explained in the Discussion section 
of this document. 
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Table VIII: IgG Test Results 
 Test results for using IgG as a capture antibody for the control line.  
Test Test Type Post-Treatment Gold Application Result 
1 Spot Test None Spot Background 
2 Spot Test 7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Spot  Background 
3 Lateral Flow 
Assay 
None Conjugate Pad Background 
4 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Conjugate Pad Background 
5 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Conjugate Pad with 
Borate + Sucrose 
Background 
6 Lateral Flow 
Assay 
None Mix Gold + VEGF None 
7 Lateral Flow 
Assay 
 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Mix Gold + VEGF None 
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Table IX: Monoclonal anti-VEGF Antibody Results 
Test results for using monoclonal anti-VEGF as a capture antibody for the detection 
line. 
Test Test Type Post-Treatment Gold Application Result 
1 Spot Test None Spot Background 
2 Spot Test 7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Spot Background  
3 Lateral Flow 
Assay 
None Conjugate Pad Background 
4 Lateral Flow 
Assay 
None Conjugate Pad Background 
5 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Conjugate Pad Background 
6 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Mix Gold + VEGF None 
7 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Mix Gold + VEGF None 
8 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Mix Gold + VEGF None 
9 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Mix Gold + VEGF None 
10 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Conjugate Pad with 
Borate + Sucrose 
Background 
11 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & SDS 
Conjugate Pad with 
Borate + Sucrose 
Background 
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Polyclonal Antibody Detection 
Six different gold conjugated antibodies concentrations were developed and tested 
in order to determine the lowest concentration possible to still allow for visible signal 
strength. The visibility of the gold at the six different concentrations is represented in 
Table X. The visual test that was done can be found in Figure 36. 
Table X: Visual Colloidal Gold Test 
 Colloidal gold test to find the optimal concentration that is the most dilute and 
provides strong visual signal. 
Test 1 2 3 4 5 6 
Concentration 1 mg/ml 0.5 mg/ml 0.1 
mg/ml 
0.05 
mg/ml 
0.01 
mg/ml 
0.002 
mg/ml 
See Signal? Yes Yes No No No No 
 
 
 
Figure 36: Gold Spot Test. Colloidal gold visualization tests using six 
separate concentrations. In this case test one and two (seen in the first two wells 
located on the left side) allow for visualization of the gold colloidal particles at 
concentrations of 1 mg/ml and 0.5 mg/ml, respectively. 
 
Along with the use of monoclonal anti-VEGF antibodies, polyclonal anti-VEGF 
antibodies were used and tested in this procedure as capture reagents in the detection 
region. A series of concentrations were tested (that were calculated in the Methods) and 
different tests, post-treatments of the membrane, and applications of gold colloidal 
particles conjugated to anti-VEGF antibodies were varying as well. This information, as 
well as the result of the test signal may be found in Table XI. 
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Table XI: Polyclonal anti-VEGF Antibody Results 
Test results for using polyclonal anti-VEGF as a capture antibody for the detection 
line. 
Test Test Type Post-
Treatment 
Gold 
Application 
Concentration Result 
1 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & 
SDS 
Mix Gold + 
VEGF 
0.424 mg/ml 
 
None 
2 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & 
SDS 
Mix Gold + 
VEGF 
0.424 mg/ml 
 
None 
3 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & 
SDS 
Conjugate 
Pad – 
Sucrose & 
Borate 
0.424 mg/ml 
 
Background 
4 Lateral Flow 
Assay 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & 
SDS 
On Paper - 
Sucrose 
0.5 mg/ml 
 
None 
5 Lateral Flow 
Assay 
30 minutes in 
1% BSA and 1 
Water Wash 
On Paper - 
Sucrose 
0.5 mg/ml 
 
Possibly 
signal – 
most likely 
background 
6 Lateral Flow 
Assay - Dip 
7 minutes in 1% 
BSA and 5 
minutes in 
Na2HPO4 & 
SDS 
On Paper - 
Sucrose 
0.5 mg/ml 
 
None 
7 Lateral Flow 
Assay - Dip 
30 minutes in 
1% BSA and 1 
Water Wash 
On Paper - 
Sucrose 
0.5 mg/ml 
 
Possibly 
signal – 
most likely 
background 
 
	  84 	  
Using the final concentration calculations in the Methods, a final series of polyclonal 
antibody lateral flow assay tests were performed to detect VEGF in sample. The results 
of these tests are demonstrated in Table XII.  
Table XII: Humidity Anti-VEGF Antibody Results 
 Polyclonal anti-VEGF antibody testing using altered concentration calculations and 
incorporation of humidity in the chamber 
Test Patterned Chip? Gold Placement on Chip Result 
1 Yes Conjugate Pad with Borate + Sucrose None 
2 No Conjugate Pad with Borate + Sucrose None 
3 Yes On Paper - Sucrose None 
4 No On Paper - Sucrose None 
 
Aptamer Testing 
Initially aptamers that were tested were pure single strands of DNA that were spot 
blotted onto the nitrocellulose membrane and treated accordingly. Table XIII presents the 
types of tests and post-treatments done to the nitrocellulose membrane and the result of 
the test.  
Table XIII: Pure Aptamer Results 
 Results from testing for detection of VEGF in sample using aptamer-based capture 
reagents  
Test Test Type Post-Treatment Result 
1 Lateral Flow Assay None No Visual Signal 
2 Lateral Flow Assay 7 minutes in 1% 
BSA and 5 minutes 
in Na2HPO4 & SDS 
No Visual Signal 
3 Spot Test None No Visual Signal 
4 Spot Test 7 minutes in 1% 
BSA and 5 minutes 
in Na2HPO4 & SDS 
No Visual Signal 
 
Again aptamer tests were completed. This time aptamers were biotinylated on one 
end to allow for further adhesion to the nitrocellulose membrane in conjunction with 
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streptavidin. After running the test with the VEGF solution, the chip revealed a pink hue 
from the gold colloidal antibodies. This implied detection due to the definitive shape of 
one of the two detection wells. An image of this may be found in Figure 37.  
 
Figure 37: Biotinylated Aptamer. Resultant test of the biotinylated aptamer-
based detection lateral flow assay for 50 ng/ml VEGF sample. 
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Discussion 
The resultant of this thesis project showed many characteristics exhibited by 
nitrocellulose membrane, the resultant of developing a three-dimensional microfluidic 
chip, and the comparison of aptamers to antibodies as possible reagents of detecting 
VEGF in sample. The discussions of these results are presented.  
Characterization 
The characterization process of this project displayed important information for 
further understanding the three-dimensional chip development for simultaneous sample 
detection. These steps furthered the understanding of wicking time and the visual 
characteristics of nitrocellulose membrane. Explanations behind the characterization 
results were important for understanding not only the results of the three-dimensional 
chip design and development process, but for future paths regarding µPad development.  
Channel Widths and Wax Reflow 
Initially, there were sets of different linear and circular channel widths that were 
designed in SolidWorks. Although this limits-of-detection aspect of this thesis was taken 
over by a fellow student, it has much importance toward this thesis project and others 
regarding lateral flow assays and paper microfluidics. First of all, by analyzing the 
channel widths that can or cannot maintain sample, it would be important in determining 
the optimal width one can design in such a device. This controls the speed of the sample 
as well as how much sample can possibly be used in order to wick through the device’s 
entirety. This minimizes resources and lowers cost. Additionally, by analyzing the 
circular designs, it would further explain why and how curvature changes wicking time 
throughout the paper-based device.  
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For studying the limits of detection by developing a chip with 225 µm, 250 µm, 
275 µm and 285 µm channel thicknesses, it was seen that for the first two widths, wax 
entirely covered the channels. For the latter two channels, the thicknesses could be 
visualized, but once placed under heat to impregnate wax into the channels, wax 
somewhat reflowed back into the open areas of nitrocellulose. This technique ended up to 
be discarded for this thesis project. The main reason was due to the fact that the chips 
being developed were to be visualized by the user. With channels this small, sample 
travel throughout the channel would have to be determined through the use of 
microscopes, which this project wanted to avoid the use of. The purpose of developing 
these chips were to allow naked eye visualization from somewhat that was or was not 
trained in healthcare diagnostics.  
For the tests comparing bibulous paper to the 0.45 µm pore size nitrocellulose 
membrane for wicking times with designs, the test ended up to yield minimal results. The 
bibulous paper had quite a bit of wax reflow when exposed to heat. The properties of 
bibulous paper, which is often made of cotton, absorbs liquid at a high rate, so as the wax 
was heated and melted, the blot paper allowed for flow of the wax into its channels. 
Additionally, when sample was placed onto the paper it wicked at an extremely high rate 
(under a minute from input to development of sample). The 0.45 µm pore size 
nitrocellulose on the other hand, when spotted on the surface, did not wick whatsoever, 
even after sitting on the membrane for thirty minutes. The reason why this membrane 
could not wick solution was due to the fact that it had no added surfactant to the material 
[16]. Naturally, nitrocellulose is a hydrophobic material; therefore as the aqueous 
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solution was placed onto the membrane, the droplet held a high contact angle on the 
paper’s surface and did not allow for wicking through the membrane.   
Optimal Channel Characteristics  
The initial testing of optimal channel widths reviewed 0.8 mm, 1.6 mm, and 2.4 
mm widths. These were chosen due to the fact that they could be visualized by the naked 
eye. After testing it was seen that the 1.6 mm channel width was the best for wicking, 
followed by 2.4 mm, then 0.8 mm. The thinnest channel width had trouble wicking from 
initial input to detection. Therefore, this channel width was not used for the duration of 
these studies. Although the 1.6 mm channel width had a better wicking time than the 2.4 
mm width, both were used throughout the project because the time difference for the two 
was not significant enough to solely use one particular channel width. Additionally, the 
2.4 mm size allowed for better visualization by the user than the 1.6 mm channel width.    
Design Combinations and Wicking Times 
The four assumptions that were considered when analyzing the data were 
normality, constant variance, independence, and model adequacy. The normality was 
violated, as the deleted residuals line curved away from the diagonal line four different 
times; this was found in the “Normal Probability Plot” in the four-in-one “Residual Plots 
for Time” showing that this assumption was violated. The independence assumption, on 
the other hand, was not violated, as the design was randomly assigned and there was no 
time series data. For model adequacy, this was also not violated, because the initial model 
considered every single interaction possible for all of the factors. Finally, for equal 
variance the “Versus Fits” plot was used. This showed a violation in the assumption due 
to the large differences in the spread of data in the plot however because only two 
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replicates were completed. If there had been more than two replicates of the experiment 
the data would have shown a more consistent variance among the results. Additionally, 
looking at the Cook’s distance for this model, there were no values larger than 0.5, 
showing that there was no moderate or extreme influence in the data. These Cook’s 
distances can be found in Appendix A. 
The data was then transformed to a logarithmic version of the response variable in 
an attempt to fix the violated assumptions. Like with the initial model, the four 
assumptions considered were normality, constant variance, independence, and model 
adequacy. By transforming the data using a logarithmic function on the response variable, 
this improved the normality. In the Normal Probability Plot, the data remained close to 
the diagonal line on the plot. The independence assumption remained non-violated 
because of the random assignment of the treatments and non-time series data. The equal 
variance, although showing a large spread of data in the Versus Fits graph, is not violated 
due to the fact that only two replicates were done in the experiment. Additionally, the 
Cook’s distance was analyzed to see if there was any influence in the data. There were no 
Cook’s distances of beyond 0.5, indicating that there were no moderate or great 
influential points in the data. This can be found in Appendix A. 
Analyzing the experiment’s residual plots and finding that various assumptions 
were violated indicated that there were problems that needed to be fixed.  Instead of 
dropping high-order, insignificant interactions (which would cause a violation to the 
model adequacy assumption) transformations of the data was attempted.  The initial 
transformation done was the log(y) function.  According to the transformation process, it 
is most beneficial to begin at the log function and progress towards square roots to 
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squares to cubes, and so on (along with their inverses).  The response (y) variable, time, 
were transformed using the Calc function in Minitab, labeling the corresponding column 
in the dataset Log(time) and using the log base 10 function.  The values were calculated 
and an identical ANOVA test was run as before, now using Log(time) as the response 
variable and the five factors (and all possible interactions) as the predictor variables. 
Once all assumptions were found to be not violated after using the log(time) 
transformation, the factors and interactions could be interpreted.  A total of 31 
factors/interactions were generated through the ANOVA test.  These were interpreted 
using an overall significance level of 10%.  10% was chosen, as opposed to 5%, due to 
the fact that this was a student run experiment with two replicates, and there was a large 
amount of interactions.  A 10% overall significance level with 31 factors/interactions 
yields a .323% individual significance level (0.10/31 = 0.003226).  The ANOVA test 
generated p-values specific to each of the 31 factors/interactions.  These individual p-
values were compared to the individual significance level of .323%.  These comparisons 
were done in order of the most complex interaction (all five factors) to the simplest main 
effect (any one of the five factors).  As soon as an interaction proved to be significant 
(contained a p-value less than the significance level, 0.00323) interactions containing the 
same factors as the significant one could be ignored.  The first significant interaction 
found (p-value of 0.001) was the interaction containing 
Backing*Curving*Porosity*Width.  This means that any other interactions (or main 
effects) containing only these factors need not be interpreted.  The next interaction 
(without only these factors) found to be significant (p-value of 0.002) contained 
Backing*Size*Width.  This interaction could be interpreted as significant due to fact that 
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size was included, while it was absent from the first significant interaction.  Now that all 
factors have been accounted for in significant interactions, multiple comparisons could be 
done for these significant interactions. 
In order to analyze the comparisons amongst each of the factor levels within the 
two significant interactions, the method of Tukey intervals were used.  Tukey intervals 
were chosen over Dunnett intervals because there was no control group in this study. 
They were chosen over Bonferonni intervals because Tukey intervals are more powerful 
and still control for Type I error.  For this study, the endpoint was a proof of concept, 
making power a high priority. However, controlling the experiment wide Type I error 
rate was also crucial, and is the reason Tukey was chosen over Fisher.  Fisher may have 
higher power than the other intervals, but it does not control the Type I error. 
Tukey intervals were run for Backing*Size*Width and 
Backing*Curving*Porosity*Width (full output of these comparisons can be found in 
Appendix A).  These comparisons generated the mean responses (mean log(time)) for 
each of the combinations of factor levels within the interaction.  These means were 
arranged from largest to smallest.  The intervals indicated any significant differences 
found between various combinations of the factor levels.  These significant differences 
were determined by finding the intervals that did not contain the number zero.  The 
combinations corresponding with these intervals are then compared to each other using a 
line/letter chart (in order of decreasing means).  Combinations that do not touch lines or 
contain the same letter are considered to be significantly different from each other. 
Based on the letter chart results (found in Appendix A) of the significant 
interaction of Backing*Curving*Porosity*Width, the following interpretations it was 
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concluded that: 
• At the overall 10% significance level, unbacked-curved-hi-wide chips have 
significantly slower median wicking times than the rest of the chip material and 
design combinations. 
• Backed-curved-lo-narrow, unbacked-straight-lo-wide, backed-curved-lo-wide, 
backed-straight-lo-narrow, and backed-straight-lo-wide do not show significant 
differences in their median wicking times. 
• Backed-straight-lo-wide has a significantly faster median wicking time than all of 
the combinations ranging from unbacked-curved-hi-wide (mean log wicking time 
of 2.8) to unbacked-straight-lo-narrow (mean log wicking time of 1.5). 
Additionally, based on the letter chart results (found in Appendix A) of the significant 
interaction of Backing*Size*Width, the following interpretations were concluded: 
• At the overall 10% significance level, backed-short-wide has a significantly faster 
median wicking time than the rest of the combinations in this interaction. 
• Combinations ranging from unbacked-long-narrow (mean log wicking time of 
2.0) to unbacked-short-narrow (mean log wicking time of 1.7) are not 
significantly different in median wicking time. 
In these interpretations, the use of median wicking time is used because of the fact that a 
transformation was done on the data.  The means generated in the comparisons are the 
means of the log(time).  This means that ten raised to these values would give the actual 
mean wicking time. 
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Wicking Time – Conjugate Pad vs. Membrane Paper 
For the experiment involving wicking time between four identical channels on 
plain nitrocellulose membrane, there was a standard deviation of 1.25 seconds and an 
average time of 42.73 seconds for the sample to reach from beginning to end. The times 
were not significantly different from one another for the four different tests. This shows 
that the nitrocellulose material was not significantly different from one area to another. 
This was important for understanding that a simultaneous detection chip could be 
developed. 
On the other hand, the four identical channels that contained a conjugate pad had 
a standard deviation of 203.9 seconds and an average time of 432.85 seconds. This 
significant difference between the different channels was firstly due to the fact that the 
conjugate pads could not be cut to an identical size every single time. Because the 
fiberglass pad soaks up a lot of liquid before saturating and sample leaving the pad, any 
slight size difference can significantly change the time. Secondly, the fiber orientation in 
the fiberglass pad changes dramatically throughout, and there was no way to account for 
the changes in each pad. Therefore, the addition of this element does not allow for 
somewhat simultaneous results and instead dramatically varies wicking time. 
Comparing the channels that did or did not contain a conjugate pad for wicking 
time, a t-test was used. The end result was a p-value of 0.0314, a statistically significant 
value (because it was less that 0.05). This means that the null hypothesis was rejected, 
that stated that there was no significant difference between wicking times of the 
experiment containing and not containing a conjugate pad. This comparison was 
important for understanding that when a three-dimensional chip contains an additional 
conjugate pad throughout the platform, it will significantly add to the time it takes to 
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reach detection. The experiments were also important in determining that it was unlikely 
that simultaneous detection would occur between different detection regions for all three-
dimensional platforms when a conjugate pad was used in the apparatus.  
Imaging 
Although the SEM technique that was used was not for quantifiable purposes of 
this project, it was important in understanding the way in which the membrane appeared 
and changed with the addition of wax. It was seen that the pores on the 0.45 µm 
membranes were significantly smaller than those on the HF 135 membrane. However, no 
noticeable addition of surfactant on the HF 135 membrane as compared to the raw 0.45 
µm pore sized nitrocellulose could be determined.   
When compared side-by-side there is no noticeable difference between HF 135 
imbedded with wax versus a bare surface. This means that the wax settles into the 
nitrocellulose membrane to an extent in which it is visually undetectable at a high 
objective. Therefore, the wax sits in and around the nitrocellulose rather than “clumping” 
along the surface of the membrane. 
At a less magnified view (~100X) the seam between bare and wax coated 
nitrocellulose can be detected in the SEM. The wax appears slightly darker but, again, the 
seam is relatively difficult to determine. This reinforces the fact that wax is relatively 
undistinguishable when impregnated in the nitrocellulose at a microscopic level. 
However, the color of the wax can be seen at a macroscopic level by the human eye.  
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Development of a Three-Dimensional Chip 
After properties of the nitrocellulose were determined, aspects of the 
manufacturing and development of the three-dimensional chip were defined to eventually 
create a working simultaneously detecting µPad. Through experimentation optimal 
materials and manufacturing processes were chosen, as well.  
Bridging Layer 
 The initial bridging layer method was to use a powdered form of nitrocellulose. 
The first powder development attempt was using the 0.45 µm pore size nitrocellulose in 
conjunction with acetone to create the appropriate consistency. However, after much 
effort toward grinding the materials to make a powder, very little material was produced. 
This method seemed relatively cumbersome for such a minor yield of nitrocellulose 
powder. Because of this, the bridging layer method for this particular membrane type was 
discarded. 
 The next powder technique with grinding HF 135 or 180 membranes with acetone 
easily created powder. When it was dried out, however, the powder pieces hardened and 
came in an array of sizes. The stiffness of the particulates often led to a difficult 
manufacturing process of the three-dimensional chip, as the powder pieces would often 
cut through the nitrocellulose membrane and make the designs unusable for testing. 
Additionally, the use of acetone as a way to make powder seemed questionable to use for 
a true lateral flow assay device, in case the reagent had an adverse affect on any of the 
reagents that could possibly be used. Likewise, when water was used instead of acetone 
to grind the nitrocellulose membrane, the process of developing a powder was 
cumbersome to produce and when dried still had the issue of stiff particulates ripping the 
nitrocellulose membrane layers. A way to resolve this issue was to place the powder 
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while still damp into its appropriate bridging areas. However, this method was still not 
preferable because it was still a messy method during the manufacturing process. The 
powder was not uniform within each designated bridging layer and created an issue for 
designing a simultaneous detecting chip. Therefore, the idea of a powder bridging layer 
was discarded for this thesis. 
 The lacquer that was created from a drugstore nail polish remover (advertised to 
be 100% acetone) when ground up with nitrocellulose membrane produced a lacquer 
rather than a powder bridging layer. A lacquer would be advantageous in terms of 
applying the bridging material down would be better controlled by the manufacturer. 
However, upon applying the lacquer down to the surface, the nitrocellulose membrane 
would disintegrate due to the acetone presence in the material.  
The final bridging layer was simply cutting out the nitrocellulose membrane to fit 
into the areas where bridging of the sample would take place. This was the preferred 
technique used for developing a three-dimensional simultaneous detecting chip. The 
characterization step that compared nitrocellulose wicking times within the four channels 
showed that there were no major differences in wicking time between different areas and 
pieces of nitrocellulose. This showed that using a fit-to-size piece of nitrocellulose 
membrane would be a relatively good bridging layer material for simultaneous detection 
due to the relatively isotropic properties of the membrane. Additionally, it was not as 
difficult to use during the assembly process. Although, cutting the pieces by hand was a 
little more difficult for smaller bridging areas. However, it was later discovered that 
specialized hole punches could be purchased and used to cut out the nitrocellulose 
membrane into specific shapes for the bridging layer. This made the cutting process much 
	  97 	  
easier and uniform between pieces of nitrocellulose and aided in a more streamlined 
process in the manufacturing of these three-dimensional chips. 
 
Testing of a Three-Dimensional Chip 
The initial two designs of the three-dimensional chip commonly did not allow for 
simultaneous detection of sample. After running a statistical characterization step 
regarding channel curvature, it became apparent that a main problem with the design 
related to the fact that there were two curved patterns within the chip designs. Although it 
was originally thought that curved lines would take the same amount of time to wick as 
linear channels, given the same path length and channel width, this ended up to not be the 
case.  
The next design used powder as a bridging layer between the nitrocellulose 
membranes. This may have been a possible issue behind the non-simultaneous detection 
in the four detection wells. This would be due to the fact that the powder particulates 
were not equal in size and the process in which the chips were developed, more powder 
may have been placed in some bridging areas over others. This would limit or add to the 
wicking time per each channel.  
The final design was preferable over the first three. The final design used 
nitrocellulose membrane in its sheet form as a bridging layer. Experiments were done 
where a conjugate pad was placed into the three-dimensional chip versus no conjugate 
pad whatsoever. Like with the two-dimensional test that was formed, it was important to 
see how much of an effect the addition of the fibrous conjugate pad would have on the 
wicking times of the four separate channels. Without the conjugate pad, the four 
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detection regions showed signal within one to two minutes from the first to the last 
channels. On the other hand, when using conjugate pads, the results showed up within ten 
minutes of one another in the detection region. This once again proved the anisotropic 
nature of the fiber orientation of the conjugate pad and the inability to truly produce a 
simultaneous detecting chip of a multi-analyte sample. 
 
Biochemistry 
	   The	  biochemistry	  aspect	  of	  this	  project	  yielded	  visual	  detection	  for	  the	  biotinylated	  aptamer	  capture	  reagents.	  However,	  all	  other	  capture	  reagents	  showed	  no	  visual	  signal.	  The	  observations	  and	  explanations	  behind	  these	  results	  are	  described.	  	  
Conjugating Gold to Antibodies 
It was seen that the solution in which gold was placed with antibodies was 
entirely clear. Without seeing this red color (from the gold nanoparticles) it was assumed 
to either not bind to the anti-VEGF or to just be far too dilute for any visualization. 
Without visualization in solution, it is unlikely that any detection will be noted for the 
sample specimen. This idea was discarded solely for the fact that there was minimal 
information on the conjugation process and because there were options to purchase anti-
VEGF antibodies that were conjugated to gold already. Additionally, the colloidal gold 
that was on-hand was smaller than the standard colloidal gold used for diagnostic 
applications, which is around 30 to 40 nanometers.  
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Monoclonal Antibody Detection 
For the initial set of antibody tests, where the gold was pre-conjugated to anti-
VEGF antibody, there were several issues of note. Firstly, the IgG that was purchased as 
a detection antibody was noted to not be of use to pair with the anti-VEGF antibody. This 
was due to the fact that the IgG was rabbit anti-mouse, and the antibody attached to gold 
was a Rabbit anti-VEGF-A. Although the IgG states that the antibody reacts with heavy 
chains of mouse IgG, it may also react with immunoglobulins from other species. 
However, typically, in order for the IgG to have bound to the anti-VEGF it would have to 
either be an anti-Rabbit, or the VEGF antibody would have to be a mouse species. 
Therefore, these experiments may not have worked due to the mismatch in species of the 
antibody origin. However, when the IgG was initially purchased, it was intended to match 
with the mouse anti-VEGF antibodies that were purchased in the gold conjugation 
experiment, and would have had appropriate binding to one another.  
With the first set of anti-VEGF antibodies that were purchased, it was noted that 
there was still no signal for the lateral flow assay tests containing VEGF sample. After 
contacting the vendor and doing a BLAST on the antibodies and their binding properties, 
it was seen that the antibodies only bound to a very specific epitope of the VEGF165 
isoform. This created competitive binding between the capture and the detection 
antibody. This inhibited two antibodies from binding to the protein and producing a 
sandwich ELISA-like assay. Therefore, a new capture antibody needed to be used in 
order to allow for the assay to work. 
Polyclonal Antibody Detection 
The next anti-VEGF antibody that was purchased was raised against the entire 
VEGF165 sequence and theoretically would allow for binding anywhere on the VEGF 
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protein. Therefore, the gold conjugated antibody could bind to the specific epitope of the 
protein and cause no competitive binding for the capture antibody. However, no results 
were found from doing any of these antibody tests. There could be several issues 
regarding what could be the problem behind this. Firstly, it could be due to a lack of 
attachment of the antibody to the nitrocellulose membrane. The lack of anchoring could 
be due to the antibodies not having been viable any longer. This would have most likely 
happened due to repeat freezing and thawing cycles of the antibody during the testing 
process. Additionally, it could be that the anti-VEGF antibody was not robust enough to 
remain attached to the membrane meaning that no initial binding was occurring using the 
spot blot biochemistry technique, or that it was washing off during the blocking step with 
1% BSA of the washing step with the sodium dodecyl sulfate and Na2HPO4. The next 
option could be that the polyester backing of the nitrocellulose could be interfering with 
the anti-VEGF’s capability of attachment to the membrane. Likewise, even after 
attempting to add humidity into the drying chamber of the antibody, there still could have 
not been a sufficient amount of liquid present in the area, which caused the evaporation 
of antibody from the surface [55]. In addition to the concept that antibodies may not have 
bound to the surface of the nitrocellulose, another possibility could be that there was an 
insufficient concentration of any reagents for the test. In the antibody spotted on the 
membrane were too high, it could be clogging the pores, and if it were too low, then it 
may not be picking up enough VEGF and colloidal gold with the antibodies to show an 
appropriate amount of signal. Another possibility is that the sample is moving too quickly 
through the chip, which would make the antibodies unable to appropriately bind to the 
proteins. This could be altered through changing channel widths of having less porous 
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paper. The antibodies could also not be appropriate to use in lateral flow assays. 
Commonly, antibodies will work well in a Western Blot application but not a lateral flow 
assay due to how the antibodies are extracted. Antibodies, when made for certain 
applications, are extracted in a way where they lose specificity for their appropriate 
proteins and can no longer recognize them post-extraction. Another issue is that the 
membrane may be blocked too much and could inhibit the signal of the proteins and the 
gold.  
A final reason could have to do with the binding kinetics between VEGF and anti-
VEGF antibody. The Surface Plasmon Resonance (SPR) thesis project headed by Heather 
Hedeen in the Biomedical and General Engineering departments at Cal Poly showed poor 
binding kinetics between the antibody and protein in her project. Binding kinetics are 
often analyzed by the dissociation constant. This value quantifies the binding strength 
between ligands and receptors. The higher the value of this is, the lower the binding 
strength between the analyzed proteins. After completing three SPR trials using the 
polyclonal anti-VEGF antibodies, her data yielded dissociation constant values of 121.9 
µM, 126.6 µM, and 16.8 µM. On the other hand, her dissociation constants for her 
aptamer (after completing two experiments with SPR) were 20 nM and 28 nM. The 
aptamers, because of their smaller value, show significantly stronger binding to the 
VEGF than the antibodies. This corresponds to the Results where some of the polyclonal 
antibodies were regarded to having “possible signal – most likely background.” Since the 
signal was so faint, it would not be realistic to use in diagnostics. Additionally, because 
background noise was so common throughout the antibody tests, it was likely that this 
faint signal could be just that. Therefore, because antibodies yielded no visual result of a 
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positive test, and the aptamers did, this aided in explaining the possibility as to why no 
signal was produced in the tests.  
Regarding the conjugate pad – there was something interesting to note. As 
recommended in correspondance with a biochemistry representative at Millipore, when 
the gold detector particle appears to be deeper purple in color, this means that the 
antibody and gold were aggregating [56]. This aggregation affects the end detection 
result, as the antibodies and gold are adhering to each other, and eventually are unable to 
bind to the capture reagent. When placing the conjugate pad in the oven, with or without 
humidity, this deep purple color appeared. This result implied aggregation. However, 
when aggregation does not occur, the color of the solution trends between a pink and 
maroon. When the conjugate pad was dried in a humid chamber at room temperature, this 
color was maintained, implying no aggregation.  
Aptamer Testing 
The initial aptamer capture reagents showed no detection when exposed to VEGF 
protein. However, the aptamer sequence was only twenty-eight base pairs long. 
Commonly, visual signal demonstrated by aptamers happens when the oligonucleotide is 
larger than 500 base pairs [56]. However, after adding a protein to the end of the single 
stranded DNA, this allows for better binding kinetics and allowance for visual signal. 
Therefore this thesis coated the surface with streptavidin and then a biotinylated VEGF 
aptamer. From there, signal was seen. Therefore it can be determined that for the VEGF 
aptamer, the addition of a protein to the end of the strand aids in further recognition of 
signal with the colloidal gold antibody for detection.  
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 The signal itself was relatively weak as compared to a signal created by lateral 
flow assays on the market (i.e. a pregnancy test). There could be several reasons behind 
this. One is that the area in which the lateral flow assays were developed were not 
necessarily in a sterile environment. In many cases a diagnostic tool is created in a clean 
room in order to limit the amount of dust particulates or proteins in the area. Because 
nitrocellulose has a high affinity for protein binding, there is a possibility that there could 
have been competition on the paper between the streptavidin that was coated onto the 
paper and what was already on the nitrocellulose to begin with. By pre-treating the 
membrane with a cleaning solution this could be prevented or by processing the reagents 
and tests in a clean room. Additionally, through a series of iterations and comparative 
testing, a more optimal procedure for aptamer application could be determined to 
strengthen the signal. Likewise, the process of developing the wax chips through the 
printer and then the oven could have an affect on the properties of the nitrocellulose. 
From experimental observation, the way in which the antibodies during the spot blot 
protocol spread on the paper were noticeably different between the wax treated paper and 
raw nitrocellulose. It was noted that the processed chips had a significant amount of 
spreading of the materials over that of the non-processed membrane.  	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Conclusion 
This thesis consisted of three main objectives. The first was to characterize the 
different components that were being used to form a paper microfluidic chip, the second 
was to design, manufacture, and test a three-dimensional chip for simultaneous detection, 
and the third was to compare the use of antibodies and aptamers as capture reagents in 
detecting the protein, VEGF. 
From analyzing the data from the characterization process, it was seen that the 
ideal channel width for nitrocellulose it 1.6 mm for the fastest wicking time. In addition, 
it was noted that the combination of backing on nitrocellulose membrane, a linear 
channel, a higher porosity, and wide channel design had the fastest wicking time. The 
other significant interaction determined was that between the backing of the 
nitrocellulose membrane, the shorter channel length, and wide channel design had the 
fastest wicking time for the nitrocellulose membrane.  Finally it was noted that channels 
patterned on different areas of the nitrocellulose membrane will not have significantly 
different wicking times, showing that the material has similar fiber orientation throughout 
its entirety. On the other hand, if a conjugate pad is added to the channels, the wicking 
time will be significantly longer for the channels, as well as significantly different 
between each conjugate-pad test. This shows that each conjugate pad has a significantly 
different fiber orientation and will add to complications in the possibility of simultaneous 
detection times.  
Analyzing the data obtained from the three-dimensional simultaneous detecting 
chip, it was determined that the bridging layer technique that was more advantageous for 
the equal spreading of sample between layers and the easiest for manufacturing was that 
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of a cut-to-size nitrocellulose membrane. Additionally, when developing a three-
dimensional chip, a design that contained four layers of linear-based channels produced 
simultaneous detection of an analyte in four detection regions. However, the 
simultaneous detection only occurred when a conjugate pad was not involved in the chip 
(i.e. all four detection regions showed detection within one to two minutes). Once the 
conjugate pad was introduced to the three-dimensional chip, this significantly altered the 
detection time of the chip as well as introduced the inability to allow for simultaneous 
detection.  
For the biochemistry, the antibodies used as capture reagents to detect VEGF in 
sample were not viable for detection. Despite many efforts and changes made to protocol, 
there was no significant visual detection of VEGF made in the lateral flow assay. 
However, a project dealing with proof-of-concept analyzing the antibody binding kinetics 
of anti-VEGF to VEGF165  (using surface Plasmon resonance) showed poor binding 
between the two. This would explain a lack of visual signal from the lateral flow assay. 
However, using aptamers with a biotin end group did show visual signal. Once again with 
the proof-of-concept project that used aptamers also provided data to agree with this as 
the aptamer provided better binding kinetics to the VEGF than the antibody. Therefore an 
aptamer may be a feasible capture reagent to use in a lateral flow assay.  
Future Work 
 As the field of paper microfluidics comes to fruition, there are many future steps 
that could be taken with this project and the field in general.  
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Characterization 
In terms of characterization, there are many more steps that could be established. 
One important aspect would be to conduct further studies on limits of detection. For 
example, looking at how small of a channel could be designed that would allow sample to 
pass through for detection and how it would provide importance to diagnostics. Likewise, 
studying the optimal amount of time nitrocellulose and printed wax should melt in the 
oven in order to prevent reflow of the wax and to maintain the exact design implemented 
on AutoCAD.  
Additionally, other materials should be analyzed for their use in paper 
microfluidics. Nitrocellulose itself is not a very strong material and can significantly 
hinder the time and viability of these devices. Membranes made of materials like nylon 
are sturdier. So the characterization of something like nylon could aid in a more robust 
device.  
Three-Dimensional Device 
Although there was initial work done to prove that a three-dimensional device 
could be created there are many more steps that could be taken for the improvement of a 
simultaneous detecting device. For example, when the conjugate pad was added to the 
device itself, it provided inability to produce a simultaneous detecting chip. If alternate 
materials were used, simultaneous detection could be possible.  
Likewise, the manufacturing process of these chips could be more streamlined 
than they currently are. A tool was developed on SolidWorks in this project that could be 
created via rapid prototyping (see Appendix C for manufacturing drawings). This tool 
would aid in the alignment of the nitrocellulose membrane layers and tape rather than 
doing it by hand. Also, costs could be cut to the manufacturing process. A demonstration 
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of the assembly of such a device may be found in Figure 38. Assembled together, there is 
a base that would perfectly fit the chip layers. The tape and paper layers would have 
designed markings on two opposite diagonal corners that would imply their immediate 
position on the device. In the base there would be two sewing needles that were press-fit 
into the base to allow aligned assembly of the layers. Where the markings are made on 
the layers would be where the needles puncture the material in order to aid in alignment. 
Finally, a top block would be placed upon the chip in order to compress the layers 
together into one device. 
	  
Figure 38: Depiction of Assembly Tool. Tool in its compressed assembly to 
allow for the manufacturing of a multi-layer paper microfluidic device. 	  
Currently, the double-sided tape layers are cut using a laser cutter. However, this 
could easily be done by designing a stamping device that cuts the patterns that the chip 
would need. This tool could be sent to a developing nation or a low-resource 
development center where the tape layers could be manufactured, rather than relying on a 
more expensive tool like a laser-cutter.  
Additionally, the designs in the detection regions of this chip could be more 
distinct for the end user. For instance, with the three-dimensional chip that was developed 
in this project, the four detection regions were not distinct from one another. Thinking 
about whom the device is catered toward, it would be easy to develop detection regions 
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that are different shapes or patterns in order to determine the different regions that 
analytes are detected in. Initial designs were developed for this and can be found in the 
Appendix C.  
Biochemistry 
Although this thesis could not provide visual signal using antibodies at the 
detection region of the two dimensional platform, it would be important to still determine 
that this can or cannot be done for the detection of VEGF. The addition of a control line 
antibody would be of use as well. Then this could provide a more comparable result 
between aptamers and antibodies as capture reagents. Likewise, using these reagents in a 
three-dimensional chip would be useful to see if the idea of using a multi-layer chip for 
detection is feasible.  
If paper microfluidics were to be implemented for clinical use, it would be 
important to be able to detect multiple biomarkers in a raw biological sample. Therefore, 
it would be of use to look into materials that could filter raw sample through a test and 
allow for detection. Likewise, if multiple biomarkers are to be detected, the use of latex 
beads rather than colloidal gold could be implemented. Latex beads come in multiple 
colors and would provide a clear difference in color for a positive signal.  
Additionally, in the developing world, although there may not be much medical 
equipment that can be used by those in low-resource regions, many people have cellular 
telephones. In recent years there has been a push in the medical community to develop 
algorithms for mobile phones to analyze and process images [3]. If the user were unable 
to determine the result of a lateral flow assay test, an image analysis program could be 
developed for the mobile phone that would process a picture taken by the user and give 
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the result of the test. Another option could be a potential reader device that enabled a chip 
to be placed into the device and analyzed to determine the diagnostic result. A concept 
was designed on SolidWorks and may be found in Figure 39. 
 
Figure 39: Conceptual design of diagnostic chip reader. 	  
 
 
 
	  110 	  
List of References 
 1.	   Andres	  W.	  Martinez,	  S.T.P.,	  George	  M.	  Whitesides,	  Emanuel	  Carrilho,	  
Diagnostics	  for	  the	  Developing	  World:	  Microfluidic	  Paper-­Based	  Analytical	  
Devices.	  Analytical	  Chemistry,	  2010.	  82(1):	  p.	  3-­‐10.	  2.	   Darren	  J.	  Carter,	  R.B.C.,	  Lateral	  flow	  microarrays:	  a	  novel	  platform	  for	  rapid	  
nucleic	  acid	  detection	  based	  on	  miniaturized	  lateral	  flow	  chromatography.	  Nucleic	  Acids	  Research,	  2007.	  35(10):	  p.	  1-­‐11.	  3.	   Paul	  Yager,	  G.J.D.,	  John	  Gerdes,	  Point-­of-­Care	  Diagnostics	  for	  Global	  Health.	  Annual	  Review	  of	  Biomedical	  Engineering,	  2008.	  10:	  p.	  107-­‐144.	  4.	   Zhichao	  Zhou,	  H.G.,	  Krishna	  Reddy,	  Xiaoping	  Duan,	  Eugenie	  Kleinerman,	  Role	  
of	  VEGF165	  and	  VEGF189	  in	  the	  growth	  and	  tumor	  vessel	  expansion	  in	  Ewing's	  
sarcoma,	  in	  American	  Association	  for	  Cancer	  Research.	  2005:	  Houston,	  TX.	  5.	   Magnus	  Blomsrtöm,	  R.E.L.,	  Mario	  Zejan,	  What	  Explains	  Developing	  Country	  
Growth?,	  in	  NBER	  Working	  Paper	  Series.	  1992,	  National	  Bureau	  of	  Economic	  Research:	  Cambridge.	  p.	  1-­‐31.	  6.	   A.C.	  Kelley,	  The	  Human	  Development	  Index:	  "Handle	  with	  Care".	  Population	  and	  Development	  Review,	  1991.	  17(2):	  p.	  315-­‐324.	  7.	   K.	  Annan,	  Address	  to	  the	  Tenth	  United	  Nations	  Conference	  on	  Trade	  and	  
Development,	  in	  United	  Nations.	  2000:	  Bangkok,	  Thailand.	  8.	   B.O.F.a.J	  Bauer,	  Part	  2:	  New	  challenges	  with	  new	  approaches.	  Developing	  highly	  sensitive,	  more	  reproducible	  lateral-­‐flow	  assays	  2006	  	  [cited	  2012	  March	  9,	  2012].	  9.	   Agustin	  Benito,	  J.M.R.,	  Poor	  Accuracy	  of	  Rapid	  Diagnostic	  Tests	  and	  
Misdiagnosis	  of	  Imported	  Malaria:	  Are	  PCR-­Based	  Reference	  Laboratories	  the	  
Answer?	  Journal	  of	  Clinical	  Microbiology	  2002.	  40(2):	  p.	  736-­‐737.	  10.	   RW	  Peeling,	  K.H.,	  D	  Mabey,	  et	  al.,	  Rapid	  tests	  for	  sexually	  transmitted	  
infections	  (STIs):	  the	  way	  forward.	  STI	  Journal,	  2006:	  p.	  1-­‐6.	  11.	   Ahmedin	  Jemal,	  F.B.,	  David	  Forman,	  Global	  Cancer	  Statistics.	  CA:	  A	  Cancer	  Journal	  for	  Clinicians,	  2011.	  61:	  p.	  69-­‐90.	  12.	   Kayhan	  Parsi,	  D.B.,	  Justin	  List,	  The	  Dread	  Disease:	  Cancer	  in	  the	  Developing	  
World.	  Hastings	  Center	  Report,	  2011:	  p.	  13-­‐14.	  13.	   R.A.	  Malkin,	  Design	  of	  Health	  Care	  Technologies	  for	  the	  Developing	  World.	  Annual	  Review	  of	  Biomedical	  Engineering,	  2007.	  9:	  p.	  567-­‐587.	  14.	   D.M.	  Kemeny,	  S.J.C.,	  ELISA	  and	  Other	  Solid	  Phase	  Immunoassays:	  Theoretical	  
and	  Practical	  Aspects.	  1988,	  Portsmouth:	  John	  WIley	  &	  Sons	  Ltd.	  15.	   S.F.	  Sun,	  Souther	  Blot,	  Northern	  Blot,	  and	  Western	  Blot,	  in	  Physical	  Chemistry	  
of	  Macromolecules:	  Basic	  Principles	  and	  Issues.	  2004,	  John	  Wiley	  &	  Sons,	  Inc.:	  Jamaica,	  New	  York.	  16.	   Raphael	  C.	  Wong,	  H.Y.T.,	  Lateral	  Flow	  Immunoassay.	  2008,	  Springer:	  New	  York,	  NY.	  p.	  39.	  17.	   Curtis	  D.	  Chin,	  V.L.,	  Samuel	  K.	  Sia,	  Lab-­on-­a-­chip	  devices	  for	  global	  health:	  Past	  
studies	  and	  future	  opportunities.	  Lab	  on	  a	  Chip,	  2006.	  7:	  p.	  41-­‐57.	  
	  111 	  
18.	   George	  Whitesides,	  George	  Whitesides:	  A	  lab	  the	  size	  of	  a	  postage	  stamp,	  in	  
TEDxBoston,	  TEDX,	  Editor.	  2009:	  Boston,	  MA.	  19.	   Andres	  W.	  Martinez,	  S.T.P.,	  George	  M.	  Whitesides,	  Three-­dimensional	  
microfluidic	  devices	  fabricated	  in	  layered	  paper	  and	  tape.	  Proceedings	  of	  National	  Academy	  of	  Sciences,	  2008.	  105(50):	  p.	  19606-­‐19611.	  20.	   Andres	  W.	  Martinez,	  S.T.P.,	  Benjamin	  J.	  Wiley,	  Malancha	  Gupta,	  George	  M.	  Whitesides,	  FLASH:	  A	  rapid	  method	  for	  prototyping	  paper-­based	  microfluidic	  
devices.	  Lab	  on	  a	  Chip,	  2008.	  8:	  p.	  2146-­‐2150.	  21.	   Emanuel	  Carrilho,	  A.W.M.,	  George	  M.	  Whitesides,	  Understanding	  Wax	  Printing	  
-­	  A	  Simple	  Micropatterning	  Process	  for	  Paper-­Based	  Microfluidics.	  Analytical	  Chemistry,	  2009.	  Manuscript:	  p.	  1-­‐18.	  22.	   Emanuel	  Carrilho,	  S.T.P.,	  Sarah	  J.	  Vella,	  Andres	  W.	  Martinez,	  George	  M.	  Whitesides,	  Paper	  Microzone	  Plates.	  Analytical	  Chemistry,	  2009.	  Manuscript:	  p.	  1-­‐32.	  23.	   Millipore	  (2008)	  Rapid	  Lateral	  Flow	  Test	  Strips.	  	  Volume,	  	  	  24.	   Weian	  Zhao,	  A.v.d.B.,	  Lab	  on	  paper.	  Lab	  on	  a	  Chip,	  2008.	  8:	  p.	  1988-­‐1991.	  25.	   Biooncology,	  G.	  Glioblastomas,	  angiogenesis,	  and	  VEGF.	  	  Volume,	  	  	  26.	   Mark	  L.	  George,	  M.G.T.,	  Frank	  Janssen,	  Abed	  Arnaout,	  A.	  Muti	  Abulafi,	  Suzanne	  A.	  Eccles,	  R.	  Ian	  Swift,	  VEGF-­A,	  VEGF-­C,	  and	  VEGF-­D	  in	  Colorectal	  
Cancer	  Progression.	  Nature,	  2001.	  3(5):	  p.	  420-­‐427.	  27.	   J.H.	  Harmey,	  VEGF	  and	  Cancer.	  2004,	  New	  York,	  NY:	  Kluwer	  Academic	  /	  Plenum	  Publishers.	  28.	   Cleber	  A.	  Trujillo,	  A.A.N.,	  Janaína	  M.	  Alves,	  Antonio	  H.	  Martins,	  Henning	  Ulrich,	  Development	  of	  the	  anti-­VEGF	  aptamer	  to	  a	  therapeutic	  agent	  for	  
clinical	  ophthamology.	  Clinical	  Ophthamology,	  2007.	  1(4):	  p.	  393-­‐402.	  29.	   Yoshihiko	  Nonaka,	  K.S.,	  Kazunori	  Ikebukuro,	  Screening	  and	  Improvement	  of	  
an	  Anti-­VEGF	  DNA	  Aptamer.	  Molecules,	  2010.	  15:	  p.	  215-­‐225.	  30.	   Itsuro	  Endo,	  T.M.,	  Maki	  Nishino,	  Yasushi	  Oshima,	  Toshio	  Matsumoto,	  Diurnal	  
Fluctuation	  of	  Edema	  Synchronized	  with	  Plasma	  VEGF	  Concentration	  in	  a	  
Patient	  with	  POEMS	  Syndrome.	  Internal	  Medicine,	  2002.	  41(12):	  p.	  1196-­‐1198.	  31.	   Marina	  Scarlato,	  S.C.P.,	  Marinella	  Carpo,	  Davide	  Pareyson,	  Chiara	  Briani,	  Roberto	  Del	  Bo,	  Eduardo	  Nobile-­‐Orazio,	  Angelo	  Quattrini,	  Giacomo	  Pietro	  Comi,	  Polyneuropathy	  in	  POEMS	  syndrome:	  role	  of	  angiogenic	  factors	  in	  
pathogenesis.	  Brain,	  2005.	  128:	  p.	  1911-­‐1920.	  32.	   N.	  Orazio,	  Serum	  VEGF	  levels	  in	  POEMS	  syndrome	  and	  in	  immune-­mediated	  
neuropathies.	  Neurology,	  2009.	  72(11):	  p.	  1024-­‐1026.	  33.	   Vittorio	  Rosti,	  M.M.,	  Rita	  Campanelli,	  Mara	  De	  Amici,	  Giovanni	  Piccolo,	  Vittorio	  Perfetti,	  Vascular	  endothelial	  growth	  factor	  promoted	  endothelial	  
progenitor	  cell	  mobilization	  intro	  the	  peripheral	  blood	  of	  a	  patient	  with	  POEMS	  
syndrome.	  The	  Hematology	  Journal,	  2007.	  92(09):	  p.	  1291-­‐1292.	  34.	   B.R.	  Lynn	  Sterling,	  Protocol	  Development	  for	  Ovarian	  Cancer	  Treatment	  in	  
Kenya.	  International	  Journal	  of	  Gynecological	  Cancer,	  2011.	  21(2):	  p.	  424-­‐427.	  35.	   Joon-­‐Hwa	  Lee,	  M.D.C.,	  Andrea	  De	  Erkenez,	  Dominik	  Krilleke,	  Yin-­‐Shan	  Ng,	  David	  T.	  Shima,	  Arthur	  Pardi,	  Fiona	  Jucker,	  A	  therapeutic	  aptamer	  inhibits	  
	  112 	  
angiogenesis	  by	  specifically	  targeting	  the	  heparin	  binding	  domain	  of	  VEGF165.	  Proceedings	  of	  National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America,	  2005.	  102(52):	  p.	  18902-­‐18907.	  36.	   Anastasios	  J.	  Karayiannakis,	  K.N.S.,	  Alexandros	  Polychronidis,	  Andrew	  Zbar,	  Gregory	  Kouraklis,	  Constantinos	  Simopoulos,	  Gabriel	  Karatzas,	  Circulating	  
VEGF	  Levels	  in	  the	  Serum	  of	  Gastric	  Cancer	  Patients.	  Annals	  of	  Surgery,	  2002.	  
236(1):	  p.	  37-­‐42.	  37.	   Laurie	  M.	  Elit,	  D.M.,	  Teaching	  Cervical	  Cancer	  Surgery	  in	  Low-­	  or	  Middle-­
Resource	  Countries.	  International	  Journal	  of	  Gynecological	  Cancer,	  2010.	  
20(9):	  p.	  1604-­‐1608.	  38.	   Edward	  Harlow,	  D.L.,	  Antibodies:	  A	  Laboratory	  Manual.	  1988,	  Cold	  Spring	  Harbor,	  NY:	  Cold	  Spring	  Harbor	  Laboratory	  Press.	  39.	   Juewen	  Liu,	  D.M.,	  and	  Yi	  Lu,	  A	  Simple	  and	  Sensitive	  "Dipstick"	  Test	  in	  Serum	  
Based	  on	  Lateral	  Flow	  Separation	  of	  Aptamer-­Linked	  Nanostructures.	  Angewandte	  Chemie	  International	  Edition	  2006.	  45:	  p.	  7955-­‐7959.	  40.	   R.M.	  L	  Taniwaki,	  AS	  Cunha-­‐Júnior,	  AAG	  Faraco,	  JAS	  Ribiero,	  IU	  Scott,	  R	  Jorge,	  
Effect	  of	  lyophilization	  on	  the	  in	  vitro	  biological	  activity	  of	  bevacizumab.	  Eye,	  2010.	  24:	  p.	  1628-­‐1629.	  41.	   Enzyme	  Linked	  Immunosorbent	  Assays	  (ELISA).	  	  	  [cited	  2012	  March	  10,	  2012];	  Available	  from:	  http://www.geneticasysid.com.br/ELISA.htm.	  42.	   M.M.	  S.	  Tombelli,	  M.	  Mascini,	  Analytical	  applications	  of	  aptamers.	  Biosensors	  and	  Bioelectronics,	  2004.	  20(2005):	  p.	  2424-­‐2434.	  43.	   S.D.	  Jayasena,	  Aptamers:	  An	  Emerging	  Class	  of	  Molecules	  That	  Rival	  Antibodies	  
in	  Diagnostics.	  Clinical	  Chemistry,	  1999.	  45(9):	  p.	  1628-­‐1650.	  44.	   Wijitar	  Dungchai,	  O.C.,	  Charles	  S.	  Henry,	  Electrochemical	  Detection	  for	  Paper-­
Based	  Microfluidics.	  Analytical	  Chemistry,	  2009.	  81(14):	  p.	  5821-­‐5826.	  45.	   Yao	  Lu,	  W.S.,	  Jianhua	  Qin,	  Bingcheng	  Lin,	  Fabrication	  and	  Characterization	  of	  
Paper-­Based	  Microfluidics	  Prepared	  in	  Nitrocellulose	  Membrane	  By	  Wax	  
Printing.	  Analytical	  Chemistry,	  2010.	  82(1):	  p.	  329-­‐335.	  46.	   R.	  Davies,	  How	  to	  attach	  antibodies	  on	  gold.	  	  	  [cited;	  Available	  from:	  https://mail.mems-­‐exchange.org/mems-­‐talk/11091/.	  47.	   Bianmei	  Cao,	  T.X.,	  David	  Hui,	  Preparation	  of	  Nanogold	  Labeled	  Goat-­Anti-­
Rabbit	  IgG	  and	  Their	  Application	  In	  An	  Immunoassay.	  Metalurgija	  -­‐	  MJoM,	  2011.	  17(2):	  p.	  79-­‐85.	  48.	   Shuo	  Wang,	  C.Z.,	  Junping	  Wang,	  Yan	  Zhang,	  Development	  of	  colloidal	  gold-­
based	  flow-­through	  and	  lateral-­flow	  immunoassays	  for	  the	  rapid	  detection	  of	  
the	  insecticide	  carbaryl.	  Alaytica	  Chimica,	  2005.	  546:	  p.	  161-­‐166.	  49.	   Weian	  Zhao,	  M.M.A.,	  Sergio	  D.	  Aguirre,	  Michael	  A.	  Brook,	  Yigfu	  Li,	  Paper-­
Based	  Bioassays	  Using	  Gold	  Nanoparticle	  Colorimetric	  Probes.	  Analytical	  Chemistry,	  2008.	  80(22):	  p.	  8431-­‐8437.	  50.	   V.	  Wu,	  Imminogen	  sequence	  of	  bsm-­4572M-­Gold,	  K.	  Clayton,	  Editor.	  2012,	  Bioss-­‐USA:	  Woburn,	  MA.	  51.	   Health,	  N.I.o.	  BLAST:	  Basic	  Local	  Alignment	  Search	  Tool.	  	  2012	  	  [cited	  2012;	  Available	  from:	  http://blast.ncbi.nlm.nih.gov/.	  52.	   Mary	  A.	  Dorman,	  C.D.B.,	  James	  K.	  Collins,	  Barry	  J.	  Beaty,	  Detection	  of	  Bovine	  
Herpesvirus	  1	  DNA	  Immobilized	  on	  Nitrocellulose	  by	  Hybridization	  with	  
	  113 	  
Biotinylated	  DNA	  Probes.	  Journal	  of	  Clinical	  Microbiology,	  1985.	  22(6):	  p.	  990-­‐995.	  53.	   Ajish	  S.R.	  Potty,	  K.K.,	  Han	  Fang,	  Peter	  Schuck,	  Richard	  C.	  Willson,	  Biophysical	  
characterization	  of	  DNA	  and	  RNA	  aptamer	  interactions	  with	  hen	  egg	  lysozyme.	  International	  Journal	  of	  Biological	  Macromolecules,	  2010.	  48(2011):	  p.	  392-­‐397.	  54.	   Bo	  Johnsson,	  S.L.,	  Gabrielle	  Lindquist,	  Åsa	  Endström,	  Rose-­‐Marie	  Müller	  Hillgren,	  Anna	  Hansson,	  Comparison	  of	  Methods	  for	  Immobilization	  to	  
Carboxymethyl	  Dextran	  Sensor	  Surfaces	  by	  Analysis	  of	  the	  Specific	  Activity	  of	  
Monoclonal	  Antibodies.	  Journal	  of	  Molecular	  Recognition,	  1995.	  8:	  p.	  125-­‐131.	  55.	   Alexander	  Volkov,	  M.M.,	  Paul	  Corstjens,	  R.	  Sam	  Niedbala,	  Rapid	  Prototyping	  of	  
Lateral	  Flow	  Assays.	  Methods	  in	  Molecular	  Biology:	  Biosensors	  and	  Biodetection,	  2009.	  504(3):	  p.	  217-­‐235.	  56.	   M.	  Mansfield,	  Millipore	  and	  Antibody	  Discussion,	  K.	  Clayton,	  Editor.	  2012,	  Millipore:	  Millerica,	  MA.	  	  
 
	  114 	  
Appendix A: Statistical Analyses for Chip Design Characteristics 
The following tables and statistical output were not using throughout the main 
report due to their insignificance in describing the conclusions reached for this thesis. 
However they are provided here for completeness, for fully understanding the methods 
followed, and the information that aided in finding results and conclusions in this project. 
Table XIV: First Thirty-Two Tests 
The first thirty-two statistical tests conducted, where treatments/experimental order were 
assigned at random using Microsoft Excel 
Treatment Backing Curving Porosity Size Width 
1 Backed Straight 75 Short Narrow 
2 Unbacked Curved 135 Short Wide 
3 Backed Curved 135 Short Narrow 
4 Backed Curved 135 Long Wide 
5 Unbacked Straight 135 Short Wide 
6 Unbacked Curved 180 Short Narrow 
7 Backed Curved 75 Long Narrow 
8 Backed Curved 75 Long Wide 
9 Unbacked Curved 180 Long Wide 
10 Backed Curved 135 Long Narrow 
11 Backed Straight 75 Long Wide 
12 Unbacked Curved 135 Long Narrow 
13 Unbacked Straight 180 Short Narrow 
14 Unbacked Curved 135 Short Narrow 
15 Backed Curved 75 Short Narrow 
16 Backed Straight 135 Long Wide 
17 Backed Curved 135 Short Wide 
18 Unbacked Curved 180 Long Narrow 
19 Backed Straight 135 Short Wide 
20 Unbacked Straight 180 Long Narrow 
21 Unbacked Curved 135 Long Wide 
22 Backed Straight 75 Long Narrow 
23 Unbacked Straight 135 Long Narrow 
24 Unbacked Straight 180 Short Wide 
25 Unbacked Straight 135 Long Wide 
26 Unbacked Straight 135 Short Narrow 
27 Backed Straight 135 Short Narrow 
28 Backed Straight 135 Long Narrow 
29 Unbacked Straight 180 Long Wide 
30 Unbacked Curved 180 Short Wide 
31 Backed Curved 75 Short Wide 
32 Backed Straight 75 Short Wide 
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Table XV: Second Thirty-Two Tests 
The second thirty-two statistical tests conducted, where treatments/experimental order 
were assigned at random using Microsoft Excel 
Treatment Backing Curving Porosity Size Width 
1 Unbacked Curved 180 Long Wide 
2 Unbacked Curved 135 Long Narrow 
3 Backed Curved 135 Long Narrow 
4 Unbacked Curved 180 Short Wide 
5 Unbacked Curved 180 Short Narrow 
6 Unbacked Curved 135 Long Wide 
7 Unbacked Straight 135 Short Narrow 
8 Unbacked Straight 135 Short Wide 
9 Unbacked Straight 180 Short Wide 
10 Backed Curved 135 Long Wide 
11 Backed Straight 75 Long Narrow 
12 Unbacked Straight 135 Long Narrow 
13 Backed Curved 75 Short Wide 
14 Backed Straight 75 Long Wide 
15 Backed Straight 75 Short Wide 
16 Backed Straight 135 Short Narrow 
17 Unbacked Curved 135 Short Narrow 
18 Unbacked Straight 135 Long Wide 
19 Unbacked Curved 180 Long Narrow 
20 Unbacked Straight 180 Long Wide 
21 Backed Straight 135 Short Wide 
22 Backed Curved 75 Long Narrow 
23 Unbacked Curved 135 Short Wide 
24 Backed Curved 75 Short Narrow 
25 Backed Curved 75 Long Wide 
26 Backed Straight 135 Long Wide 
27 Unbacked Straight 180 Short Narrow 
28 Unbacked Straight 180 Long Narrow 
29 Backed Straight 75 Short Narrow 
30 Backed Curved 135 Short Narrow 
31 Backed Straight 135 Long Narrow 
32 Backed Curved 135 Short Wide 	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Here is the Minitab output comparing all interactions possible regarding the backing, 
curvature, porosity, lengths, and widths of designs on nitrocellulose membrane in regard 
to wicking time. 
 
Analysis of Variance for log(time), using Adjusted SS for Tests 
 
Source                               DF    Seq SS   Adj SS   Adj MS       F 
Backing                               1   3.92230  3.92230  3.92230  110.98 
Curving                               1   1.46350  1.46350  1.46350   41.41 
Porosity                              1   5.43164  5.43164  5.43164  153.69 
Size                                  1   3.63407  3.63407  3.63407  102.83 
Width                                 1   0.12649  0.12649  0.12649    3.58 
Backing*Curving                       1   0.01984  0.01984  0.01984    0.56 
Backing*Porosity                      1   0.18685  0.18685  0.18685    5.29 
Backing*Size                          1   0.88287  0.88287  0.88287   24.98 
Backing*Width                         1   0.28513  0.28513  0.28513    8.07 
Curving*Porosity                      1   0.00759  0.00759  0.00759    0.21 
Curving*Size                          1   0.02229  0.02229  0.02229    0.63 
Curving*Width                         1   0.13143  0.13143  0.13143    3.72 
Porosity*Size                         1   0.38576  0.38576  0.38576   10.92 
Porosity*Width                        1   0.34372  0.34372  0.34372    9.73 
Size*Width                            1   0.01934  0.01934  0.01934    0.55 
Backing*Curving*Porosity              1   0.14515  0.14515  0.14515    4.11 
Backing*Curving*Size                  1   0.17992  0.17992  0.17992    5.09 
Backing*Curving*Width                 1   0.06833  0.06833  0.06833    1.93 
Backing*Porosity*Size                 1   0.12423  0.12423  0.12423    3.52 
Backing*Porosity*Width                1   0.10047  0.10047  0.10047    2.84 
Backing*Size*Width                    1   0.41725  0.41725  0.41725   11.81 
Curving*Porosity*Size                 1   0.20512  0.20512  0.20512    5.80 
Curving*Porosity*Width                1   0.15846  0.15846  0.15846    4.48 
Curving*Size*Width                    1   0.00019  0.00019  0.00019    0.01 
Porosity*Size*Width                   1   0.34707  0.34707  0.34707    9.82 
Backing*Curving*Porosity*Size         1   0.09133  0.09133  0.09133    2.58 
Backing*Curving*Porosity*Width        1   0.45561  0.45561  0.45561   12.89 
Backing*Curving*Size*Width            1   0.01903  0.01903  0.01903    0.54 
Backing*Porosity*Size*Width           1   0.12568  0.12568  0.12568    3.56 
Curving*Porosity*Size*Width           1   0.05602  0.05602  0.05602    1.58 
Backing*Curving*Porosity*Size*Width   1   0.00083  0.00083  0.00083    0.02 
Error                                32   1.13094  1.13094  0.03534 
Total                                63  20.48842 
 
Source                                   P 
Backing                              0.000 
Curving                              0.000 
Porosity                             0.000 
Size                                 0.000 
Width                                0.068 
Backing*Curving                      0.459 
Backing*Porosity                     0.028 
Backing*Size                         0.000 
Backing*Width                        0.008 
Curving*Porosity                     0.646 
Curving*Size                         0.433 
Curving*Width                        0.063 
Porosity*Size                        0.002 
Porosity*Width                       0.004 
Size*Width                           0.465 
Backing*Curving*Porosity             0.051 
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Backing*Curving*Size                 0.031 
Backing*Curving*Width                0.174 
Backing*Porosity*Size                0.070 
Backing*Porosity*Width               0.102 
Backing*Size*Width                   0.002 
Curving*Porosity*Size                0.022 
Curving*Porosity*Width               0.042 
Curving*Size*Width                   0.943 
Porosity*Size*Width                  0.004 
Backing*Curving*Porosity*Size        0.118 
Backing*Curving*Porosity*Width       0.001 
Backing*Curving*Size*Width           0.468 
Backing*Porosity*Size*Width          0.068 
Curving*Porosity*Size*Width          0.217 
Backing*Curving*Porosity*Size*Width  0.879 
Error 
Total	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ANOVA Output for the Initial Model 
 
General Linear Model: Time versus Backing, Curving, ...  
 
Factor    Type   Levels  Values 
Backing   fixed       2  Backed, Unbacked 
Curving   fixed       2  Curved, Straight 
Porosity  fixed       2  hi, lo 
Size      fixed       2  Long, Short 
Width     fixed       2  Narrow, Wide 
 
 
Analysis of Variance for Time, using Adjusted SS for Tests 
 
Source                               DF   Seq SS  Adj SS  Adj MS       F      P 
Backing                               1   264440  264440  264440  411.74  0.000 
Curving                               1   154046  154046  154046  239.86  0.000 
Porosity                              1   305933  305933  305933  476.35  0.000 
Size                                  1     1512    1512    1512    2.35  0.135 
Width                                 1    66596   66596   66596  103.69  0.000 
Backing*Curving                       1    89125   89125   89125  138.77  0.000 
Backing*Porosity                      1   181189  181189  181189  282.12  0.000 
Backing*Size                          1    57091   57091   57091   88.89  0.000 
Backing*Width                         1    81375   81375   81375  126.70  0.000 
Curving*Porosity                      1    95581   95581   95581  148.82  0.000 
Curving*Size                          1    58582   58582   58582   91.21  0.000 
Curving*Width                         1   122579  122579  122579  190.86  0.000 
Porosity*Size                         1    39526   39526   39526   61.54  0.000 
Porosity*Width                        1    81560   81560   81560  126.99  0.000 
Size*Width                            1    77960   77960   77960  121.39  0.000 
Backing*Curving*Porosity              1    86238   86238   86238  134.28  0.000 
Backing*Curving*Size                  1    97992   97992   97992  152.58  0.000 
Backing*Curving*Width                 1   128854  128854  128854  200.63  0.000 
Backing*Porosity*Size                 1    73123   73123   73123  113.86  0.000 
Backing*Porosity*Width                1    87283   87283   87283  135.90  0.000 
Backing*Size*Width                    1    87594   87594   87594  136.39  0.000 
Curving*Porosity*Size                 1    90518   90518   90518  140.94  0.000 
Curving*Porosity*Width                1   147101  147101  147101  229.04  0.000 
Curving*Size*Width                    1    30928   30928   30928   48.16  0.000 
Porosity*Size*Width                   1    85432   85432   85432  133.02  0.000 
Backing*Curving*Porosity*Size         1    91091   91091   91091  141.83  0.000 
Backing*Curving*Porosity*Width        1   154321  154321  154321  240.28  0.000 
Backing*Curving*Size*Width            1    31351   31351   31351   48.81  0.000 
Backing*Porosity*Size*Width           1    88202   88202   88202  137.33  0.000 
Curving*Porosity*Size*Width           1    23543   23543   23543   36.66  0.000 
Backing*Curving*Porosity*Size*Width   1    25724   25724   25724   40.05  0.000 
Error                                32    20552   20552     642 
Total                                63  3026943 
 
 
S = 25.3426   R-Sq = 99.32%   R-Sq(adj) = 98.66% 
 
 
Unusual Observations for Time 
 
Obs     Time      Fit  SE Fit  Residual  St Resid 
  9   357.50   311.30   17.92     46.20      2.58 R 
 13    97.40    60.20   17.92     37.20      2.08 R 
 25    20.00    62.95   17.92    -42.95     -2.40 R 
 30  1200.00  1245.30   17.92    -45.30     -2.53 R 
 33   265.10   311.30   17.92    -46.20     -2.58 R 
 36  1290.60  1245.30   17.92     45.30      2.53 R 
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 50   105.90    62.95   17.92     42.95      2.40 R 
 59    23.00    60.20   17.92    -37.20     -2.08 R 
 
R denotes an observation with a large standardized residual. 
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The following values are for the Cook’s distances for the initial statistical model.  
 
COOK4  
0.000002  
0.076924  
0.020970  
0.033003  
0.057922  
0.004520  
0.000006  
0.001996  
0.007456  
0.004872  
0.000085  
0.016967  
0.173713  
0.000246  
0.008772  
0.052204  
0.092205  
0.000601  
0.040064  
0.000454  
0.070392  
0.000517  
0.026726  
0.001515  
0.231658  
0.000009  
0.054164  
0.001944  
0.014258  
0.000442  
0.005063  
0.000331  
0.007456  
0.016967  
0.004872  
0.000442  
0.004520  
0.070392  
0.000009  
0.057922  
0.001515  
0.033003  
0.000517  
0.026726  
0.005063  
0.000085  
0.000331  
0.054164  
0.000246  
0.231658  
0.000601  
0.014258  
0.040064  
0.000006  
0.076924  
0.008772  
0.001996  
0.052204  
0.173713  
0.000454  
0.000002  
0.020970  
0.001944  
0.092205  	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 ANOVA Output for the Transformed log() Model 
General Linear Model: log(time) versus Backing, Curving, ...  
 
Factor    Type   Levels  Values 
Backing   fixed       2  Backed, Unbacked 
Curving   fixed       2  Curved, Straight 
Porosity  fixed       2  hi, lo 
Size      fixed       2  Long, Short 
Width     fixed       2  Narrow, Wide 
 
 
Analysis of Variance for log(time), using Adjusted SS for Tests 
 
Source                               DF    Seq SS   Adj SS   Adj MS       F 
Backing                               1   3.92230  3.92230  3.92230  110.98 
Curving                               1   1.46350  1.46350  1.46350   41.41 
Porosity                              1   5.43164  5.43164  5.43164  153.69 
Size                                  1   3.63407  3.63407  3.63407  102.83 
Width                                 1   0.12649  0.12649  0.12649    3.58 
Backing*Curving                       1   0.01984  0.01984  0.01984    0.56 
Backing*Porosity                      1   0.18685  0.18685  0.18685    5.29 
Backing*Size                          1   0.88287  0.88287  0.88287   24.98 
Backing*Width                         1   0.28513  0.28513  0.28513    8.07 
Curving*Porosity                      1   0.00759  0.00759  0.00759    0.21 
Curving*Size                          1   0.02229  0.02229  0.02229    0.63 
Curving*Width                         1   0.13143  0.13143  0.13143    3.72 
Porosity*Size                         1   0.38576  0.38576  0.38576   10.92 
Porosity*Width                        1   0.34372  0.34372  0.34372    9.73 
Size*Width                            1   0.01934  0.01934  0.01934    0.55 
Backing*Curving*Porosity              1   0.14515  0.14515  0.14515    4.11 
Backing*Curving*Size                  1   0.17992  0.17992  0.17992    5.09 
Backing*Curving*Width                 1   0.06833  0.06833  0.06833    1.93 
Backing*Porosity*Size                 1   0.12423  0.12423  0.12423    3.52 
Backing*Porosity*Width                1   0.10047  0.10047  0.10047    2.84 
Backing*Size*Width                    1   0.41725  0.41725  0.41725   11.81 
Curving*Porosity*Size                 1   0.20512  0.20512  0.20512    5.80 
Curving*Porosity*Width                1   0.15846  0.15846  0.15846    4.48 
Curving*Size*Width                    1   0.00019  0.00019  0.00019    0.01 
Porosity*Size*Width                   1   0.34707  0.34707  0.34707    9.82 
Backing*Curving*Porosity*Size         1   0.09133  0.09133  0.09133    2.58 
Backing*Curving*Porosity*Width        1   0.45561  0.45561  0.45561   12.89 
Backing*Curving*Size*Width            1   0.01903  0.01903  0.01903    0.54 
Backing*Porosity*Size*Width           1   0.12568  0.12568  0.12568    3.56 
Curving*Porosity*Size*Width           1   0.05602  0.05602  0.05602    1.58 
Backing*Curving*Porosity*Size*Width   1   0.00083  0.00083  0.00083    0.02 
Error                                32   1.13094  1.13094  0.03534 
Total                                63  20.48842 
 
Source                                   P 
Backing                              0.000 
Curving                              0.000 
Porosity                             0.000 
Size                                 0.000 
Width                                0.068 
Backing*Curving                      0.459 
Backing*Porosity                     0.028 
Backing*Size                         0.000 
Backing*Width                        0.008 
Curving*Porosity                     0.646 
Curving*Size                         0.433 
Curving*Width                        0.063 
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Porosity*Size                        0.002 
Porosity*Width                       0.004 
Size*Width                           0.465 
Backing*Curving*Porosity             0.051 
Backing*Curving*Size                 0.031 
Backing*Curving*Width                0.174 
Backing*Porosity*Size                0.070 
Backing*Porosity*Width               0.102 
Backing*Size*Width                   0.002 
Curving*Porosity*Size                0.022 
Curving*Porosity*Width               0.042 
Curving*Size*Width                   0.943 
Porosity*Size*Width                  0.004 
Backing*Curving*Porosity*Size        0.118 
Backing*Curving*Porosity*Width       0.001 
Backing*Curving*Size*Width           0.468 
Backing*Porosity*Size*Width          0.068 
Curving*Porosity*Size*Width          0.217 
Backing*Curving*Porosity*Size*Width  0.879 
Error 
Total 
 
 
S = 0.187994   R-Sq = 94.48%   R-Sq(adj) = 89.13% 
 
 
Unusual Observations for log(time) 
 
Obs  log(time)      Fit   SE Fit  Residual  St Resid 
 13    1.98856  1.67514  0.13293   0.31342      2.36 R 
 25    1.30103  1.66296  0.13293  -0.36193     -2.72 R 
 50    2.02490  1.66296  0.13293   0.36193      2.72 R 
 59    1.36173  1.67514  0.13293  -0.31342     -2.36 R 
 
R denotes an observation with a large standardized residual. 
 
 
Grouping Information Using Tukey Method and 99.8% Confidence 
 
Backing   Size    N  Mean  Grouping 
Unbacked  Long   16   2.0  A 
Unbacked  Short  16   1.8  A 
Backed    Long   16   1.7  A 
Backed    Short  16   1.0    B 
 
Means that do not share a letter are significantly different. 
 
 
Tukey 99.8% Simultaneous Confidence Intervals 
Response Variable log(time) 
All Pairwise Comparisons among Levels of Backing*Size 
Backing = Backed 
Size = Long  subtracted from: 
 
Backing   Size     Lower   Center    Upper 
Backed    Short  -0.9813  -0.7115  -0.4417 
Unbacked  Long   -0.0096   0.2602   0.5300 
Unbacked  Short  -0.2512   0.0185   0.2883 
 
Backing   Size   ----+---------+---------+---------+-- 
Backed    Short  (---*---) 
Unbacked  Long                 (---*---) 
Unbacked  Short            (---*---) 
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                 ----+---------+---------+---------+-- 
                  -0.70      0.00      0.70      1.40 
 
 
Backing = Backed 
Size = Short  subtracted from: 
 
Backing   Size    Lower  Center   Upper  ----+---------+---------+---------+-- 
Unbacked  Long   0.7019  0.9717  1.2415                          (---*---) 
Unbacked  Short  0.4603  0.7300  0.9998                       (--*---) 
                                         ----+---------+---------+---------+-- 
                                          -0.70      0.00      0.70      1.40 
 
 
Backing = Unbacked 
Size = Long  subtracted from: 
 
Backing   Size     Lower   Center    Upper 
Unbacked  Short  -0.5115  -0.2417  0.02809 
 
Backing   Size   ----+---------+---------+---------+-- 
Unbacked  Short         (---*--) 
                 ----+---------+---------+---------+-- 
                  -0.70      0.00      0.70      1.40 
 
 
Tukey Simultaneous Tests 
Response Variable log(time) 
All Pairwise Comparisons among Levels of Backing*Size 
Backing = Backed 
Size = Long  subtracted from: 
 
                 Difference       SE of           Adjusted 
Backing   Size     of Means  Difference  T-Value   P-Value 
Backed    Short     -0.7115     0.06647   -10.70    0.0000 
Unbacked  Long       0.2602     0.06647     3.92    0.0024 
Unbacked  Short      0.0185     0.06647     0.28    0.9923 
 
 
Backing = Backed 
Size = Short  subtracted from: 
 
                 Difference       SE of           Adjusted 
Backing   Size     of Means  Difference  T-Value   P-Value 
Unbacked  Long       0.9717     0.06647    14.62    0.0000 
Unbacked  Short      0.7300     0.06647    10.98    0.0000 
 
 
Backing = Unbacked 
Size = Long  subtracted from: 
 
                 Difference       SE of           Adjusted 
Backing   Size     of Means  Difference  T-Value   P-Value 
Unbacked  Short     -0.2417     0.06647   -3.636    0.0051 
 
 
Grouping Information Using Tukey Method and 99.8% Confidence 
 
Backing   Curving   Porosity  Width   N  Mean  Grouping 
Unbacked  Curved    hi        Wide    4   2.8  A 
Unbacked  Curved    hi        Narrow  4   2.1    B 
Unbacked  Straight  hi        Narrow  4   2.1    B C 
Unbacked  Straight  hi        Wide    4   1.9    B C D 
	  124 	  
Backed    Curved    hi        Narrow  4   1.8    B C D E 
Unbacked  Curved    lo        Narrow  4   1.8    B C D E 
Backed    Curved    hi        Wide    4   1.6    B C D E 
Backed    Straight  hi        Narrow  4   1.6    B C D E 
Unbacked  Curved    lo        Wide    4   1.5    B C D E 
Backed    Straight  hi        Wide    4   1.5    B C D E 
Unbacked  Straight  lo        Narrow  4   1.5    B C D E 
Backed    Curved    lo        Narrow  4   1.4      C D E F 
Unbacked  Straight  lo        Wide    4   1.4        D E F 
Backed    Curved    lo        Wide    4   1.2          E F 
Backed    Straight  lo        Narrow  4   1.2          E F 
Backed    Straight  lo        Wide    4   0.8            F 
 
Means that do not share a letter are significantly different. 
 
 
Tukey 99.8% Simultaneous Confidence Intervals 
Response Variable log(time) 
All Pairwise Comparisons among Levels of Backing*Curving*Porosity*Width 
Backing = Backed 
Curving = Curved 
Porosity = hi 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower  Center    Upper 
Backed    Curved    hi        Wide    -0.869  -0.199   0.4712 
Backed    Curved    lo        Narrow  -1.073  -0.403   0.2672 
Backed    Curved    lo        Wide    -1.268  -0.598   0.0720 
Backed    Straight  hi        Narrow  -0.908  -0.238   0.4325 
Backed    Straight  hi        Wide    -1.019  -0.349   0.3214 
Backed    Straight  lo        Narrow  -1.319  -0.649   0.0210 
Backed    Straight  lo        Wide    -1.704  -1.033  -0.3632 
Unbacked  Curved    hi        Narrow  -0.383   0.287   0.9570 
Unbacked  Curved    hi        Wide     0.311   0.981   1.6517 
Unbacked  Curved    lo        Narrow  -0.697  -0.027   0.6433 
Unbacked  Curved    lo        Wide    -0.991  -0.320   0.3498 
Unbacked  Straight  hi        Narrow  -0.414   0.256   0.9266 
Unbacked  Straight  hi        Wide    -0.568   0.103   0.7727 
Unbacked  Straight  lo        Narrow  -1.030  -0.360   0.3104 
Unbacked  Straight  lo        Wide    -1.099  -0.429   0.2415 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Curved    hi        Wide            (----*---) 
Backed    Curved    lo        Narrow         (---*----) 
Backed    Curved    lo        Wide          (---*---) 
Backed    Straight  hi        Narrow          (---*----) 
Backed    Straight  hi        Wide           (----*---) 
Backed    Straight  lo        Narrow       (----*---) 
Backed    Straight  lo        Wide       (---*----) 
Unbacked  Curved    hi        Narrow             (----*---) 
Unbacked  Curved    hi        Wide                    (----*---) 
Unbacked  Curved    lo        Narrow           (----*---) 
Unbacked  Curved    lo        Wide           (----*---) 
Unbacked  Straight  hi        Narrow             (----*---) 
Unbacked  Straight  hi        Wide              (----*---) 
Unbacked  Straight  lo        Narrow         (----*---) 
Unbacked  Straight  lo        Wide           (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Curved 
	  125 	  
Porosity = hi 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center    Upper 
Backed    Curved    lo        Narrow  -0.874  -0.2040   0.4662 
Backed    Curved    lo        Wide    -1.069  -0.3992   0.2710 
Backed    Straight  hi        Narrow  -0.709  -0.0387   0.6315 
Backed    Straight  hi        Wide    -0.820  -0.1498   0.5204 
Backed    Straight  lo        Narrow  -1.120  -0.4502   0.2200 
Backed    Straight  lo        Wide    -1.505  -0.8344  -0.1642 
Unbacked  Curved    hi        Narrow  -0.184   0.4858   1.1560 
Unbacked  Curved    hi        Wide     0.510   1.1805   1.8507 
Unbacked  Curved    lo        Narrow  -0.498   0.1722   0.8424 
Unbacked  Curved    lo        Wide    -0.792  -0.1213   0.5489 
Unbacked  Straight  hi        Narrow  -0.215   0.4554   1.1256 
Unbacked  Straight  hi        Wide    -0.369   0.3016   0.9718 
Unbacked  Straight  lo        Narrow  -0.831  -0.1607   0.5095 
Unbacked  Straight  lo        Wide    -0.900  -0.2297   0.4405 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Curved    lo        Narrow          (----*---) 
Backed    Curved    lo        Wide           (---*----) 
Backed    Straight  hi        Narrow           (----*---) 
Backed    Straight  hi        Wide             (---*---) 
Backed    Straight  lo        Narrow         (---*---) 
Backed    Straight  lo        Wide        (---*----) 
Unbacked  Curved    hi        Narrow               (---*----) 
Unbacked  Curved    hi        Wide                     (----*---) 
Unbacked  Curved    lo        Narrow             (---*----) 
Unbacked  Curved    lo        Wide             (---*----) 
Unbacked  Straight  hi        Narrow               (---*----) 
Unbacked  Straight  hi        Wide                (---*---) 
Unbacked  Straight  lo        Narrow          (----*---) 
Unbacked  Straight  lo        Wide            (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Curved 
Porosity = lo 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center    Upper 
Backed    Curved    lo        Wide    -0.865  -0.1952  0.47498 
Backed    Straight  hi        Narrow  -0.505   0.1653  0.83552 
Backed    Straight  hi        Wide    -0.616   0.0542  0.72438 
Backed    Straight  lo        Narrow  -0.916  -0.2462  0.42403 
Backed    Straight  lo        Wide    -1.301  -0.6304  0.03978 
Unbacked  Curved    hi        Narrow   0.020   0.6898  1.36004 
Unbacked  Curved    hi        Wide     0.714   1.3845  2.05467 
Unbacked  Curved    lo        Narrow  -0.294   0.3762  1.04637 
Unbacked  Curved    lo        Wide    -0.588   0.0827  0.75286 
Unbacked  Straight  hi        Narrow  -0.011   0.6594  1.32960 
Unbacked  Straight  hi        Wide    -0.165   0.5055  1.17575 
Unbacked  Straight  lo        Narrow  -0.627   0.0433  0.71346 
Unbacked  Straight  lo        Wide    -0.696  -0.0257  0.64452 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Curved    lo        Wide            (----*---) 
Backed    Straight  hi        Narrow             (---*----) 
Backed    Straight  hi        Wide              (---*----) 
Backed    Straight  lo        Narrow          (---*----) 
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Backed    Straight  lo        Wide         (----*---) 
Unbacked  Curved    hi        Narrow                (----*---) 
Unbacked  Curved    hi        Wide                       (---*----) 
Unbacked  Curved    lo        Narrow              (----*---) 
Unbacked  Curved    lo        Wide              (----*---) 
Unbacked  Straight  hi        Narrow                (---*----) 
Unbacked  Straight  hi        Wide                 (---*----) 
Unbacked  Straight  lo        Narrow            (---*----) 
Unbacked  Straight  lo        Wide             (----*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Curved 
Porosity = lo 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center   Upper 
Backed    Straight  hi        Narrow  -0.310   0.3605  1.0307 
Backed    Straight  hi        Wide    -0.421   0.2494  0.9196 
Backed    Straight  lo        Narrow  -0.721  -0.0510  0.6192 
Backed    Straight  lo        Wide    -1.105  -0.4352  0.2350 
Unbacked  Curved    hi        Narrow   0.215   0.8851  1.5553 
Unbacked  Curved    hi        Wide     0.909   1.5797  2.2499 
Unbacked  Curved    lo        Narrow  -0.099   0.5714  1.2416 
Unbacked  Curved    lo        Wide    -0.392   0.2779  0.9481 
Unbacked  Straight  hi        Narrow   0.184   0.8546  1.5248 
Unbacked  Straight  hi        Wide     0.031   0.7008  1.3710 
Unbacked  Straight  lo        Narrow  -0.432   0.2385  0.9087 
Unbacked  Straight  lo        Wide    -0.501   0.1695  0.8397 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Straight  hi        Narrow              (---*----) 
Backed    Straight  hi        Wide               (----*---) 
Backed    Straight  lo        Narrow           (----*---) 
Backed    Straight  lo        Wide           (---*----) 
Unbacked  Curved    hi        Narrow                 (----*---) 
Unbacked  Curved    hi        Wide                        (----*---) 
Unbacked  Curved    lo        Narrow               (----*---) 
Unbacked  Curved    lo        Wide               (----*---) 
Unbacked  Straight  hi        Narrow                 (----*---) 
Unbacked  Straight  hi        Wide                  (----*---) 
Unbacked  Straight  lo        Narrow             (----*---) 
Unbacked  Straight  lo        Wide               (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Straight 
Porosity = hi 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center    Upper 
Backed    Straight  hi        Wide    -0.781  -0.1111   0.5591 
Backed    Straight  lo        Narrow  -1.082  -0.4115   0.2587 
Backed    Straight  lo        Wide    -1.466  -0.7957  -0.1255 
Unbacked  Curved    hi        Narrow  -0.146   0.5245   1.1947 
Unbacked  Curved    hi        Wide     0.549   1.2192   1.8894 
Unbacked  Curved    lo        Narrow  -0.459   0.2109   0.8811 
Unbacked  Curved    lo        Wide    -0.753  -0.0827   0.5875 
Unbacked  Straight  hi        Narrow  -0.176   0.4941   1.1643 
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Unbacked  Straight  hi        Wide    -0.330   0.3402   1.0104 
Unbacked  Straight  lo        Narrow  -0.792  -0.1221   0.5481 
Unbacked  Straight  lo        Wide    -0.861  -0.1910   0.4792 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Straight  hi        Wide             (---*----) 
Backed    Straight  lo        Narrow         (---*----) 
Backed    Straight  lo        Wide        (----*---) 
Unbacked  Curved    hi        Narrow               (---*----) 
Unbacked  Curved    hi        Wide                      (---*----) 
Unbacked  Curved    lo        Narrow             (---*----) 
Unbacked  Curved    lo        Wide             (---*----) 
Unbacked  Straight  hi        Narrow               (---*----) 
Unbacked  Straight  hi        Wide                (---*----) 
Unbacked  Straight  lo        Narrow           (---*----) 
Unbacked  Straight  lo        Wide            (----*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Straight 
Porosity = hi 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center     Upper 
Backed    Straight  lo        Narrow  -0.971  -0.3004   0.36984 
Backed    Straight  lo        Wide    -1.355  -0.6846  -0.01440 
Unbacked  Curved    hi        Narrow  -0.035   0.6357   1.30585 
Unbacked  Curved    hi        Wide     0.660   1.3303   2.00049 
Unbacked  Curved    lo        Narrow  -0.348   0.3220   0.99219 
Unbacked  Curved    lo        Wide    -0.642   0.0285   0.69868 
Unbacked  Straight  hi        Narrow  -0.065   0.6052   1.27542 
Unbacked  Straight  hi        Wide    -0.219   0.4514   1.12156 
Unbacked  Straight  lo        Narrow  -0.681  -0.0109   0.65928 
Unbacked  Straight  lo        Wide    -0.750  -0.0799   0.59034 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Straight  lo        Narrow          (---*---) 
Backed    Straight  lo        Wide         (---*----) 
Unbacked  Curved    hi        Narrow                (---*----) 
Unbacked  Curved    hi        Wide                      (----*---) 
Unbacked  Curved    lo        Narrow              (---*----) 
Unbacked  Curved    lo        Wide              (---*----) 
Unbacked  Straight  hi        Narrow                (---*----) 
Unbacked  Straight  hi        Wide                 (---*---) 
Unbacked  Straight  lo        Narrow           (----*---) 
Unbacked  Straight  lo        Wide             (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Straight 
Porosity = lo 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center   Upper 
Backed    Straight  lo        Wide    -1.054  -0.3842  0.2860 
Unbacked  Curved    hi        Narrow   0.266   0.9360  1.6062 
Unbacked  Curved    hi        Wide     0.960   1.6306  2.3008 
Unbacked  Curved    lo        Narrow  -0.048   0.6223  1.2925 
Unbacked  Curved    lo        Wide    -0.341   0.3288  0.9990 
	  128 	  
Unbacked  Straight  hi        Narrow   0.235   0.9056  1.5758 
Unbacked  Straight  hi        Wide     0.082   0.7517  1.4219 
Unbacked  Straight  lo        Narrow  -0.381   0.2894  0.9596 
Unbacked  Straight  lo        Wide    -0.450   0.2205  0.8907 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Straight  lo        Wide           (---*----) 
Unbacked  Curved    hi        Narrow                  (---*----) 
Unbacked  Curved    hi        Wide                        (----*---) 
Unbacked  Curved    lo        Narrow                (---*----) 
Unbacked  Curved    lo        Wide                (---*----) 
Unbacked  Straight  hi        Narrow                  (---*----) 
Unbacked  Straight  hi        Wide                   (---*---) 
Unbacked  Straight  lo        Narrow             (----*---) 
Unbacked  Straight  lo        Wide               (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Straight 
Porosity = lo 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width      Lower  Center  Upper 
Unbacked  Curved    hi        Narrow   0.65005  1.3203  1.990 
Unbacked  Curved    hi        Wide     1.34469  2.0149  2.685 
Unbacked  Curved    lo        Narrow   0.33639  1.0066  1.677 
Unbacked  Curved    lo        Wide     0.04288  0.7131  1.383 
Unbacked  Straight  hi        Narrow   0.61962  1.2898  1.960 
Unbacked  Straight  hi        Wide     0.46577  1.1360  1.806 
Unbacked  Straight  lo        Narrow   0.00348  0.6737  1.344 
Unbacked  Straight  lo        Wide    -0.06546  0.6047  1.275 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Curved    hi        Narrow                    (----*---) 
Unbacked  Curved    hi        Wide                           (---*----) 
Unbacked  Curved    lo        Narrow                  (----*---) 
Unbacked  Curved    lo        Wide                  (----*---) 
Unbacked  Straight  hi        Narrow                    (----*---) 
Unbacked  Straight  hi        Wide                     (----*---) 
Unbacked  Straight  lo        Narrow                (---*----) 
Unbacked  Straight  lo        Wide                  (---*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = hi 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center     Upper 
Unbacked  Curved    hi        Wide     0.024   0.6946   1.36484 
Unbacked  Curved    lo        Narrow  -0.984  -0.3137   0.35654 
Unbacked  Curved    lo        Wide    -1.277  -0.6072   0.06302 
Unbacked  Straight  hi        Narrow  -0.701  -0.0304   0.63977 
Unbacked  Straight  hi        Wide    -0.854  -0.1843   0.48591 
Unbacked  Straight  lo        Narrow  -1.317  -0.6466   0.02363 
Unbacked  Straight  lo        Wide    -1.386  -0.7155  -0.04532 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Curved    hi        Wide                  (----*---) 
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Unbacked  Curved    lo        Narrow         (----*---) 
Unbacked  Curved    lo        Wide         (----*---) 
Unbacked  Straight  hi        Narrow           (----*---) 
Unbacked  Straight  hi        Wide            (----*---) 
Unbacked  Straight  lo        Narrow       (----*---) 
Unbacked  Straight  lo        Wide         (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = hi 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower  Center    Upper 
Unbacked  Curved    lo        Narrow  -1.679  -1.008  -0.3381 
Unbacked  Curved    lo        Wide    -1.972  -1.302  -0.6316 
Unbacked  Straight  hi        Narrow  -1.395  -0.725  -0.0549 
Unbacked  Straight  hi        Wide    -1.549  -0.879  -0.2087 
Unbacked  Straight  lo        Narrow  -2.011  -1.341  -0.6710 
Unbacked  Straight  lo        Wide    -2.080  -1.410  -0.7400 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Curved    lo        Narrow     (---*----) 
Unbacked  Curved    lo        Wide     (---*----) 
Unbacked  Straight  hi        Narrow       (---*----) 
Unbacked  Straight  hi        Wide        (---*----) 
Unbacked  Straight  lo        Narrow   (---*----) 
Unbacked  Straight  lo        Wide    (----*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = lo 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center   Upper 
Unbacked  Curved    lo        Wide    -0.964  -0.2935  0.3767 
Unbacked  Straight  hi        Narrow  -0.387   0.2832  0.9534 
Unbacked  Straight  hi        Wide    -0.541   0.1294  0.7996 
Unbacked  Straight  lo        Narrow  -1.003  -0.3329  0.3373 
Unbacked  Straight  lo        Wide    -1.072  -0.4019  0.2683 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Curved    lo        Wide            (---*----) 
Unbacked  Straight  hi        Narrow             (----*---) 
Unbacked  Straight  hi        Wide              (----*---) 
Unbacked  Straight  lo        Narrow         (----*---) 
Unbacked  Straight  lo        Wide           (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = lo 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width     Lower   Center   Upper 
Unbacked  Straight  hi        Narrow  -0.0935   0.5767  1.2469 
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Unbacked  Straight  hi        Wide    -0.2473   0.4229  1.0931 
Unbacked  Straight  lo        Narrow  -0.7096  -0.0394  0.6308 
Unbacked  Straight  lo        Wide    -0.7785  -0.1083  0.5619 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Straight  hi        Narrow               (----*---) 
Unbacked  Straight  hi        Wide                (----*---) 
Unbacked  Straight  lo        Narrow           (----*---) 
Unbacked  Straight  lo        Wide             (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Straight 
Porosity = hi 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center     Upper 
Unbacked  Straight  hi        Wide    -0.824  -0.1539   0.51635 
Unbacked  Straight  lo        Narrow  -1.286  -0.6161   0.05406 
Unbacked  Straight  lo        Wide    -1.355  -0.6851  -0.01488 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Straight  hi        Wide             (---*---) 
Unbacked  Straight  lo        Narrow       (----*---) 
Unbacked  Straight  lo        Wide         (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Straight 
Porosity = hi 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center   Upper 
Unbacked  Straight  lo        Narrow  -1.132  -0.4623  0.2079 
Unbacked  Straight  lo        Wide    -1.201  -0.5312  0.1390 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Straight  lo        Narrow        (----*---) 
Unbacked  Straight  lo        Wide          (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Straight 
Porosity = lo 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower    Center   Upper 
Unbacked  Straight  lo        Wide   -0.7391  -0.06894  0.6013 
 
Backing   Curving   Porosity  Width  ----+---------+---------+---------+-- 
Unbacked  Straight  lo        Wide            (----*---) 
                                     ----+---------+---------+---------+-- 
                                      -1.5       0.0       1.5       3.0 
 
 
Tukey Simultaneous Tests 
Response Variable log(time) 
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All Pairwise Comparisons among Levels of Backing*Curving*Porosity*Width 
Backing = Backed 
Curving = Curved 
Porosity = hi 
Width = Narrow  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Backed    Curved    hi        Wide        -0.199      0.1329   -1.497    0.9748 
Backed    Curved    lo        Narrow      -0.403      0.1329   -3.032    0.2115 
Backed    Curved    lo        Wide        -0.598      0.1329   -4.500    0.0068 
Backed    Straight  hi        Narrow      -0.238      0.1329   -1.788    0.9032 
Backed    Straight  hi        Wide        -0.349      0.1329   -2.624    0.4175 
Backed    Straight  lo        Narrow      -0.649      0.1329   -4.884    0.0024 
Backed    Straight  lo        Wide        -1.033      0.1329   -7.774    0.0000 
Unbacked  Curved    hi        Narrow       0.287      0.1329    2.158    0.7174 
Unbacked  Curved    hi        Wide         0.981      0.1329    7.383    0.0000 
Unbacked  Curved    lo        Narrow      -0.027      0.1329   -0.202    1.0000 
Unbacked  Curved    lo        Wide        -0.320      0.1329   -2.410    0.5539 
Unbacked  Straight  hi        Narrow       0.256      0.1329    1.929    0.8441 
Unbacked  Straight  hi        Wide         0.103      0.1329    0.771    1.0000 
Unbacked  Straight  lo        Narrow      -0.360      0.1329   -2.706    0.3692 
Unbacked  Straight  lo        Wide        -0.429      0.1329   -3.225    0.1450 
 
 
Backing = Backed 
Curving = Curved 
Porosity = hi 
Width = Wide  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Backed    Curved    lo        Narrow     -0.2040      0.1329   -1.535    0.9691 
Backed    Curved    lo        Wide       -0.3992      0.1329   -3.003    0.2231 
Backed    Straight  hi        Narrow     -0.0387      0.1329   -0.291    1.0000 
Backed    Straight  hi        Wide       -0.1498      0.1329   -1.127    0.9984 
Backed    Straight  lo        Narrow     -0.4502      0.1329   -3.386    0.1034 
Backed    Straight  lo        Wide       -0.8344      0.1329   -6.277    0.0001 
Unbacked  Curved    hi        Narrow      0.4858      0.1329    3.655    0.0567 
Unbacked  Curved    hi        Wide        1.1805      0.1329    8.880    0.0000 
Unbacked  Curved    lo        Narrow      0.1722      0.1329    1.295    0.9933 
Unbacked  Curved    lo        Wide       -0.1213      0.1329   -0.913    0.9999 
Unbacked  Straight  hi        Narrow      0.4554      0.1329    3.426    0.0949 
Unbacked  Straight  hi        Wide        0.3016      0.1329    2.268    0.6469 
Unbacked  Straight  lo        Narrow     -0.1607      0.1329   -1.209    0.9966 
Unbacked  Straight  lo        Wide       -0.2297      0.1329   -1.728    0.9235 
 
 
Backing = Backed 
Curving = Curved 
Porosity = lo 
Width = Narrow  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Backed    Curved    lo        Wide       -0.1952      0.1329   -1.469    0.9787 
Backed    Straight  hi        Narrow      0.1653      0.1329    1.244    0.9955 
Backed    Straight  hi        Wide        0.0542      0.1329    0.408    1.0000 
Backed    Straight  lo        Narrow     -0.2462      0.1329   -1.852    0.8784 
Backed    Straight  lo        Wide       -0.6304      0.1329   -4.742    0.0036 
Unbacked  Curved    hi        Narrow      0.6898      0.1329    5.189    0.0011 
Unbacked  Curved    hi        Wide        1.3845      0.1329   10.415    0.0000 
Unbacked  Curved    lo        Narrow      0.3762      0.1329    2.830    0.3027 
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Unbacked  Curved    lo        Wide        0.0827      0.1329    0.622    1.0000 
Unbacked  Straight  hi        Narrow      0.6594      0.1329    4.960    0.0020 
Unbacked  Straight  hi        Wide        0.5055      0.1329    3.803    0.0399 
Unbacked  Straight  lo        Narrow      0.0433      0.1329    0.325    1.0000 
Unbacked  Straight  lo        Wide       -0.0257      0.1329   -0.193    1.0000 
 
 
Backing = Backed 
Curving = Curved 
Porosity = lo 
Width = Wide  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Backed    Straight  hi        Narrow      0.3605      0.1329    2.712    0.3659 
Backed    Straight  hi        Wide        0.2494      0.1329    1.876    0.8681 
Backed    Straight  lo        Narrow     -0.0510      0.1329   -0.383    1.0000 
Backed    Straight  lo        Wide       -0.4352      0.1329   -3.274    0.1312 
Unbacked  Curved    hi        Narrow      0.8851      0.1329    6.658    0.0001 
Unbacked  Curved    hi        Wide        1.5797      0.1329   11.883    0.0000 
Unbacked  Curved    lo        Narrow      0.5714      0.1329    4.298    0.0116 
Unbacked  Curved    lo        Wide        0.2779      0.1329    2.090    0.7578 
Unbacked  Straight  hi        Narrow      0.8546      0.1329    6.429    0.0001 
Unbacked  Straight  hi        Wide        0.7008      0.1329    5.272    0.0009 
Unbacked  Straight  lo        Narrow      0.2385      0.1329    1.794    0.9011 
Unbacked  Straight  lo        Wide        0.1695      0.1329    1.275    0.9942 
 
 
Backing = Backed 
Curving = Straight 
Porosity = hi 
Width = Narrow  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Backed    Straight  hi        Wide       -0.1111      0.1329   -0.836    0.9999 
Backed    Straight  lo        Narrow     -0.4115      0.1329   -3.095    0.1874 
Backed    Straight  lo        Wide       -0.7957      0.1329   -5.986    0.0002 
Unbacked  Curved    hi        Narrow      0.5245      0.1329    3.946    0.0282 
Unbacked  Curved    hi        Wide        1.2192      0.1329    9.171    0.0000 
Unbacked  Curved    lo        Narrow      0.2109      0.1329    1.586    0.9596 
Unbacked  Curved    lo        Wide       -0.0827      0.1329   -0.622    1.0000 
Unbacked  Straight  hi        Narrow      0.4941      0.1329    3.717    0.0490 
Unbacked  Straight  hi        Wide        0.3402      0.1329    2.559    0.4574 
Unbacked  Straight  lo        Narrow     -0.1221      0.1329   -0.918    0.9998 
Unbacked  Straight  lo        Wide       -0.1910      0.1329   -1.437    0.9824 
 
 
Backing = Backed 
Curving = Straight 
Porosity = hi 
Width = Wide  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Backed    Straight  lo        Narrow     -0.3004      0.1329   -2.259    0.6528 
Backed    Straight  lo        Wide       -0.6846      0.1329   -5.150    0.0012 
Unbacked  Curved    hi        Narrow      0.6357      0.1329    4.782    0.0032 
Unbacked  Curved    hi        Wide        1.3303      0.1329   10.007    0.0000 
Unbacked  Curved    lo        Narrow      0.3220      0.1329    2.422    0.5459 
Unbacked  Curved    lo        Wide        0.0285      0.1329    0.214    1.0000 
Unbacked  Straight  hi        Narrow      0.6052      0.1329    4.553    0.0059 
Unbacked  Straight  hi        Wide        0.4514      0.1329    3.395    0.1014 
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Unbacked  Straight  lo        Narrow     -0.0109      0.1329   -0.082    1.0000 
Unbacked  Straight  lo        Wide       -0.0799      0.1329   -0.601    1.0000 
 
 
Backing = Backed 
Curving = Straight 
Porosity = lo 
Width = Narrow  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Backed    Straight  lo        Wide       -0.3842      0.1329   -2.891    0.2729 
Unbacked  Curved    hi        Narrow      0.9360      0.1329    7.041    0.0001 
Unbacked  Curved    hi        Wide        1.6306      0.1329   12.267    0.0000 
Unbacked  Curved    lo        Narrow      0.6223      0.1329    4.682    0.0042 
Unbacked  Curved    lo        Wide        0.3288      0.1329    2.474    0.5122 
Unbacked  Straight  hi        Narrow      0.9056      0.1329    6.812    0.0001 
Unbacked  Straight  hi        Wide        0.7517      0.1329    5.655    0.0003 
Unbacked  Straight  lo        Narrow      0.2894      0.1329    2.177    0.7052 
Unbacked  Straight  lo        Wide        0.2205      0.1329    1.659    0.9431 
 
 
Backing = Backed 
Curving = Straight 
Porosity = lo 
Width = Wide  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Unbacked  Curved    hi        Narrow      1.3203      0.1329    9.932    0.0000 
Unbacked  Curved    hi        Wide        2.0149      0.1329   15.157    0.0000 
Unbacked  Curved    lo        Narrow      1.0066      0.1329    7.572    0.0000 
Unbacked  Curved    lo        Wide        0.7131      0.1329    5.364    0.0007 
Unbacked  Straight  hi        Narrow      1.2898      0.1329    9.703    0.0000 
Unbacked  Straight  hi        Wide        1.1360      0.1329    8.545    0.0000 
Unbacked  Straight  lo        Narrow      0.6737      0.1329    5.068    0.0015 
Unbacked  Straight  lo        Wide        0.6047      0.1329    4.549    0.0060 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = hi 
Width = Narrow  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Unbacked  Curved    hi        Wide        0.6946      0.1329    5.226    0.0010 
Unbacked  Curved    lo        Narrow     -0.3137      0.1329   -2.360    0.5872 
Unbacked  Curved    lo        Wide       -0.6072      0.1329   -4.568    0.0057 
Unbacked  Straight  hi        Narrow     -0.0304      0.1329   -0.229    1.0000 
Unbacked  Straight  hi        Wide       -0.1843      0.1329   -1.386    0.9872 
Unbacked  Straight  lo        Narrow     -0.6466      0.1329   -4.864    0.0026 
Unbacked  Straight  lo        Wide       -0.7155      0.1329   -5.383    0.0006 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = hi 
Width = Wide  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Unbacked  Curved    lo        Narrow      -1.008      0.1329    -7.59    0.0000 
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Unbacked  Curved    lo        Wide        -1.302      0.1329    -9.79    0.0000 
Unbacked  Straight  hi        Narrow      -0.725      0.1329    -5.45    0.0005 
Unbacked  Straight  hi        Wide        -0.879      0.1329    -6.61    0.0001 
Unbacked  Straight  lo        Narrow      -1.341      0.1329   -10.09    0.0000 
Unbacked  Straight  lo        Wide        -1.410      0.1329   -10.61    0.0000 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = lo 
Width = Narrow  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Unbacked  Curved    lo        Wide       -0.2935      0.1329   -2.208    0.6858 
Unbacked  Straight  hi        Narrow      0.2832      0.1329    2.131    0.7339 
Unbacked  Straight  hi        Wide        0.1294      0.1329    0.973    0.9997 
Unbacked  Straight  lo        Narrow     -0.3329      0.1329   -2.504    0.4924 
Unbacked  Straight  lo        Wide       -0.4019      0.1329   -3.023    0.2150 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = lo 
Width = Wide  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Unbacked  Straight  hi        Narrow      0.5767      0.1329   4.3386    0.0104 
Unbacked  Straight  hi        Wide        0.4229      0.1329   3.1812    0.1584 
Unbacked  Straight  lo        Narrow     -0.0394      0.1329  -0.2964    1.0000 
Unbacked  Straight  lo        Wide       -0.1083      0.1329  -0.8150    1.0000 
 
 
Backing = Unbacked 
Curving = Straight 
Porosity = hi 
Width = Narrow  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Unbacked  Straight  hi        Wide       -0.1539      0.1329   -1.157    0.9978 
Unbacked  Straight  lo        Narrow     -0.6161      0.1329   -4.635    0.0048 
Unbacked  Straight  lo        Wide       -0.6851      0.1329   -5.154    0.0012 
 
 
Backing = Unbacked 
Curving = Straight 
Porosity = hi 
Width = Wide  subtracted from: 
 
                                      Difference       SE of           Adjusted 
Backing   Curving   Porosity  Width     of Means  Difference  T-Value   P-Value 
Unbacked  Straight  lo        Narrow     -0.4623      0.1329   -3.478    0.0847 
Unbacked  Straight  lo        Wide       -0.5312      0.1329   -3.996    0.0249 
 
 
Backing = Unbacked 
Curving = Straight 
Porosity = lo 
Width = Narrow  subtracted from: 
 
                                     Difference       SE of           Adjusted 
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Backing   Curving   Porosity  Width    of Means  Difference  T-Value   P-Value 
Unbacked  Straight  lo        Wide     -0.06894      0.1329  -0.5186     1.000 	  
The following values are for the Cook’s distances for the initial statistical model.  	  
COOK1 
0.000000 
0.005474 
0.000763 
0.029125 
0.002838 
0.023835 
0.000024 
0.006867 
0.207713 
0.004975 
0.000107 
0.050588 
0.134668 
0.000097 
0.003388 
0.006073 
0.000709 
0.002384 
0.000041 
0.010934 
0.088755 
0.000683 
0.013208 
0.003924 
0.179517 
0.000001 
0.001676 
0.000249 
0.021316 
0.199699 
0.000351 
0.000016 
0.207713 
0.050588 
0.004975 
0.199699 
0.004520  
0.070392  
0.000009  
0.057922  
0.001515  
0.033003  
0.000517  
0.026726  
0.005063  
0.000085  
0.000331  
0.054164  
0.000246  
0.231658  
0.000601  
0.014258  
0.040064  
0.000006  
0.076924  
0.008772  
0.001996  
0.052204  
0.173713  
0.000454  
0.000002  
0.020970  
0.001944  
0.09220
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ANOVA Output for the Tukey Model for Significant Interactions 	  
COMPARISON DATA 
Grouping Information Using Tukey Method and 99.7% Confidence 
 
Backing   Curving   Porosity  Width   N  Mean  Grouping 
Unbacked  Curved    hi        Wide    4   2.8  A 
Unbacked  Curved    hi        Narrow  4   2.1    B 
Unbacked  Straight  hi        Narrow  4   2.1    B C 
Unbacked  Straight  hi        Wide    4   1.9    B C D 
Backed    Curved    hi        Narrow  4   1.8    B C D E 
Unbacked  Curved    lo        Narrow  4   1.8    B C D E F 
Backed    Curved    hi        Wide    4   1.6    B C D E F 
Backed    Straight  hi        Narrow  4   1.6    B C D E F 
Unbacked  Curved    lo        Wide    4   1.5    B C D E F 
Backed    Straight  hi        Wide    4   1.5      C D E F 
Unbacked  Straight  lo        Narrow  4   1.5      C D E F 
Backed    Curved    lo        Narrow  4   1.4        D E F G 
Unbacked  Straight  lo        Wide    4   1.4        D E F G 
Backed    Curved    lo        Wide    4   1.2          E F G 
Backed    Straight  lo        Narrow  4   1.2            F G 
Backed    Straight  lo        Wide    4   0.8              G 
 
Means that do not share a letter are significantly different. 
 
 
Tukey 99.7% Simultaneous Confidence Intervals 
Response Variable log(time) 
All Pairwise Comparisons among Levels of Backing*Curving*Porosity*Width 
Backing = Backed 
Curving = Curved 
Porosity = hi 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower  Center    Upper 
Backed    Curved    hi        Wide    -0.834  -0.199   0.4364 
Backed    Curved    lo        Narrow  -1.038  -0.403   0.2324 
Backed    Curved    lo        Wide    -1.234  -0.598   0.0372 
Backed    Straight  hi        Narrow  -0.873  -0.238   0.3977 
Backed    Straight  hi        Wide    -0.984  -0.349   0.2866 
Backed    Straight  lo        Narrow  -1.285  -0.649  -0.0138 
Backed    Straight  lo        Wide    -1.669  -1.033  -0.3980 
Unbacked  Curved    hi        Narrow  -0.349   0.287   0.9222 
Unbacked  Curved    hi        Wide     0.346   0.981   1.6169 
Unbacked  Curved    lo        Narrow  -0.662  -0.027   0.6086 
Unbacked  Curved    lo        Wide    -0.956  -0.320   0.3151 
Unbacked  Straight  hi        Narrow  -0.379   0.256   0.8918 
Unbacked  Straight  hi        Wide    -0.533   0.103   0.7379 
Unbacked  Straight  lo        Narrow  -0.995  -0.360   0.2757 
Unbacked  Straight  lo        Wide    -1.064  -0.429   0.2067 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Curved    hi        Wide            (----*---) 
Backed    Curved    lo        Narrow         (---*----) 
Backed    Curved    lo        Wide          (---*---) 
Backed    Straight  hi        Narrow          (---*----) 
Backed    Straight  hi        Wide           (----*---) 
Backed    Straight  lo        Narrow       (----*---) 
Backed    Straight  lo        Wide       (---*---) 
Unbacked  Curved    hi        Narrow              (---*---) 
Unbacked  Curved    hi        Wide                    (----*---) 
Unbacked  Curved    lo        Narrow            (---*---) 
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Unbacked  Curved    lo        Wide            (---*---) 
Unbacked  Straight  hi        Narrow             (----*---) 
Unbacked  Straight  hi        Wide              (----*---) 
Unbacked  Straight  lo        Narrow         (----*---) 
Unbacked  Straight  lo        Wide           (---*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Curved 
Porosity = hi 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center    Upper 
Backed    Curved    lo        Narrow  -0.839  -0.2040   0.4314 
Backed    Curved    lo        Wide    -1.035  -0.3992   0.2362 
Backed    Straight  hi        Narrow  -0.674  -0.0387   0.5967 
Backed    Straight  hi        Wide    -0.785  -0.1498   0.4856 
Backed    Straight  lo        Narrow  -1.086  -0.4502   0.1853 
Backed    Straight  lo        Wide    -1.470  -0.8344  -0.1990 
Unbacked  Curved    hi        Narrow  -0.150   0.4858   1.1213 
Unbacked  Curved    hi        Wide     0.545   1.1805   1.8159 
Unbacked  Curved    lo        Narrow  -0.463   0.1722   0.8076 
Unbacked  Curved    lo        Wide    -0.757  -0.1213   0.5141 
Unbacked  Straight  hi        Narrow  -0.180   0.4554   1.0908 
Unbacked  Straight  hi        Wide    -0.334   0.3016   0.9370 
Unbacked  Straight  lo        Narrow  -0.796  -0.1607   0.4747 
Unbacked  Straight  lo        Wide    -0.865  -0.2297   0.4057 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Curved    lo        Narrow          (----*---) 
Backed    Curved    lo        Wide           (---*----) 
Backed    Straight  hi        Narrow            (---*---) 
Backed    Straight  hi        Wide             (---*---) 
Backed    Straight  lo        Narrow         (---*---) 
Backed    Straight  lo        Wide        (---*----) 
Unbacked  Curved    hi        Narrow               (---*---) 
Unbacked  Curved    hi        Wide                      (---*---) 
Unbacked  Curved    lo        Narrow             (---*---) 
Unbacked  Curved    lo        Wide             (---*---) 
Unbacked  Straight  hi        Narrow               (---*---) 
Unbacked  Straight  hi        Wide                (---*---) 
Unbacked  Straight  lo        Narrow           (---*---) 
Unbacked  Straight  lo        Wide            (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Curved 
Porosity = lo 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center    Upper 
Backed    Curved    lo        Wide    -0.831  -0.1952  0.44020 
Backed    Straight  hi        Narrow  -0.470   0.1653  0.80074 
Backed    Straight  hi        Wide    -0.581   0.0542  0.68960 
Backed    Straight  lo        Narrow  -0.882  -0.2462  0.38925 
Backed    Straight  lo        Wide    -1.266  -0.6304  0.00500 
Unbacked  Curved    hi        Narrow   0.054   0.6898  1.32526 
Unbacked  Curved    hi        Wide     0.749   1.3845  2.01989 
Unbacked  Curved    lo        Narrow  -0.259   0.3762  1.01159 
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Unbacked  Curved    lo        Wide    -0.553   0.0827  0.71808 
Unbacked  Straight  hi        Narrow   0.024   0.6594  1.29482 
Unbacked  Straight  hi        Wide    -0.130   0.5055  1.14097 
Unbacked  Straight  lo        Narrow  -0.592   0.0433  0.67868 
Unbacked  Straight  lo        Wide    -0.661  -0.0257  0.60974 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Curved    lo        Wide            (----*---) 
Backed    Straight  hi        Narrow             (---*---) 
Backed    Straight  hi        Wide              (---*----) 
Backed    Straight  lo        Narrow          (---*----) 
Backed    Straight  lo        Wide          (---*---) 
Unbacked  Curved    hi        Narrow                (----*---) 
Unbacked  Curved    hi        Wide                       (---*---) 
Unbacked  Curved    lo        Narrow              (----*---) 
Unbacked  Curved    lo        Wide              (----*---) 
Unbacked  Straight  hi        Narrow                (---*----) 
Unbacked  Straight  hi        Wide                 (---*----) 
Unbacked  Straight  lo        Narrow            (---*----) 
Unbacked  Straight  lo        Wide              (---*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Curved 
Porosity = lo 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center   Upper 
Backed    Straight  hi        Narrow  -0.275   0.3605  0.9960 
Backed    Straight  hi        Wide    -0.386   0.2494  0.8848 
Backed    Straight  lo        Narrow  -0.686  -0.0510  0.5845 
Backed    Straight  lo        Wide    -1.071  -0.4352  0.2002 
Unbacked  Curved    hi        Narrow   0.250   0.8851  1.5205 
Unbacked  Curved    hi        Wide     0.944   1.5797  2.2151 
Unbacked  Curved    lo        Narrow  -0.064   0.5714  1.2068 
Unbacked  Curved    lo        Wide    -0.358   0.2779  0.9133 
Unbacked  Straight  hi        Narrow   0.219   0.8546  1.4900 
Unbacked  Straight  hi        Wide     0.065   0.7008  1.3362 
Unbacked  Straight  lo        Narrow  -0.397   0.2385  0.8739 
Unbacked  Straight  lo        Wide    -0.466   0.1695  0.8050 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Straight  hi        Narrow              (---*----) 
Backed    Straight  hi        Wide               (----*---) 
Backed    Straight  lo        Narrow           (----*---) 
Backed    Straight  lo        Wide           (---*---) 
Unbacked  Curved    hi        Narrow                  (---*---) 
Unbacked  Curved    hi        Wide                        (----*---) 
Unbacked  Curved    lo        Narrow                (---*---) 
Unbacked  Curved    lo        Wide                (---*---) 
Unbacked  Straight  hi        Narrow                 (----*---) 
Unbacked  Straight  hi        Wide                  (----*---) 
Unbacked  Straight  lo        Narrow             (----*---) 
Unbacked  Straight  lo        Wide               (---*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Straight 
Porosity = hi 
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Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center    Upper 
Backed    Straight  hi        Wide    -0.747  -0.1111   0.5243 
Backed    Straight  lo        Narrow  -1.047  -0.4115   0.2239 
Backed    Straight  lo        Wide    -1.431  -0.7957  -0.1603 
Unbacked  Curved    hi        Narrow  -0.111   0.5245   1.1599 
Unbacked  Curved    hi        Wide     0.584   1.2192   1.8546 
Unbacked  Curved    lo        Narrow  -0.425   0.2109   0.8463 
Unbacked  Curved    lo        Wide    -0.718  -0.0827   0.5528 
Unbacked  Straight  hi        Narrow  -0.141   0.4941   1.1295 
Unbacked  Straight  hi        Wide    -0.295   0.3402   0.9756 
Unbacked  Straight  lo        Narrow  -0.757  -0.1221   0.5134 
Unbacked  Straight  lo        Wide    -0.826  -0.1910   0.4444 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Straight  hi        Wide             (---*---) 
Backed    Straight  lo        Narrow         (---*---) 
Backed    Straight  lo        Wide        (----*---) 
Unbacked  Curved    hi        Narrow               (---*----) 
Unbacked  Curved    hi        Wide                      (---*---) 
Unbacked  Curved    lo        Narrow             (---*----) 
Unbacked  Curved    lo        Wide             (---*----) 
Unbacked  Straight  hi        Narrow               (---*----) 
Unbacked  Straight  hi        Wide                (---*----) 
Unbacked  Straight  lo        Narrow           (---*---) 
Unbacked  Straight  lo        Wide            (----*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Straight 
Porosity = hi 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center     Upper 
Backed    Straight  lo        Narrow  -0.936  -0.3004   0.33507 
Backed    Straight  lo        Wide    -1.320  -0.6846  -0.04918 
Unbacked  Curved    hi        Narrow   0.000   0.6357   1.27107 
Unbacked  Curved    hi        Wide     0.695   1.3303   1.96571 
Unbacked  Curved    lo        Narrow  -0.313   0.3220   0.95741 
Unbacked  Curved    lo        Wide    -0.607   0.0285   0.66390 
Unbacked  Straight  hi        Narrow  -0.030   0.6052   1.24064 
Unbacked  Straight  hi        Wide    -0.184   0.4514   1.08678 
Unbacked  Straight  lo        Narrow  -0.646  -0.0109   0.62450 
Unbacked  Straight  lo        Wide    -0.715  -0.0799   0.55556 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Straight  lo        Narrow          (---*---) 
Backed    Straight  lo        Wide         (---*----) 
Unbacked  Curved    hi        Narrow                (---*---) 
Unbacked  Curved    hi        Wide                       (---*---) 
Unbacked  Curved    lo        Narrow              (---*---) 
Unbacked  Curved    lo        Wide              (---*---) 
Unbacked  Straight  hi        Narrow                (---*---) 
Unbacked  Straight  hi        Wide                 (---*---) 
Unbacked  Straight  lo        Narrow            (---*---) 
Unbacked  Straight  lo        Wide             (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
	  140 	  
Backing = Backed 
Curving = Straight 
Porosity = lo 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center   Upper 
Backed    Straight  lo        Wide    -1.020  -0.3842  0.2512 
Unbacked  Curved    hi        Narrow   0.301   0.9360  1.5714 
Unbacked  Curved    hi        Wide     0.995   1.6306  2.2661 
Unbacked  Curved    lo        Narrow  -0.013   0.6223  1.2578 
Unbacked  Curved    lo        Wide    -0.307   0.3288  0.9643 
Unbacked  Straight  hi        Narrow   0.270   0.9056  1.5410 
Unbacked  Straight  hi        Wide     0.116   0.7517  1.3871 
Unbacked  Straight  lo        Narrow  -0.346   0.2894  0.9249 
Unbacked  Straight  lo        Wide    -0.415   0.2205  0.8559 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Backed    Straight  lo        Wide           (---*----) 
Unbacked  Curved    hi        Narrow                  (---*---) 
Unbacked  Curved    hi        Wide                         (---*---) 
Unbacked  Curved    lo        Narrow                (---*---) 
Unbacked  Curved    lo        Wide                (---*---) 
Unbacked  Straight  hi        Narrow                  (---*---) 
Unbacked  Straight  hi        Wide                   (---*---) 
Unbacked  Straight  lo        Narrow              (---*---) 
Unbacked  Straight  lo        Wide               (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Backed 
Curving = Straight 
Porosity = lo 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width      Lower  Center  Upper 
Unbacked  Curved    hi        Narrow   0.68483  1.3203  1.956 
Unbacked  Curved    hi        Wide     1.37947  2.0149  2.650 
Unbacked  Curved    lo        Narrow   0.37117  1.0066  1.642 
Unbacked  Curved    lo        Wide     0.07766  0.7131  1.348 
Unbacked  Straight  hi        Narrow   0.65440  1.2898  1.925 
Unbacked  Straight  hi        Wide     0.50055  1.1360  1.771 
Unbacked  Straight  lo        Narrow   0.03826  0.6737  1.309 
Unbacked  Straight  lo        Wide    -0.03068  0.6047  1.240 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Curved    hi        Narrow                     (---*---) 
Unbacked  Curved    hi        Wide                           (---*----) 
Unbacked  Curved    lo        Narrow                  (----*---) 
Unbacked  Curved    lo        Wide                   (---*---) 
Unbacked  Straight  hi        Narrow                    (----*---) 
Unbacked  Straight  hi        Wide                     (----*---) 
Unbacked  Straight  lo        Narrow                (---*----) 
Unbacked  Straight  lo        Wide                  (---*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = hi 
Width = Narrow  subtracted from: 
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Backing   Curving   Porosity  Width    Lower   Center     Upper 
Unbacked  Curved    hi        Wide     0.059   0.6946   1.33006 
Unbacked  Curved    lo        Narrow  -0.949  -0.3137   0.32176 
Unbacked  Curved    lo        Wide    -1.243  -0.6072   0.02824 
Unbacked  Straight  hi        Narrow  -0.666  -0.0304   0.60499 
Unbacked  Straight  hi        Wide    -0.820  -0.1843   0.45113 
Unbacked  Straight  lo        Narrow  -1.282  -0.6466  -0.01115 
Unbacked  Straight  lo        Wide    -1.351  -0.7155  -0.08010 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Curved    hi        Wide                  (----*---) 
Unbacked  Curved    lo        Narrow          (---*---) 
Unbacked  Curved    lo        Wide          (---*---) 
Unbacked  Straight  hi        Narrow            (---*---) 
Unbacked  Straight  hi        Wide             (---*---) 
Unbacked  Straight  lo        Narrow       (----*---) 
Unbacked  Straight  lo        Wide         (---*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = hi 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower  Center    Upper 
Unbacked  Curved    lo        Narrow  -1.644  -1.008  -0.3729 
Unbacked  Curved    lo        Wide    -1.937  -1.302  -0.6664 
Unbacked  Straight  hi        Narrow  -1.360  -0.725  -0.0897 
Unbacked  Straight  hi        Wide    -1.514  -0.879  -0.2435 
Unbacked  Straight  lo        Narrow  -1.977  -1.341  -0.7058 
Unbacked  Straight  lo        Wide    -2.046  -1.410  -0.7747 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Curved    lo        Narrow     (---*----) 
Unbacked  Curved    lo        Wide     (---*----) 
Unbacked  Straight  hi        Narrow       (---*---) 
Unbacked  Straight  hi        Wide        (---*---) 
Unbacked  Straight  lo        Narrow   (---*---) 
Unbacked  Straight  lo        Wide    (----*---) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = lo 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center   Upper 
Unbacked  Curved    lo        Wide    -0.929  -0.2935  0.3419 
Unbacked  Straight  hi        Narrow  -0.352   0.2832  0.9186 
Unbacked  Straight  hi        Wide    -0.506   0.1294  0.7648 
Unbacked  Straight  lo        Narrow  -0.968  -0.3329  0.3025 
Unbacked  Straight  lo        Wide    -1.037  -0.4019  0.2336 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Curved    lo        Wide            (---*---) 
Unbacked  Straight  hi        Narrow              (---*---) 
Unbacked  Straight  hi        Wide               (---*---) 
Unbacked  Straight  lo        Narrow          (---*---) 
Unbacked  Straight  lo        Wide           (---*----) 
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                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Curved 
Porosity = lo 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width     Lower   Center   Upper 
Unbacked  Straight  hi        Narrow  -0.0587   0.5767  1.2122 
Unbacked  Straight  hi        Wide    -0.2125   0.4229  1.0583 
Unbacked  Straight  lo        Narrow  -0.6748  -0.0394  0.5960 
Unbacked  Straight  lo        Wide    -0.7438  -0.1083  0.5271 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Straight  hi        Narrow                (---*---) 
Unbacked  Straight  hi        Wide                 (---*---) 
Unbacked  Straight  lo        Narrow            (---*---) 
Unbacked  Straight  lo        Wide             (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Straight 
Porosity = hi 
Width = Narrow  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center     Upper 
Unbacked  Straight  hi        Wide    -0.789  -0.1539   0.48157 
Unbacked  Straight  lo        Narrow  -1.252  -0.6161   0.01928 
Unbacked  Straight  lo        Wide    -1.321  -0.6851  -0.04966 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Straight  hi        Wide             (---*---) 
Unbacked  Straight  lo        Narrow        (---*---) 
Unbacked  Straight  lo        Wide         (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Straight 
Porosity = hi 
Width = Wide  subtracted from: 
 
Backing   Curving   Porosity  Width    Lower   Center   Upper 
Unbacked  Straight  lo        Narrow  -1.098  -0.4623  0.1731 
Unbacked  Straight  lo        Wide    -1.167  -0.5312  0.1042 
 
Backing   Curving   Porosity  Width   ----+---------+---------+---------+-- 
Unbacked  Straight  lo        Narrow         (---*---) 
Unbacked  Straight  lo        Wide          (---*----) 
                                      ----+---------+---------+---------+-- 
                                       -1.5       0.0       1.5       3.0 
 
 
Backing = Unbacked 
Curving = Straight 
Porosity = lo 
Width = Narrow  subtracted from: 
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Backing   Curving   Porosity  Width    Lower    Center   Upper 
Unbacked  Straight  lo        Wide   -0.7044  -0.06894  0.5665 
 
Backing   Curving   Porosity  Width  ----+---------+---------+---------+-- 
Unbacked  Straight  lo        Wide            (----*---) 
                                     ----+---------+---------+---------+-- 
                                      -1.5       0.0       1.5       3.0 
 
 
	  144 	  
 
Grouping Information Using Tukey Method and 99.7% Confidence 
 
Backing   Size   Width   N  Mean  Grouping 
Unbacked  Long   Narrow  8   2.0  A 
Unbacked  Long   Wide    8   2.0  A 
Unbacked  Short  Wide    8   1.8  A 
Backed    Long   Narrow  8   1.7  A 
Backed    Long   Wide    8   1.7  A 
Unbacked  Short  Narrow  8   1.7  A 
Backed    Short  Narrow  8   1.2    B 
Backed    Short  Wide    8   0.8      C 
 
Means that do not share a letter are significantly different. 
 
 
Tukey 99.7% Simultaneous Confidence Intervals 
Response Variable log(time) 
All Pairwise Comparisons among Levels of Backing*Size*Width 
Backing = Backed 
Size = Long 
Width = Narrow  subtracted from: 
 
Backing   Size   Width    Lower   Center    Upper 
Backed    Long   Wide    -0.432  -0.0262   0.3793 
Backed    Short  Narrow  -0.921  -0.5152  -0.1098 
Backed    Short  Wide    -1.339  -0.9339  -0.5284 
Unbacked  Long   Narrow  -0.117   0.2882   0.6937 
Unbacked  Long   Wide    -0.199   0.2061   0.6115 
Unbacked  Short  Narrow  -0.486  -0.0802   0.3253 
Unbacked  Short  Wide    -0.314   0.0911   0.4966 
 
Backing   Size   Width   ---+---------+---------+---------+--- 
Backed    Long   Wide             (---*---) 
Backed    Short  Narrow      (---*---) 
Backed    Short  Wide    (---*---) 
Unbacked  Long   Narrow              (---*---) 
Unbacked  Long   Wide               (---*---) 
Unbacked  Short  Narrow          (---*---) 
Unbacked  Short  Wide              (---*---) 
                         ---+---------+---------+---------+--- 
                         -1.0       0.0       1.0       2.0 
 
 
Backing = Backed 
Size = Long 
Width = Wide  subtracted from: 
 
Backing   Size   Width    Lower   Center    Upper 
Backed    Short  Narrow  -0.895  -0.4891  -0.0836 
Backed    Short  Wide    -1.313  -0.9077  -0.5023 
Unbacked  Long   Narrow  -0.091   0.3144   0.7198 
Unbacked  Long   Wide    -0.173   0.2322   0.6377 
Unbacked  Short  Narrow  -0.459  -0.0540   0.3514 
Unbacked  Short  Wide    -0.288   0.1173   0.5227 
 
Backing   Size   Width   ---+---------+---------+---------+--- 
Backed    Short  Narrow      (---*---) 
Backed    Short  Wide    (---*---) 
Unbacked  Long   Narrow              (---*---) 
Unbacked  Long   Wide               (---*---) 
Unbacked  Short  Narrow          (---*----) 
Unbacked  Short  Wide              (---*---) 
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                         ---+---------+---------+---------+--- 
                         -1.0       0.0       1.0       2.0 
 
 
Backing = Backed 
Size = Short 
Width = Narrow  subtracted from: 
 
Backing   Size   Width     Lower   Center     Upper 
Backed    Short  Wide    -0.8241  -0.4187  -0.01322 
Unbacked  Long   Narrow   0.3980   0.8034   1.20888 
Unbacked  Long   Wide     0.3159   0.7213   1.12674 
Unbacked  Short  Narrow   0.0296   0.4350   0.84048 
Unbacked  Short  Wide     0.2009   0.6063   1.01179 
 
Backing   Size   Width   ---+---------+---------+---------+--- 
Backed    Short  Wide         (---*---) 
Unbacked  Long   Narrow                   (---*---) 
Unbacked  Long   Wide                    (---*---) 
Unbacked  Short  Narrow               (---*---) 
Unbacked  Short  Wide                   (---*---) 
                         ---+---------+---------+---------+--- 
                         -1.0       0.0       1.0       2.0 
 
 
Backing = Backed 
Size = Short 
Width = Wide  subtracted from: 
 
Backing   Size   Width    Lower  Center  Upper 
Unbacked  Long   Narrow  0.8167  1.2221  1.628 
Unbacked  Long   Wide    0.7345  1.1400  1.545 
Unbacked  Short  Narrow  0.4483  0.8537  1.259 
Unbacked  Short  Wide    0.6196  1.0250  1.430 
 
Backing   Size   Width   ---+---------+---------+---------+--- 
Unbacked  Long   Narrow                       (---*---) 
Unbacked  Long   Wide                        (---*---) 
Unbacked  Short  Narrow                   (----*---) 
Unbacked  Short  Wide                       (---*---) 
                         ---+---------+---------+---------+--- 
                         -1.0       0.0       1.0       2.0 
 
 
Backing = Unbacked 
Size = Long 
Width = Narrow  subtracted from: 
 
Backing   Size   Width     Lower   Center    Upper 
Unbacked  Long   Wide    -0.4876  -0.0821  0.32331 
Unbacked  Short  Narrow  -0.7738  -0.3684  0.03705 
Unbacked  Short  Wide    -0.6025  -0.1971  0.20835 
 
Backing   Size   Width   ---+---------+---------+---------+--- 
Unbacked  Long   Wide            (---*---) 
Unbacked  Short  Narrow       (---*---) 
Unbacked  Short  Wide           (---*---) 
                         ---+---------+---------+---------+--- 
                         -1.0       0.0       1.0       2.0 
 
 
Backing = Unbacked 
Size = Long 
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Width = Wide  subtracted from: 
 
Backing   Size   Width     Lower   Center   Upper 
Unbacked  Short  Narrow  -0.6917  -0.2863  0.1192 
Unbacked  Short  Wide    -0.5204  -0.1150  0.2905 
 
Backing   Size   Width   ---+---------+---------+---------+--- 
Unbacked  Short  Narrow        (---*---) 
Unbacked  Short  Wide            (---*---) 
                         ---+---------+---------+---------+--- 
                         -1.0       0.0       1.0       2.0 
 
 
Backing = Unbacked 
Size = Short 
Width = Narrow  subtracted from: 
 
Backing   Size   Width    Lower  Center   Upper 
Unbacked  Short  Wide   -0.2341  0.1713  0.5767 
 
Backing   Size   Width  ---+---------+---------+---------+--- 
Unbacked  Short  Wide              (---*---) 
                        ---+---------+---------+---------+--- 
                        -1.0       0.0       1.0       2.0 	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Appendix B: Three-Dimensional AutoCAD Chip Drawings and Designs The	  engineering	  designs	  for	  the	  three-­‐dimensional	  chip	  iterations	  are	  presented	  in	  this	  section.	  The	  initial	  set	  of	  designs	  will	  apply	  to	  the	  first	  iteration	  of	  the	  designed	  chip.	  Following	  will	  be	  the	  altered	  base	  chip	  for	  the	  second	  design	  iteration.	  After,	  is	  the	  altered	  final	  layer	  of	  the	  third	  design	  iteration.	  Then,	  the	  designs	  for	  the	  final	  design	  iteration	  are	  presented.	  	  These	  chip	  designs	  are	  followed	  by	  the	  design	  that	  was	  used	  in	  the	  statistical	  analyses	  of	  wicking	  time.	  Likewise,	  the	  designs	  that	  looked	  at	  wicking	  time	  with	  and	  without	  a	  conjugate	  pad	  follow.	  Finally,	  this	  is	  followed	  by	  the	  conceptual	  SolidWorks	  engineering	  drawings	  for	  the	  manufacturing	  tool	  to	  be	  rapid	  prototyped	  and	  used	  to	  piece	  together	  the	  multi-­‐layer	  chip.	  	  Finally	  presented	  are	  a	  series	  of	  conceptual	  designs	  that	  could	  be	  used	  in	  the	  future.	  The	  detection	  regions	  on	  these	  chips	  have	  different	  shapes	  in	  order	  for	  the	  user	  to	  distinguish	  the	  result	  and	  the	  analyte	  that	  is	  detected	  between	  each	  zone.	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Figure 40: 2D Two Analyte Detection Design. A proposed future design 
for a 2D, two analyte detection chip. The two detection regions are different 
shapes for the user to more easily distinguish the end result. 	  
	  
Figure 41: 2D Three Analyte Detection Design. A proposed future design 
for a 2D, three analyte detection chip. The three detection regions are different 
shapes for the user to more easily distinguish the end result. 	  
	  
Figure 42: 3D Six Analyte Detection Design. A proposed future design for 
a six analyte detection chip. The six detection regions are different shapes for the 
user to more easily distinguish the end result. The input is on the far left to the 
observation on the far right – solid blocks are paper layers and hatched designs 
are tape layers. 
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Appendix C: Two-Dimensional AutoCAD Chip Drawings and Designs This	  section	  presents	  the	  various	  two-­‐dimensional	  chip	  designs	  that	  were	  used	  to	  test	  the	  antibody	  and	  aptamer	  capture	  reagents	  in	  detecting	  VEGF	  in	  sample.	  Following	  are	  the	  laser	  cut	  transparency	  drawings.	  Then,	  this	  is	  followed	  by	  the	  design	  used	  for	  the	  colloidal	  gold	  visual	  detection	  test.	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Appendix D: Biochemistry Dilution Calculations 
Diluting anti-VEGF Antibodies Conjugated With Gold 
• According to literature, the antibody should be diluted to anywhere between 1 
ng/ml to 2 µg/ml  
• However, this range of concentrations are too dilute to see any gold with the 
naked eye, therefore the solution was diluted to 0.5 mg/ml for the sake of visual 
detection 
• Given 100 ug of antibody and adding 0.2 ml of 0.01 M PBS (pH 7.4) stock 
solution, this provides 0.5 mg/ml of antibody 
• Store this antibody at 2-4 degrees Celsius and it will be stable for two weeks of 
use 
 
Diluting Polyclonal anti-VEGF Antibodies 
• The polyclonal antibodies were provided as 0.5 mg/ml by the company (in PBS) 
• For further dilution, add 1X PBS 
• These must be stored at -20 degrees Celsius and fully thawed before every use 
 
Diluting VEGF 
• VEGF was diluted into concentrations of 1.5 mg/ml, 10 ug/ml, and 50 ng/ml 
using 1% BSA as recommended by the provider 
• Instructions state that when the lyophilized VEGF is dissolved in 135 ul of 1% 
BSA it provides a concentration of 1.5 mg/ml 
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• For the 10 ug/ml concentration, 10 ul was removed from the 1.5 mg/ml 
concentration and combined with 1.5 mL of BSA 
    
 
 
• For the 50 ng/ml concentration, 50 ul of the VEGF solution was removed from 
the 10 ug/ml concentration and 10 mL of 1% BSA was added 
 
 
 
• All VEGF should be placed at -20 degrees Celsius to be used in 1 year 
 
Diluting IgG Antibodies 
• IgG was provided in a liquid form at a concentration of 2.4 mg/ml, with 2.0 mg of 
total solution 
• 0.01M sodium phosphate and 0.25 M NaCl were needed for diluting the IgG 
• According to literature, the antibody should be diluted to 1 mg/ml 
• Calculations for appropriate dilution: 
   in order to find the total volume of stock IgG 
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  where 2 ml represents the buffer solution necessary to dilute the 
IgG 
 
• Calculations for 0.01M sodium phosphate 
 
The stock solution of sodium phosphate is 0.05 M, therefore: 
 
0.1 L was chosen to demonstrate an overall volume of water to lower the molarity 
of sodium phosphate from 0.5 M to 0.01 M. This number can change based on 
how much stock solution is wanted. 
=0.002 L of sodium phosphate  
  of water 
• Calculations for 0.25M NaCl 
In this scenario, making 100 mL of 0.25 M stock solution 
 
Molecular weight of NaCl = 22.99 + 35.453 = 58.443 grams 
 
 
• Therefore, weigh out 1.461 grams of NaCl and combine with 100 mL of water 
• Add 2 mL of sodium phosphate to the 0.25 M NaCl solution 
• Measure the pH to ensure it is around 7.6  
• Store solution at 2-4 degrees Celsius 
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1% BSA Solution 
• Measure out 5 grams of lyophilized BSA  
• Add 500 mL of buffer solution (water) to reconstitute for 1% BSA 
 
1% Sucrose Solution 
• Measure out 5 grams of sucrose  
• Add 500 mL of buffer solution (in this case the borate) to reconstitute for 1% 
sucrose solution 
5% Sucrose Solution 
• Measure out 5 grams of sucrose 
• Add 100 mL of buffer solution (in this case water) to reconstitute for 5% sucrose 
solution 
 
0.05% SDS Solution  
• Use 100% stock solution of SDS  
• Weigh 0.05 grams of SDS in 100 mL of water for 0.05% 
 
5 mM Na2HPO4 with a pH of 7.5 
• The stock solution of Na2HPO4 was originally 0.5 M and needed to be diluted 
further for nitrocellulose post treatment 
•  
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• Where volume1 is the amount of stock that should be removed and combined 
with 5 mL of water in order to make a 5mM solution  
 
2 mM Borate Solution 
• Borate Buffer pH 7.4-9.2 
• Borax(sodium tetraborate) 0.2M = 76.2 gm/ml 
• Na2B407*120H20 (MW = 381.37) 
• Boric acid 0.2M = 12.37 gm/1 
• H3BO3 (MW = 61.83) 
• Add boric acid to borax solution until desired pH is reached. Dilute to desired 
molarity with ddH20. 
 
Diluting Aptamers Without Biotinylated End 
• Briefly spin the tube containing the lyophilized powder VEGF oligonucleotide 
prior to opening 
• Pour distilled water into a beaker and pH appropriately to allow a pH between 7.0 
and 8.0 
o Do this by adding pH buffer to the solution, drop at a time, measuring, and 
testing by dipping a pH strip into the solvent 
• Pipette 940.46 µL of appropriate pH water 
According to the given instructions, adding 47023 µL of water will allow for 100 
µM of aptamer solution.  
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This allows for a concentration of 
 
However, literature provides that aptamers should have a concentration of 1 
mg/ml 
 
 
Therefore, remove 22.8 µL of the diluted aptamer and combine with 1 mL of 
distilled water at appropriate pH for 1 mg/ml concentration 
• Vortex well (at a speed of 10 for around one minute) 
• Allow the solution to equilibrate for 5 minutes 
• Vortex again to completely resuspend the aptamer 
• Store the aptamer at -20 degrees Celsius (will maintain viability for up to 1 year) 
 
Diluting Aptamers With Biotinylated End 
• According to the given instructions, adding 45164 µL of water will allow for 100 
µM of aptamer solution.  
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The mass of the entire dried aptamer was 41389.2 µg. This allows for a 
concentration of: 
 
However, literature provides that aptamers should have a concentration of 1 
mg/ml. 
 
 
Therefore, remove 22.8 µL of the diluted aptamer and combine with 1 mL of 
distilled water at appropriate pH for 1 mg/ml concentration. 
 
Dilutions were calculated for six different concentrations of gold conjugated antibodies 
for a gold visual signal spot detection test. In Table XVI, the removed volume was how 
much solution was removed from the previous test concentration in order to make the 
next dilution. The volume of added buffer was how much was added to the removed gold 
to further dilute the material. Additionally, the total volume was how much was created 
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from the removed volume added to the volume of added buffer. The volume after 
removal was how much solution was left after the removed volume for that test occurred. 
Finally, the total volume after one test incorporates how much material was left post-
removing the solution for the next test dilution, as well as how much was removed for the 
spot test.  
Table XVI: Gold Spot Test Values 
Volumes and concentrations for the gold spot test in order to determine what minimal 
concentration allowed for gold visualization. 
Test 1 2 3 4 5 6 
Concentration 
(mg/ml) 
1 0.5 0.1 0.05 0.01 0.002 
Spot Volume 
(ml) 
0.0003 0.0003 0.0003 0.0003 0.0003 0.0003 
Removed 
Volume (ml) 
0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 
Volume 
Added Buffer 
(ml) 
0.1 0.0012 0.003 0.0012 0.003 0.003 
Total Volume 
(ml) 
0.1 0.0018 0.0036 0.0018 0.0036 0.0036 
Total Volume 
After 
Removal (ml) 
0.1 0.0012 0.003 0.0012 0.003 0.003 
Total Volume 
After 1 Test 
(ml) 
0.0997 0.0009 0.0027 0.0009 0.0027 0.0027 
Signal? Yes Yes No No No No 
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Appendix E: Instructions on Running A BLAST Test 
Given an immunogen sequence (usually from a vendor) one can run a BLAST. This 
determines the specificity of an antibody, protein, or DNA sequence. In the case of this 
thesis, the immunogen sequence of the monoclonal antibody that was used was: 
PQTCKCSCKNT 
This letter sequence was through the 158-168 region of the entire 191 letter protein 
sequence.  
Google “BLAST” and c lick the first link from the search result (Figure 43). 
 
Figure 43: Google BLAST Link. Google result to link user to run a BLAST 
test for protein specificity. 
 
For proteins and immunogens, click the “protein blast” link on the web page. Input 
the given immunogen/protein sequence into the highlighted yellow box and click the 
“BLAST” button at the bottom of the webpage (Figure 44).  
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Figure 44: BLAST Testing. Inputting the sequence of the immunogen or 
protein in order to find its specificity. 
 
Wait for 10-20 seconds, as database is being searched for a match to the sequence. 
Then, the top of the page will have results that look similar to Figure 45. 
 
Figure 45: Results of BLAST. Resultant page from running the immunogen 
sequence for a monoclonal anti-VEGF antibody. 
 
The results will yield proteins that are “above threshold”. This means that there is a 
high significance (p-value of less than 0.05). That implies that these proteins are specific 
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to the immunogen sequence that was searched. An example of this is demonstrated in 
Figure 46. 
 
Figure 46: BLAST "Above Threshold". Demonstration of an “above 
threshold” list for proteins that show significance compared to the 
immunogen/protein sequence that is inputted. 
 
On the bottom half of the search results there is a section called “worse than 
threshold.” This means that the significance of the specificity of the protein/immunogen 
to those proteins has a significance of below 5%. This implies that these are possible 
proteins with the binding sequence – but aren’t very likely to be so. These results also 
link you to further scientific information about the proteins. BLAST is a unique tool in 
order to determine specificities when developing diagnostic tests. 
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Appendix F: Biochemistry Test Combinations  
Many antibody and aptamer tests were performed in order to see if visual signal 
would be provided after running the two-dimensional lateral flow assay test. The 
combinations tested (with no result) are presented in a series of tables. Table XVII and 
Table XVIII present the combinations of chip designs and application of gold to the chip 
for the monoclonal anti-VEGF antibody and IgG antibody, respectively. Table XIX and 
Table XX present all data combination data for the experiments done involving the 
polyclonal anti-VEGF antibody. Finally, Table XXI comprises of data for experiments 
done with the pure aptamer (in other words, the aptamer with no biotinylated end).  
Additionally, example images of the failed experiments are presented in this 
section. For instance, Figure 47 presents an example of spot test results from IgG 
whereas Figure 48 shows spot test results from VEGF. Likewise, Figure 49 presents 
“dead zones” or zones where the colloidal gold or other pigment sits throughout the 
lateral flow assay rather than wicking up and through the test. Additionally, test 8 done 
with the polyclonal antibody, where no colloidal gold is visible in either the detection 
region or the conjugate pad (as the pad has been washed out).  
 
Figure 47: Spot testing for VEGF. Note how there is no distinct color or 
shape to prove detection of the VEGF. 
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Table XVII: Monoclonal Anti-VEGF Antibody Design Combinations 
Monoclonal Anti-VEGF Antibody 
Test Gold Application Input Test Type Drying 
Technique 
Design 
1 Conjugate Pad Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
Large Square 
Wells 
2 Conjugate Pad Lateral Flow 
Assay 
Room 
Temperature 
Large Square 
Wells 
3 Conjugate Pad Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
“Jumper” 
Design 
4 Spotted Spot Test Oven 37 
Degrees 2 
hours 
Single Square 
Well 
5 Spotted Spot Test Room 
Temperature 
Single Square 
Well 
6 Mixed Gold + VEGF Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
Large Square 
Wells 
7 Mixed Gold + VEGF Lateral Flow 
Assay 
Room 
Temperature 
Large Square 
Wells 
8 Mixed Gold + VEGF Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
“Jumper” 
Design 
9 Mixed Gold + VEGF Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
Small Square 
Wells 
10 Conjugate Pad + 
Sucrose 
Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
Large Square 
Wells 
11 Conjugate Pad + 
Sucrose 
Lateral Flow 
Assay 
Room 
Temperature 
Large Square 
Wells 
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Figure 48: Spot testing for IgG. Note how there is no distinct color or shape 
to prove detection of the VEGF. 
 
 
Figure 49: Design Dead Zones. The use of a more square shaped chip leads 
to “dead zones” – i.e. where the gold aggregates on the membrane. 
 
 
Figure 50: Chip Flow Pattern. Using the large square well design creates a 
unique flow pattern where in each well a parabolic shape is formed by the sample 
– this is important for comparing the unique shape of the gold in the detected 
aptamer chip (a spot shape) and the fact that this gold tends to eventually dilute 
out, whereas in the aptamer chip it did not. 
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Table XVIII: IgG Antibody Design Combinations 
IgG Antibody 
Test Gold Application Input Test Type Drying 
Technique 
Design 
1 Conjugate Pad Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
Large Square 
Wells 
2 Conjugate Pad Lateral Flow 
Assay 
Room 
Temperature 
Large Square 
Wells 
3 Conjugate Pad Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
“Jumper” 
Design 
4 Spotted Spot Test Oven 37 
Degrees 2 
hours 
Single Square 
Well 
5 Spotted Spot Test Room 
Temperature 
Single Square 
Well 
6 Mixed Gold + VEGF Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
“Jumper” 
Design 
7 Mixed Gold + VEGF Lateral Flow 
Assay 
Room 
Temperature 
Large Square 
Well 
 
 
Table XIX: Polyclonal Anti-VEGF Post-Treatments 
Polyclonal Anti-VEGF Antibody 
Test  Post-Treatment Wash 
1 1% BSA for 7 minutes 0.05% SDS / 5 mM Na2HPO4 for 10 min 
2 1% BSA for 7 minutes 0.05% SDS / 5 mM Na2HPO4 for 10 min 
3 1% BSA for 7 minutes 0.05% SDS / 5 mM Na2HPO4 for 10 min 
4 1% BSA for 7 minutes 0.05% SDS / 5 mM Na2HPO4 for 10 min 
5 1% BSA for 30 minutes Water Wash - 1 time 
6 1% BSA for 7 minutes 0.05% SDS / 5 mM Na2HPO4 for 10 min 
7 1% BSA for 30 minutes Water Wash - 1 time 
8 1% BSA for 7 minutes 0.05% SDS / 5 mM Na2HPO4 for 10 min 
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Table XX: Polyclonal Anti-VEGF Antibody Design Combinations 
Polyclonal Anti-VEGF Antibody 
Test Gold Application Input Test Type Drying 
Technique 
Design 
1 Mixed Gold + 
VEGF 
Lateral Flow 
Assay 
Oven 37 Degrees 
2 hours 
Small Circular 
Well 
2 Mixed Gold + 
VEGF 
Lateral Flow 
Assay 
Room 
Temperature 
Small Circular 
Well 
3 Conjugate Pad – 
Sucrose + Borate 
Lateral Flow 
Assay 
Oven 37 Degrees 
2 hours 
Small Circular 
Well 
4 Conjugate Pad – 
Sucrose + Borate 
Lateral Flow 
Assay 
Room 
Temperature 
Small Circular 
Well 
5 Gold On Paper + 
Sucrose 
Lateral Flow 
Assay 
Room 
Temperature 
Small Circular 
Well 
6 Gold On Paper + 
Sucrose 
Lateral Flow 
Assay 
Room 
Temperature 
Small Circular 
Well 
7 Gold On Paper + 
Sucrose 
Lateral Flow 
Assay 
Room 
Temperature 
Rounded 
Rectangular 
Well 
8 Conjugate Pad – 
Sucrose + Borate 
Lateral Flow 
Assay 
Room 
Temperature + 
Humidity 
Large Square 
Well 
 
 
 
Figure 51: Results for the polyclonal VEGF antibody. Using the 
polyclonal anti-VEGF antibody as a capture reagent, it is seen that through the 
colloidal gold was eventually washed out of the conjugate pad, diluted, and 
absorbed, leaving no capturing or signal of VEGF in the detection region. 
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Table XXI: Pure Aptamer Design Combinations 
Pure Aptamer 
Test Gold Application Input Test 
Type 
Drying 
Technique 
Design 
1 Conjugate Pad + 
Sucrose 
Lateral Flow 
Assay 
Room 
Temperature 
Large Square 
Wells 
2 Conjugate Pad + 
Sucrose 
Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
Large Square 
Wells 
3 Spotted Spot Test Room 
Temperature  
Single Square 
Well 
4 Spotted Spot Test Oven 37 
Degrees 2 
hours 
Single Square 
Well 
5 Mixed Gold + VEGF Lateral Flow 
Assay 
Room 
Temperature 
Large Square 
Well 
6 Mixed Gold + VEGF Lateral Flow 
Assay 
Oven 37 
Degrees 2 
hours 
Large Square 
Well 
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Appendix G: Biochemistry Optimal Concentration Calculations 
 
Chip Design Area/Volume Calculations 
In order to calculate the minimum volumes and concentrations of reagents to use for the 
two-dimensional lateral flow assay, the areas and volumes of the nitrocellulose chip were 
calculated. Initially the areas of parts of the chip (and the entirety of the chip) were 
calculated. The known identified values of radii and lengths are demonstrated in 
calculations, with their labels in Figure 52. Then, the chip was broken down to a first 
area and second area. This distinction may be found in Figure 53. 
 
Figure 52: Chip Dimensions. Radii, width, and lengths of the two 
dimensional chip, labeled for the purposes of understanding the givens in the 
chip design area and volume calculations. 
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Total Chip Volume 
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Figure 53: Chip Areas. Two-dimensional chip broken up into two distinct 
areas. 
 
Area 1 
 
 
Area 2 
 
Volume Fraction 
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X-Spot Area/Volume Calculation 
The area of the X region of the laser cut transparency was calculated, as well as its 
corresponding volume if applied to nitrocellulose membrane. This was in order to 
eventually calculate the minimum amount of antibody that could be applied to the 
detection region of the two-dimensional chip. This X is comprised of a circular center 
with four spokes. The labeled drawing may be found in Figure 54. 
 
Figure 54: Described X-Shaped Design. AutoCAD representation of X 
shaped design to strip detection antibody onto nitrocellulose membrane. The 
“spokes” and “circle” labels are for further understanding the calculations 
regarding antibody volume at the detection region. 
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Area 
 
 
Volume 
 
 
Calculations for Detection Region and Gold-Antibody Conjugate Minimums 
Givens:  
• Molar mass of gold – 197 g/mole 
• Mass concentration of gold conjugated antibody – 0.75 mg/ml (from visual gold 
experiments test) 
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• Radius of gold colloid – 30 nm or 3.00E-8 m 
• Density of gold – 19.3 g/cc (19300000 g/m3) 
 
Volume per colloid: 
Assuming spherical shape of the colloidal particle 
 
 
Mass per colloid: 
 
 
The experiment that analyzed the optimal mass concentration of colloidal gold by doing a 
spot test was used in order to calculate the volume of polyclonal antibody to spot down 
onto the nitrocellulose membrane (using the X pattern). 0.3 µL of gold antibody was 
spotted down in a 2 mm diameter circle designed on nitrocellulose.  
Grams of colloid in a 0.3 µL sample: 
 
 
Minimum number of gold colloids in a 0.3 µL sample: 
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Adjusted Spot Volume: 
This takes into consideration that the visual depth of the nitrocellulose paper was 10 µm 
deep and that there is a porosity value of 82% for the membrane. 
 
 
Adjusted X Volume: 
 
 
Polyclonal Antibody Volume for X Region: 
This was determined by doing a ratio for the spot volume with its adjusted membrane 
visible volume to finding the polyclonal antibody volume compared to the adjusted X 
area volume. 
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Grams of colloid in a 0.986 µL sample: 
 
 
Minimum number of gold colloids in a 4.94 µL sample: 
 
Visible Colloid per Liter in Detection Region: 
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Number of visible colloids in the Detection Region: 
 
 
It was previously found that the volume fraction from the detection region to the end of 
the lateral flow assay was 0.328. The number of colloidal gold particles that must be in 
the initial sample was calculated.  
Colloidal gold particles in initial sample: 
 
 
Translated to moles: 
 
 
It was given that the molecular weight of the gold conjugated antibody was 45000 
Daltons (or grams/mole). From this the mass was determined.  
Mass of the Gold Conjugated Antibodies: 
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Minimum concentration of Au-Antibody for detection: 
 
 
The molecular weight of the polyclonal capture antibody was given as 38200 g/mole. 
 
Minimum concentration of Polyclonal Antibody for detection: 
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Next the concentrations and volumes of VEGF must be found. From the AutoCAD chip 
design, the input can hold around 120 µL of sample. Therefore, that will be the volume of 
VEGF that will be used. 
 
For the concentration, it must be noted that every antibody holds two proteins. Therefore, 
the number of molecules of VEGF must be twice as much as the polyclonal antibody. 
Therefore: 
 
 
 
Next, using Avogadro’s number, the number of moles may be calculated. 
	  
 
The given molecular weight of VEGF is 19200 g/mole. The mass and concentration of 
VEGF may be found. 
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Appendix H: SEM Images of Nitrocellulose 
 Extra images were taken on the SEM of the HF 135 nitrocellulose with and 
without wax. The initial bare nitrocellulose membrane was taken with a 2500X objective 
(Figure 55). Then the impregnated wax membrane (Figure 56) and bare membranes were 
imaged at a 1000X objective (Figure 57).  
 
 
Figure 55: HF 135 SEM 2500X Objective. HF 135 backed nitrocellulose 
membrane without wax at 2500X lens. 
 
 
Figure 56: Wax HF 135 SEM 1000X Objective. HF 135 backed 
nitrocellulose membrane impregnated with wax in at 1000X magnification. 
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Figure 57: Bare HF 135 SEM 1000X Objective. HF 135 backed bare 
nitrocellulose membrane in at 1000X magnification. 
 
 	  
